<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006323.pub2" GROUP_ID="ARI" ID="046006040503003823" MERGED_FROM="" MODIFIED="2013-10-02 22:19:14 +0100" MODIFIED_BY="Liz Dooley" REVIEW_NO="A126" REVMAN_SUB_VERSION="5.2.6 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.2">
<COVER_SHEET MODIFIED="2013-10-02 22:19:14 +0100" MODIFIED_BY="Liz Dooley">
<TITLE MODIFIED="2013-07-16 11:12:14 +1000" MODIFIED_BY="Liz Dooley">Pelargonium sidoides extract for treating acute respiratory tract infections</TITLE>
<CONTACT MODIFIED="2013-10-02 22:19:14 +0100" MODIFIED_BY="Liz Dooley"><PERSON ID="C3DB143C82E26AA2014A559479172D27" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Antje</FIRST_NAME><LAST_NAME>Timmer</LAST_NAME><SUFFIX>MD, MSc.</SUFFIX><EMAIL_1>timmer@bips.uni-bremen.de</EMAIL_1><ADDRESS><DEPARTMENT>Clinical Epidemiology</DEPARTMENT><ORGANISATION>Leibniz Institute for Prevention Research and Epidemiology -  BIPS GmbH</ORGANISATION><ADDRESS_1>Achterstrasse 30</ADDRESS_1><CITY>Bremen</CITY><ZIP>28359</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 421 218-56881</PHONE_1><PHONE_2>+49 89 7095-7486</PHONE_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-10-02 22:19:14 +0100" MODIFIED_BY="Liz Dooley"><PERSON ID="C3DB143C82E26AA2014A559479172D27" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Antje</FIRST_NAME><LAST_NAME>Timmer</LAST_NAME><SUFFIX>MD, MSc.</SUFFIX><EMAIL_1>timmer@bips.uni-bremen.de</EMAIL_1><ADDRESS><DEPARTMENT>Clinical Epidemiology</DEPARTMENT><ORGANISATION>Leibniz Institute for Prevention Research and Epidemiology -  BIPS GmbH</ORGANISATION><ADDRESS_1>Achterstrasse 30</ADDRESS_1><CITY>Bremen</CITY><ZIP>28359</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 421 218-56881</PHONE_1><PHONE_2>+49 89 7095-7486</PHONE_2></ADDRESS></PERSON><PERSON ID="AAFFD3D282E26AA20071EDC0B072C6D3" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Judith</FIRST_NAME><LAST_NAME>Günther</LAST_NAME><POSITION>Pharmacist</POSITION><EMAIL_1>jg@phacts.de</EMAIL_1><ADDRESS><ORGANISATION>Pharmafacts GmbH - Research and Consulting in Drug Care</ORGANISATION><ADDRESS_1>Ludwigstr. 37</ADDRESS_1><CITY>Freiburg</CITY><ZIP>79104</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 761 383 6957</PHONE_1><FAX_1>+49 761 383 6958</FAX_1></ADDRESS></PERSON><PERSON ID="12126" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Edith</FIRST_NAME><LAST_NAME>Motschall</LAST_NAME><POSITION>Medical Librarian</POSITION><EMAIL_1>motschall@imbi.uni-freiburg.de</EMAIL_1><URL>http://www.imbi.uni-freiburg.de/biblio/</URL><ADDRESS><DEPARTMENT>German Cochrane Centre</DEPARTMENT><ORGANISATION>Institute of Medical Biometry and Medical Informatics, University Medical Center Freiburg</ORGANISATION><ADDRESS_1>Stefan-Meier-Str. 26</ADDRESS_1><CITY>Freiburg</CITY><ZIP>79104</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 761 203 6723</PHONE_1><FAX_1>+49 761 203 6711</FAX_1></ADDRESS></PERSON><PERSON ID="0CFB145382E26AA2005EE6A627852244" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Gerta</FIRST_NAME><LAST_NAME>Rücker</LAST_NAME><POSITION>Statistician</POSITION><EMAIL_1>ruecker@imbi.uni-freiburg.de</EMAIL_1><ADDRESS><DEPARTMENT>German Cochrane Centre</DEPARTMENT><ORGANISATION>Institute of Medical Biometry and Medical Informatics, University Medical Center Freiburg</ORGANISATION><ADDRESS_1>Stefan-Meier-Str. 26</ADDRESS_1><CITY>Freiburg</CITY><ZIP>79104</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 761 203 6673</PHONE_1><FAX_1>+49 761 203 6680</FAX_1></ADDRESS></PERSON><PERSON ID="5929" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Gerd</FIRST_NAME><LAST_NAME>Antes</LAST_NAME><POSITION>Director of the German Cochrane Centre</POSITION><EMAIL_1>antes@cochrane.de</EMAIL_1><URL>http://www.cochrane.de</URL><ADDRESS><DEPARTMENT>German Cochrane Centre</DEPARTMENT><ORGANISATION>Institute of Medical Biometry and Medical Informatics, University Medical Center Freiburg</ORGANISATION><ADDRESS_1>Berliner Allee 29</ADDRESS_1><CITY>Freiburg</CITY><ZIP>79110</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 761 203 6715</PHONE_1><FAX_1>+49 761 203 6712</FAX_1></ADDRESS></PERSON><PERSON ID="674AE86D82E26AA201E0E19DCED95C18" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Winfried</FIRST_NAME><MIDDLE_INITIALS>V</MIDDLE_INITIALS><LAST_NAME>Kern</LAST_NAME><POSITION>Head, Division of Infectious Diseases</POSITION><EMAIL_1>kern@if-freiburg.de</EMAIL_1><URL>http://www.if-freiburg.de</URL><ADDRESS><DEPARTMENT>Department of Medicine</DEPARTMENT><ORGANISATION>Center for Infectious Diseases and Travel Medicine, University Hospital</ORGANISATION><ADDRESS_1>Hugstetter Strasse 55</ADDRESS_1><CITY>Freiburg</CITY><ZIP>D-79106</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 761 270 1819</PHONE_1><PHONE_2>+49 160 111 7914</PHONE_2><FAX_1>+49 761 270 1820</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-07-01 10:51:15 +1000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="23" MONTH="4" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="23" MONTH="4" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="23" MONTH="4" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="4" YEAR="2013"/>
<DESCRIPTION>
<P>We changed the types of outcome measures, i.e. we dropped the option of analyzing symptom scores rather than individual symptoms as a secondary outcome.<BR/>We changed the inclusion criteria and added double-blinding.<BR/>We clarified the exclusion criteria, i.e. "Also, studies restricted to patients with underlying chronic disease were not included." This was not entirely unequivocal from the previous wording, but current planned subanalyses did not accommodate this option. This criterion should be reconsidered and will probably be changed in subsequent updates of this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-07-16 14:20:39 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="4" YEAR="2013"/>
<DESCRIPTION>
<P>We updated our searches. No new trials were identified. All previously included unpublished studies are now published and are, therefore, renamed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-03-09 08:15:26 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-03-09 08:15:26 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="5" YEAR="2009"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-05-08 16:44:12 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="17" MONTH="12" YEAR="2007"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-05-08 16:44:12 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="9" MONTH="12" YEAR="2007"/>
<DESCRIPTION>
<P>Searches conducted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Faculty of Medicine, Freiburg</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>German Ministry of Health (BMG)</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-10-03 07:18:02 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-10-02 07:34:24 +1000" MODIFIED_BY="Liz Dooley">
<TITLE MODIFIED="2013-08-20 09:49:59 +1000" MODIFIED_BY="Liz Dooley">
<I>Pelargonium sidoides</I> (Umckaloabo), a herbal remedy, for treating acute respiratory tract infections</TITLE>
<SUMMARY_BODY MODIFIED="2013-10-02 07:34:24 +1000" MODIFIED_BY="Liz Dooley" NOTES="&lt;p&gt;The original of 2008 quotes single study reports here which I consider grossly inappropriate for a systematic review. I am not sure how it go in. It is changed now. &lt;/p&gt;" NOTES_MODIFIED="2013-10-02 07:34:24 +1000" NOTES_MODIFIED_BY="Liz Dooley">
<P>Umckaloabo is a herbal extract derived from the plant<I> Pelargonium sidoides </I>(<I>P. sidoides</I>) and is available in both tablet and liquid forms. The extract is used for the treatment of acute respiratory tract infections (ARIs) where antibiotic use is unnecessary. In the light of inappropriate antibiotic use and increasing drug resistance rates worldwide, the need for an alternative, effective remedy for these medical conditions is crucial. On the other hand, there are concerns as to the safety of Umckaloabo.</P>
<P>We reviewed 10 randomized clinical trials of which eight were of sufficient quality for inclusion into the analyses. Three trials dealt with acute bronchitis in adults and showed inconsistent but overall positive results for resolution of symptoms (all symptoms, cough and sputum production). For acute bronchitis in children, there were also three studies showing an inconsistent but overall positive combined effect. The available data indicate that the tablet form may be less effective compared to the alcoholic extract. However, the number of trials is not sufficient to prove this. One study each was available for the treatment of acute sinusitis and the common cold in adults. Both showed that the drug was effective in resolving all symptoms including headaches and nasal discharge when taken for an extended time period. Adverse events were more common with <I>P. sidoides</I>, but none were severe.</P>
<P>Overall we considered the quality of the evidence low or very low for all major outcomes as there were few studies per disease entity, and all were from the same investigator (the manufacturer) and performed in the same region (Ukraine and Russia). Thus, in summary, there is limited evidence for the effectiveness of <I>P. sidoides</I> in the treatment of ARIs. The evidence is up to date as of April 2013.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-09-07 00:42:51 +1000" MODIFIED_BY="Liz Dooley">
<ABS_BACKGROUND MODIFIED="2008-04-28 08:46:08 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Pelargonium sidoides </I>(<I>P. sidoides</I>), also known as Umckaloabo, is a herbal remedy thought to be effective in the treatment of acute respiratory infections (ARIs).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-04-28 08:46:11 +1000" MODIFIED_BY="[Empty name]">
<P>To assess the efficacy and safety of <I>P. sidoides</I> for the treatment of ARIs in children and adults.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-09-07 00:42:51 +1000" MODIFIED_BY="Liz Dooley">
<P>In April 2013 we searched MEDLINE, Journals@Ovid, <I>The Cochrane Library</I>, Biosis Previews, Web of Science, CINAHL, CCMed, XToxline, Global Health, AMED, Derwent Drug File and Backfile, IPA, ISTPB + ISTP/ISSHP, EMBASE, Cambase, LILACS, PubMed component &#8220;Supplied by Publisher&#8221;, TRIPdatabase, the publisher databases: Deutsches Ärzteblatt, Thieme, Springer, ScienceDirect from Elsevier. We conducted a cited reference search (forward) in Web of Science of relevant papers for inclusion. In addition we searched the study registries ClinicalTrials.gov, Deutsches Register klinischer Studien DRKS (German Clinical Trials Register), International Clinical Trials Registry Platform (ICTRP) &#8211; WHO ICTRP, Current Controlled Trials and EU Clinical Trials Register.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-07-02 07:23:24 +1000" MODIFIED_BY="Liz Dooley">
<P>Double-blind, randomized controlled trials (RCTs) examining the efficacy of <I>P. sidoides</I> preparations in ARIs compared to placebo or any other treatment. Complete resolution of all symptoms was defined as the primary outcome; in addition, we examined resolution of predefined key symptoms.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>At least two review authors (AT, JG, WK) independently extracted and quality scored the data. We performed separate analyses by age group and disease entity. Subanalysis considered type of preparation (liquid, tablets). We examined heterogeneity using the I<SUP>2</SUP> statistic. We calculated pooled risk ratios (RR) using a fixed-effect model if heterogeneity was absent (I<SUP>2</SUP> &lt; 5%; P &gt; 0.1), or a random-effects model in the presence of heterogeneity. If heterogeneity was substantial (I<SUP>2</SUP> &gt; 50%; P &lt; 0.10), a pooled effect was not calculated.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Of 10 eligible studies eight were included in the analyses; two were of insufficient quality. Three trials (746 patients, low quality of evidence) of efficacy in acute bronchitis in adults showed effectiveness for most outcomes in the liquid preparation but not for tablets. Three other trials (819 children, low quality of evidence) showed similar results for acute bronchitis in children. For both meta-analyses, we did not pool subtotals due to relevant heterogeneity induced by type of preparation.</P>
<P>One study in patients with sinusitis (n = 103 adults, very low quality of evidence) showed significant treatment effects (complete resolution at day 21; RR 0.43, 95% confidence interval (CI) 0.30 to 0.62). One study in the common cold demonstrated efficacy after 10 days, but not five days (very low quality of evidence). We rated the study quality as moderate for all studies (unvalidated outcome assessment, minor attrition problems, investigator-initiated trials only). Based on the funnel plot there was suspicion of publication bias.</P>
<P>There were no valid data for the treatment of other acute respiratory tract infections. Adverse events were more common with <I>P. sidoides</I>, but none were serious.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-06-19 23:58:53 +1000" MODIFIED_BY="Liz Dooley">
<P>
<I>P. sidoides </I>may be effective in alleviating symptoms of acute rhinosinusitis and the common cold in adults, but doubt exists. It may be effective in relieving symptoms in acute bronchitis in adults and children, and sinusitis in adults. The overall quality of the evidence was considered low for main outcomes in acute bronchitis in children and adults, and very low for acute sinusitis and the common cold. Reliable data on treatment for other ARIs were not identified.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-10-02 07:40:12 +1000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-09-07 00:49:21 +1000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2013-09-07 00:47:25 +1000" MODIFIED_BY="[Empty name]">
<P>Acute respiratory infections (ARIs) are divided into two types: those of the upper respiratory tract, such as tonsillopharyngitis, sinusitis, otitis media or common cold, and those of the lower respiratory tract, such as acute bronchitis. These infections are characterized by an acute inflammation of the mucosa associated with edema and increased mucus production. Typical symptoms are congestion and increased secretions and discharge, sore throat, cough and localized pain. The majority of acute respiratory tract infections are caused by viruses and are self limited. Generally in adults and older children, a common cold tends to last about one week, but coughs may persist for up to three weeks. In younger children symptoms tend to last 10 to 14 days (<LINK REF="REF-CKS-Guideline-2011" TYPE="REFERENCE">CKS Guideline 2011</LINK>). Acute bronchitis may take up to three weeks to resolve (<LINK REF="REF-CKS-Guideline-2010" TYPE="REFERENCE">CKS Guideline 2010</LINK>). Based on observations in general practice, the median time for symptoms associated with acute bronchitis to resolve following consultation varies between five days (for dyspnea) and 11 days for cough (<LINK REF="REF-Moore-2008" TYPE="REFERENCE">Moore 2008</LINK>). Subjective complaints may persist for four weeks or more in a minority of patients (<LINK REF="REF-Moore-2008" TYPE="REFERENCE">Moore 2008</LINK>).</P>
<P>Patients with acute sinusitis usually have symptoms for a median duration of seven days (<LINK REF="REF-Williamson-2007" TYPE="REFERENCE">Williamson 2007</LINK>), and 50 (based on absence of restrictions) to 80 per cent (based on symptom resolution) of patients are considered cured after two weeks (<LINK REF="REF-Bucher-2003" TYPE="REFERENCE">Bucher 2003</LINK>; <LINK REF="REF-Williamson-2007" TYPE="REFERENCE">Williamson 2007</LINK>) although complete resolution may take up to 12 weeks in a minority of patients (<LINK REF="REF-CKS-Guideline-2009" TYPE="REFERENCE">CKS Guideline 2009</LINK>).</P>
<P>ARIs are the major cause of sick certificates and days of loss of work (<LINK REF="REF-Gonzales-2000" TYPE="REFERENCE">Gonzales 2000</LINK>; <LINK REF="REF-Wenzel-2006" TYPE="REFERENCE">Wenzel 2006</LINK>) and a reduction of the duration of illness is, therefore, desirable.</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-09-07 00:48:18 +1000" MODIFIED_BY="[Empty name]">
<P>Umckaloabo is a herbal remedy derived from the roots of <I>Pelargonium sidoides</I> (<I>P. sidoides</I>), which is native to South Africa. It is also sold as Umckabo, Umcka, Kaloba or Zucol. The medication was first marketed in Britain in 1897 for its supposed anti-tuberculotic properties but lost popularity with the advent of antibacterial therapy (<LINK REF="REF-Schulz-2003" TYPE="REFERENCE">Schulz 2003</LINK>; <LINK REF="REF-Taylor-2005" TYPE="REFERENCE">Taylor 2005</LINK>). Since the early 2000s it has again attracted attention from primary care physicians, infectious diseases specialists and public health bodies. A liquid alcohol containing preparation of <I>P. sidoides</I> (drops) was approved for the treatment of acute bronchitis in Germany in December 2005, where it is now one of the most frequently prescribed childhood medications, and subsequently in other countries. Other preparations like tablets (approved in May 2009), syrups for children (approved in October 2010) and quick dissolving lozenges (US - market) are also available.</P>
</INTERVENTION>
<THEORY MODIFIED="2013-09-07 00:49:21 +1000" MODIFIED_BY="[Empty name]">
<P>Bench research has found weak antibacterial effects of <I>P. sidoides</I> ethanolic extract (EPs 7630) (<LINK REF="REF-Kayser-1997" TYPE="REFERENCE">Kayser 1997</LINK>; <LINK REF="REF-Kayser-2001" TYPE="REFERENCE">Kayser 2001</LINK>; <LINK REF="REF-Kolodziej-2003" TYPE="REFERENCE">Kolodziej 2003</LINK>), which are unlikely to be relevant in vivo. <I>P. sidoides</I> extract EPs 7630 may interfere with the invasion and adherence of <I>Streptococcus pyogenes (S. pyogenes) </I>to human cells, potentially preventing bacterial superinfection (<LINK REF="REF-Conrad-2007a" TYPE="REFERENCE">Conrad 2007a</LINK>). Other hypotheses include similar effects on viral adherence and immunomodulation by the extract (<LINK REF="REF-Conrad-2007b" TYPE="REFERENCE">Conrad 2007b</LINK>; <LINK REF="REF-Kolodziej-2003" TYPE="REFERENCE">Kolodziej 2003</LINK>; <LINK REF="REF-Kolodziej-2007" TYPE="REFERENCE">Kolodziej 2007</LINK>; <LINK REF="STD-Luna-2011" TYPE="STUDY">Luna 2011</LINK>). The drug may also have mucolytic properties (it improves cilia function <I>in vitro</I>) (<LINK REF="REF-Neugebauer-2005" TYPE="REFERENCE">Neugebauer 2005</LINK>). It is currently regarded as a cough expectorant.</P>
<P>Claims of effectiveness in various ARIs, such as acute bronchitis, sinusitis and non-streptococcal tonsillopharyngitis, have been based on a number of clinical studies, including several randomized controlled trials (RCTs) (<LINK REF="REF-Conrad-2007c" TYPE="REFERENCE">Conrad 2007c</LINK>; <LINK REF="REF-Schulz-2003" TYPE="REFERENCE">Schulz 2003</LINK>). Specifically, trials have been performed in acute bronchitis, sinusitis and non-streptococcal tonsillopharyngitis, in both children and in adults. Almost all trials published so far have been manufacturer-initiated.</P>
<P>There is potential for serious side effects. Concerns relate to the presence of natural coumarins in <I>P. sidoides</I> extract which could lead to hemorrhagic complications (<LINK REF="REF-Latte-2000" TYPE="REFERENCE">Latte 2000</LINK>; <LINK REF="REF-Zimmermann-1965" TYPE="REFERENCE">Zimmermann 1965</LINK>). Hypersensitivity reactions and hepatotoxic reactions have also been described (<LINK REF="REF-de-Boer-2007" TYPE="REFERENCE">de Boer 2007</LINK>; <LINK REF="REF-Teschke-2012a" TYPE="REFERENCE">Teschke 2012a</LINK>; <LINK REF="REF-Teschke-2012b" TYPE="REFERENCE">Teschke 2012b</LINK>)</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>ARIs are among the most common acute diseases in the community and are often the cause for a consultation of a general practitioner (<LINK REF="REF-Wenzel-2006" TYPE="REFERENCE">Wenzel 2006</LINK>). After seeing their doctor both children and adults often receive an empiric antibiotic prescription, although the limited effectiveness of this approach in a predominantly viral disease is well known. The increasing prevalence of community-acquired, drug-resistant infections is stimulating strategies to reduce antibiotic prescribing (<LINK REF="REF-Gonzales-2001" TYPE="REFERENCE">Gonzales 2001</LINK>). Beneficial treatment effects of <I>P. sidoides</I> in acute bronchitis or other self limiting respiratory tract infections could therefore lead to a decrease in unnecessary antibiotic prescriptions.</P>
<P>As concerns have been raised as to a potential for serious side effects of this frequently used herbal remedy, a critical review of the evidence is important.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-07-01 10:53:50 +1000" MODIFIED_BY="[Empty name]">
<P>To assess the efficacy and safety of <I>P. sidoides</I> for the treatment of ARIs in children and adults.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-09-21 01:30:59 +1000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-07-02 07:23:29 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind, randomized controlled trials (RCTs).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley">
<P>We included participants of any age, and planned separate analyses for adults (&#8805; 18 years of ages) and children (&#8804; 14 years of age). Those aged 15 to 17 years were considered as either adults or children, depending on the definitions used in the respective studies. Participants were to have one or more ARI not necessitating antibiotic therapy; that is, sore throat (pharyngitis, retropharyngitis, laryngitis), bronchitis, tracheitis, sinusitis, rhinitis, otitis media, non-streptococcal tonsillitis and non-specific respiratory tract infection (common cold).</P>
<P>We excluded any condition for which an antibiotic or other specific therapy was recommended, such as streptococcal infections, pneumonia, diphtheria, tuberculosis, infections in immunocompromised or elderly persons, or any life-threatening condition. Also, studies restricted to patients with underlying chronic disease, such as asthma or chronic obstructive airways disease (COPD), or any other condition potentially impacting on the management and outcome of ARI were not included.</P>
<P>All identified studies used a threshold of &lt; 48 hours from disease onset for defining acute disease.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-04-23 02:02:05 +1000" MODIFIED_BY="[Empty name]">
<P>Included studies had to compare <I>P. sidoides</I> ethanol extract (Umckaloabo) or other <I>P. sidoides</I> preparations to placebo or any active comparator. Active comparators could include, for example, physical therapy, mucolytics/expectorants or prophylactic antibiotic therapy.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Only studies providing information on improvement or resolution of symptoms were eligible.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to complete resolution of all symptoms (in days), or number of patients not resolved at a predefined time.</LI>
<LI>Time to complete resolution of key symptoms (in days), or number of patients with key symptoms not resolved at a predefined time.</LI>
</OL>
<P>The following symptoms were expected to be of primary interest (key symptoms).</P>
<UL>
<LI>Bronchitis: cough, productive cough, sputum production.</LI>
<LI>Tonsillitis or pharyngitis: pain on swallowing, sore throat.</LI>
<LI>Laryngitis: hoarseness.</LI>
<LI>Rhinitis and sinusitis: nasal discharge, purulent nasal discharge, headache.</LI>
<LI>Common cold: sore throat, nasal congestion, nasal discharge.</LI>
<LI>All: fever, malaise, absence of general well-being.</LI>
</UL>
<P>We considered time to complete recovery from key symptoms the most appropriate endpoint. However, this was not available for any of the studies. We had defined an alternative main outcome as the proportion of participants with continuing symptoms at predefined days of follow-up. Day seven was identified as a commonly reported time point of reference in most ARIs (<LINK REF="REF-Agbabiaka-2008" TYPE="REFERENCE">Agbabiaka 2008</LINK>). Day 21 was considered relevant in the subset of sinusitis studies. We considered data on individual symptoms more appropriate than symptom scores and sought these from the trial authors if not reported.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-07-01 15:31:28 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Reduction in severity of symptoms on a prespecified day (that is, improvement).</LI>
<LI>Need for antibiotics at follow-up.</LI>
<LI>Quality of life measures.</LI>
<LI>Days off work or days off school, number of return visits, hospitalization.</LI>
<LI>Side effects (any, and side effects leading to withdrawal from the trial).</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-09-09 10:10:31 +1000" MODIFIED_BY="[Empty name]">
<P>We performed all searches without language and time restrictions.</P>
<ELECTRONIC_SEARCHES MODIFIED="2013-09-09 10:10:31 +1000" MODIFIED_BY="[Empty name]">
<P>The most recent searches were performed from 24 April to 3 May 2013 in all electronic databases as listed in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>, complemented by a Cited Reference Search (forward) of relevant articles in Web of Science up to 26 April 2013. Terms searched varied by the database used. As an example, the search strategy in MEDLINE (via Ovid SP) is shown in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>. For details of the search strategies in all databases, see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.</P>
<P>In addition we searched relevant clinical study registries (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-05-11 01:49:55 +1000" MODIFIED_BY="[Empty name]">
<P>We contacted the manufacturer, drug approval authorities (for Germany: Federal Institute for Drugs and Medical Devices (BfArM, Bonn), 2009 version only) and authors of relevant articles to identify any unpublished material. We checked references of relevant articles and performed a cited reference search.<BR/>
</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-09-21 01:30:59 +1000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2013-07-01 15:32:28 +1000" MODIFIED_BY="[Empty name]">
<P>At least two review authors (AT, JG or MD) screened all studies by title and abstract (if available). All controlled clinical trials and all prospective cohort studies on the therapeutic effect of <I>P. sidoides</I> were made available to all review authors in full text. Three review authors (AT, JG, WK) selected relevant RCTs. We resolved any disagreement on the inclusion of studies by discussion with all review authors.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-09-21 01:30:59 +1000" MODIFIED_BY="[Empty name]">
<P>Three review authors (AT, JG, WK) extracted data using standardized extraction forms. We extracted information on data source; participants (age range, exclusion criteria, pre-treatment, disease type); details of intervention (dosing, duration of treatment) and comparison treatment; outcomes studied and duration of follow-up; study design features (including method of randomization, allocation concealment, intention-to-treat (ITT) analysis); and results, including adverse events and loss to follow-up. We resolved discrepancies in the data extractions by consensus. If an agreement was not reached, we consulted a fourth review author who served as the final arbiter (GA). For unclear or non-reported data, we approached the manufacturing company. Missing data were supplied by the statistician in charge at the manufacturing company (2008 version).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>We assessed the studies for internal validity using criteria based on the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (domain-based evaluation) (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). This included an assessment of the likelihood for selection bias (sequence generation, allocation concealment), performance bias (blinding of patients and caregivers, co-interventions), detection bias (blinding of outcome assessment, robustness of endpoint), attrition bias (completeness of follow-up, ITT analysis) and reporting bias. For missing information on details of study conduct we sought clarification from investigators wherever possible.</P>
<P>Individual domains are presented using the 'Risk of bias' tool provided by <LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>, including summaries of risk of bias for major outcomes within a study and across studies (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>; <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>).</P>
<P>In accordance with the review protocol of 2007, we graded within-study quality as follows:</P>
<P>Grade <I>A trials: Low risk of bias (plausible bias unlikely to seriously alter the results, all quality criteria met).<BR/>Grade B trials: Moderate risk of bias (plausible bias that raises some doubt about the results, one or more criteria partially met).<BR/>Grade C trials: High risk of bias (plausible bias that seriously weakens confidence in the results, one or more criteria not met).</I>
</P>
<P>Analyses were restricted to studies at low or moderate (or unclear) overall risk of bias (see chapter 8.8.3.1 (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>We considered randomization adequate if allocation occurred by chance. Adequate measures included the use of random number tables or computer-based random number generation. We considered allocation concealment adequate if measures were taken to ensure allocation was unknown before inclusion into the study. Methods include the use of sealed envelopes, central randomization or distribution of coded bottles by the pharmacy. If this information was unavailable from the reports, we requested it from the manufacturer or trial author.</P>
<P>Three review authors (AT, JG, WK) independently graded the studies. Disagreements were discussed by these three review authors. If a consensus was not reached, a fourth review author (GA) acted as arbiter. Preceding the final analysis, a statistician (GR) checked all data and quality scorings for potential errors, based on the study reports. For the 2013 update, two review authors (AT, JG) reassessed all studies to complete the 'Risk of bias' assessment.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>We calculated treatment effects as risk ratios (RR) with 95% confidence intervals, with an RR &lt; 1.0 corresponding to a decreased risk for not being free of symptoms at the specified time (benefit of treatment). Time to event data were not available.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Neither cluster-randomized trials nor cross-over trials were identified.</P>
<P>For trials with multiple arms, we treated all treatment arms as a separate study, using the proportionate number of controls for assessment of efficacy. For example, in a trial with three different treatment arms (<LINK REF="STD-Kamin-2010b" TYPE="STUDY">Kamin 2010b</LINK>), the trial was reported as three substudies<I> </I>(<LINK REF="STD-Kamin-2010b-_x002d_-10-mg" TYPE="STUDY">Kamin 2010b - 10 mg</LINK>; <LINK REF="STD-Kamin-2010b-_x002d_-20-mg" TYPE="STUDY">Kamin 2010b - 20 mg</LINK>; <LINK REF="STD-Kamin-2010b-_x002d_-30-mg" TYPE="STUDY">Kamin 2010b - 30 mg</LINK>), each with a third of the number of controls.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Wherever possible, information was sought on missing data from the investigators.</P>
<P>In the case of missing outcome data due to drop-out, we applied a worst-case scenario for dichotomous variables. This means that all dropped out cases were considered treatment failure. High differential drop-out which might have resulted in the worst scenario leading to a clinically relevant difference in effect estimate as compared to a best-case scenario, was considered a source of high risk of bias, and led to the exclusion of the respective study from the analysis. Continuous outcome data were not used.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>We examined heterogeneity by calculating the I<SUP>2</SUP> statistic and performing the Chi<SUP>2</SUP> test. If heterogeneity was considered relevant, e.g. I<SUP>2</SUP> statistic greater than 0.50 and P &lt; 0.10, we performed subanalyses as deemed clinically relevant, and subtotals only, or single trial results were reported.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-07-01 15:46:18 +1000" MODIFIED_BY="[Empty name]">
<P>We assessed publication bias (positive outcome bias) or small study bias by drawing a funnel plot based on the primary outcome (failure to resolve all symptoms at prespecified day) from all trials, irrespective of disease type. As only eight trials were included in the analysis, statistical tests for funnel plot asymmetry were not applied.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>We included only grade A and B quality trials in the analysis. Separate meta-analyses were to be performed for children and adults, and by disease type. For adverse events, we pooled all studies irrespective of the indicated disease type and the dosage used.</P>
<P>Since time-to-event data were not available for any of the studies, complete recovery at day seven was used as the primary outcome. We pooled data using the Mantel-Haenszel method. In the absence of evidence for heterogeneity, e.g. I<SUP>2</SUP> statistic less than 0.05 and P &gt; 0.10, we used a fixed-effect model. Otherwise, we performed random-effects modeling.</P>
<P>We considered an absolute risk reduction of 10%, or a reduction in time to recovery of more than one day, to be a clinically relevant effect.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-07-01 15:47:11 +1000" MODIFIED_BY="[Empty name]">
<P>Planned subgroup analyses were to be performed by type of control, dosing and type of preparation (liquid, tablet, syrup). All included trials used placebo controls, and most studies used comparable dosing. Thus subgroup analyses were restricted to type of preparation (liquid versus tablet).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-02-26 20:34:52 +1000" MODIFIED_BY="[Empty name]">
<P>We planned sensitivity analyses to examine the effects of study quality, in particular adequacy of allocation concealment, but these could not be performed as most quality characteristics were identical in all studies. </P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-10-02 07:36:38 +1000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-09-07 00:56:34 +1000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>In total 1565 citations were identified; after elimination of duplicates with the Endnote® software 844 citations remained. The investigator notified us of eight published studies (all duplicates) and supplied further details on five more yet unpublished studies (no duplicates). Searching in clinical trial registries identified 56 hits, of which 34 were duplicates (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
<P>Overall, we screened 182 papers from the database search in more detail and selected 38 for full-text assessment. There were seven full reports on five RCTs, including two pairs of duplicate publications (<LINK REF="STD-Bereznoy-2003" TYPE="STUDY">Bereznoy 2003</LINK>; <LINK REF="STD-Blochin-1999" TYPE="STUDY">Blochin 1999</LINK>; <LINK REF="STD-Blochin-2000" TYPE="STUDY">Blochin 2000</LINK>; <LINK REF="STD-Chuchalin-2005" TYPE="STUDY">Chuchalin 2005</LINK>; <LINK REF="STD-Matthys-2003" TYPE="STUDY">Matthys 2003</LINK>). Two additional studies were reported in a single abstract (<LINK REF="STD-Bachert-2005" TYPE="STUDY">Bachert 2005</LINK>). One RCT was identified later during an updated search (<LINK REF="STD-Lizogub-2007" TYPE="STUDY">Lizogub 2007</LINK>). For the first version of this review the manufacturer had supplied nine unpublished manuscripts, of which six were RCTs, including the paper mentioned before by Lizogub. All others were also published as full papers by the time the current update was prepared and were identified by the search update (<LINK REF="STD-Bachert-2009" TYPE="STUDY">Bachert 2009</LINK>; <LINK REF="STD-Kamin-2010a" TYPE="STUDY">Kamin 2010a</LINK>; <LINK REF="STD-Kamin-2010b" TYPE="STUDY">Kamin 2010b</LINK>; <LINK REF="STD-Kamin-2012" TYPE="STUDY">Kamin 2012</LINK>; <LINK REF="STD-Matthys-2010" TYPE="STUDY">Matthys 2010</LINK>). There was evidence for two trials on sore throat from a non-systematic review (<LINK REF="REF-Schulz-2003" TYPE="REFERENCE">Schulz 2003</LINK>) based on data submitted for the drug approval procedure, but the available information was insufficient for evaluation and inclusion, and details on these trials were not available so these could not be listed as separate studies. The drug approval agency (BfArM) did not supply any information on trials (2008 version).</P>
<P>Five recently supplied, currently unpublished studies are still under consideration (1320 patients) (<LINK REF="STD-Bachert-2004" TYPE="STUDY">Bachert 2004</LINK>; <LINK REF="STD-Beck-2001" TYPE="STUDY">Beck 2001</LINK>; <LINK REF="STD-Heger-2002" TYPE="STUDY">Heger 2002</LINK>; <LINK REF="STD-Heger-2003" TYPE="STUDY">Heger 2003</LINK>; <LINK REF="STD-Wolf-2011" TYPE="STUDY">Wolf 2011</LINK>) as information was insufficient at the time the analyses were completed (April 2013).</P>
<P>Of the 22 citations identified in the clinical registry search, eight will be considered for inclusion once data are available. Seven of these are still ongoing (recruiting, or being analyzed) (<LINK REF="STD-EUCTR2007_x002d_004923_x002d_39_x002d_DE" TYPE="STUDY">EUCTR2007-004923-39-DE</LINK>; <LINK REF="STD-EUCTR2007_x002d_005579_x002d_33_x002d_BG" TYPE="STUDY">EUCTR2007-005579-33-BG</LINK>; <LINK REF="STD-EUCTR2007_x002d_005797_x002d_31_x002d_BG" TYPE="STUDY">EUCTR2007-005797-31-BG</LINK>; <LINK REF="STD-EUCTR2011_x002d_002652_x002d_14_x002d_DE" TYPE="STUDY">EUCTR2011-002652-14-DE</LINK>; <LINK REF="STD-ISRCTN77419032" TYPE="STUDY">ISRCTN77419032</LINK>; <LINK REF="STD-JPRN_x002d_UMIN000003815" TYPE="STUDY">JPRN-UMIN000003815</LINK>; <LINK REF="STD-NCT01420445" TYPE="STUDY">NCT01420445</LINK>). One was completed several years ago, but more information could not yet been secured (<LINK REF="STD-ISRCTN86579667" TYPE="STUDY">ISRCTN86579667</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-09-07 00:56:34 +1000" MODIFIED_BY="[Empty name]">
<P>Overall, 10 double-blind RCTs (all published at the time of the current review update) were selected for inclusion. Of these, four dealt with acute bronchitis in adults (<LINK REF="STD-Chuchalin-2005" TYPE="STUDY">Chuchalin 2005</LINK>; <LINK REF="STD-Matthys-2003" TYPE="STUDY">Matthys 2003</LINK>; <LINK REF="STD-Matthys-2007a" TYPE="STUDY">Matthys 2007a</LINK>; <LINK REF="STD-Matthys-2010" TYPE="STUDY">Matthys 2010</LINK>) and three with acute bronchitis in children (<LINK REF="STD-Kamin-2010a" TYPE="STUDY">Kamin 2010a</LINK>; <LINK REF="STD-Kamin-2010b" TYPE="STUDY">Kamin 2010b</LINK>; <LINK REF="STD-Kamin-2012" TYPE="STUDY">Kamin 2012</LINK>). There was one trial on sinusitis in adults (<LINK REF="STD-Bachert-2009" TYPE="STUDY">Bachert 2009</LINK>), one on the common cold in adults (<LINK REF="STD-Lizogub-2007" TYPE="STUDY">Lizogub 2007</LINK>) and one on sore throat in children (<LINK REF="STD-Bereznoy-2003" TYPE="STUDY">Bereznoy 2003</LINK>).</P>
<P>Two of the trials were multi-arm trials, comparing three different doses of <I>P. sidoides</I> versus placebo in a tablet preparation (10 mg, 20 mg, 30 mg three times a day) (<LINK REF="STD-Kamin-2010b" TYPE="STUDY">Kamin 2010b</LINK>; <LINK REF="STD-Matthys-2010" TYPE="STUDY">Matthys 2010</LINK>). All other trials used a liquid preparation (alcoholic extract). All were placebo-controlled. There were no completed trials using the newly available syrup. All trials were initiated and funded by the manufacturing company, and performed in Eastern Europe (Russia, Ukraine). All identified studies used a threshold of less than 48 hours from the onset of symptoms for defining acute disease.</P>
<P>There were no trials for any of the other conditions, such as rhinitis, laryngitis or otitis media.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Characteristics of excluded studies are presented in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table. Most often, studies were excluded because there was no control group. All studies using active comparators were open-label and were thus excluded (<LINK REF="STD-Blochin-1999" TYPE="STUDY">Blochin 1999</LINK>; <LINK REF="STD-Blochin-2000" TYPE="STUDY">Blochin 2000</LINK>). Five studies were excluded as they did not deal with upper respiratory tract infection in otherwise healthy persons. There were two RCTs in children with asthma (<LINK REF="STD-Tahan-2013" TYPE="STUDY">Tahan 2013</LINK>) or immunosuppression (hypogammaglobulinemia) (<LINK REF="STD-Patiroglu-2012" TYPE="STUDY">Patiroglu 2012</LINK>), and one study in adults with COPD (<LINK REF="STD-Matthys-2013" TYPE="STUDY">Matthys 2013</LINK>). Two studies were performed in healthy volunteers: one evaluating effects on running performance (<LINK REF="STD-Luna-2011" TYPE="STUDY">Luna 2011</LINK>), the other one examining interaction effects when Umckaloabo was used with penicillin V (<LINK REF="STD-Roots-2004" TYPE="STUDY">Roots 2004</LINK>).</P>
<P>Of the studies still under consideration one dealt with acute bronchitis in children (<LINK REF="STD-Heger-2002" TYPE="STUDY">Heger 2002</LINK>) and adults (<LINK REF="STD-Heger-2003" TYPE="STUDY">Heger 2003</LINK>), sinusitis in adults (<LINK REF="STD-Bachert-2004" TYPE="STUDY">Bachert 2004</LINK>), children with non-streptococcal angina (<LINK REF="STD-Bachert-2004" TYPE="STUDY">Bachert 2004</LINK>) and healthy volunteers (<LINK REF="STD-Wolf-2011" TYPE="STUDY">Wolf 2011</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>The risk of bias is illustrated in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<ALLOCATION MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>All included studies used central randomization procedures, blocking with concealed block sizes and other concealment procedures, such as using labeled containers. Confirmation on this was sought and received from the investigator (manufacturer) for all included studies.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blinding was reported for all studies and confirmed by the investigators. However, none of the studies attempted to examine the success and integrity of blinding. This was considered the more relevant due to the highly subjective nature of the outcome criterion and the obvious problems with differential drop-out (see below).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Two studies were excluded for high differential drop-out (<LINK REF="STD-Bereznoy-2003" TYPE="STUDY">Bereznoy 2003</LINK>; <LINK REF="STD-Matthys-2007b" TYPE="STUDY">Matthys 2007b</LINK>). High differential drop-out was considered particularly problematic as the last observation carried forward approach was applied in these diseases with rapid spontaneous recovery. In both affected trials, the higher drop-out occurred within the placebo-treated group and was likely to have resulted in severe overestimation of the effect of Umckaloabo. In all other studies, drop-out rates per arm were below 10% with little difference between groups (<LINK REF="STD-Chuchalin-2005" TYPE="STUDY">Chuchalin 2005</LINK>; <LINK REF="STD-Matthys-2007a" TYPE="STUDY">Matthys 2007a</LINK>) or close to 0 (remainder). All studies used ITT analysis, and most presented exact numbers on drop-outs and reasons for drop-out using flow charts. Numbers of drop-outs and reasons for loss were all confirmed (if reported), or supplied (if missing) by the investigator on request.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Generally, the primary outcomes as defined by the investigators were presented quantitatively, as well as a selection of secondary outcomes. In one study, reporting of results was restricted to one of two studied dosings (<LINK REF="STD-Lizogub-2007" TYPE="STUDY">Lizogub 2007</LINK>). The reason for this unclear; we sought clarification but has so far not been received.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-06-20 00:00:19 +1000" MODIFIED_BY="[Empty name]">
<P>All studies suffered from poor outcome criteria definition. A change in symptom score was used as a primary outcome based on non-validated instruments in all assessed studies. However, upon request, data on the number of patients with complete resolution of symptoms (all symptoms, key symptoms) and other essential information were supplied by the investigator (manufacturer) for all included studies. Complete resolution was, in this case, assumed for a symptom score = 0.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-10-02 07:36:38 +1000" MODIFIED_BY="Liz Dooley">
<P>Three studies including a total of 746 patients were included in the analysis of the treatment of acute bronchitis in adults (<LINK REF="STD-Chuchalin-2005" TYPE="STUDY">Chuchalin 2005</LINK>; <LINK REF="STD-Matthys-2007a" TYPE="STUDY">Matthys 2007a</LINK>; <LINK REF="STD-Matthys-2010" TYPE="STUDY">Matthys 2010</LINK>). There were no data on the time to complete resolution. The individual trials mostly showed positive effects for <I>P. sidoides</I> (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). However, heterogeneity was high for all primary outcomes assessed (complete resolution of all symptoms, I<SUP>2</SUP> statistic = 98%, cough I<SUP>2</SUP> statistic = 98%, sputum I<SUP>2</SUP> statistic = 44%). This was not completely explained by type of preparation. In particular, heterogeneity was still present for the studies using liquid preparations, with the exception of sputum production (complete resolution of all symptoms, I<SUP>2</SUP> statistic = 74%, cough I<SUP>2</SUP> statistic = 78%, sputum I<SUP>2</SUP> statistic = 0%) (<LINK REF="STD-Chuchalin-2005" TYPE="STUDY">Chuchalin 2005</LINK>; <LINK REF="STD-Matthys-2007a" TYPE="STUDY">Matthys 2007a</LINK>). Therefore we only calculated pooled effects for failure to resolve sputum, the key symptom, which showed the superiority of <I>P. sidoides</I> (risk ratio (RR) 0.70, 95% confidence interval (CI) 0.60 to 0.82) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<P>For acute bronchitis in children, three reports were eligible for inclusion (<LINK REF="STD-Kamin-2010a" TYPE="STUDY">Kamin 2010a</LINK>; <LINK REF="STD-Kamin-2010b" TYPE="STUDY">Kamin 2010b</LINK>; <LINK REF="STD-Kamin-2012" TYPE="STUDY">Kamin 2012</LINK>), comprising 819 children (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). As for the adults, there was considerable heterogeneity (complete resolution of all symptoms, I<SUP>2</SUP> statistic = 59%, cough I<SUP>2</SUP> = 65%, sputum I<SUP>2</SUP> statistic = 66%) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). Subgroup analyses showed some efficacy for the liquid preparation (complete resolution of all symptoms, RR 0.82, 95% CI 0.77 to 0.88; cough RR 0.82, 95% CI 0.76 to 0.88) (<LINK REF="STD-Kamin-2010a" TYPE="STUDY">Kamin 2010a</LINK>; <LINK REF="STD-Kamin-2012" TYPE="STUDY">Kamin 2012</LINK>), but not for the tablet preparation (complete resolution of all symptoms, RR 0.96, 95% CI 0.89 to 1.03; cough RR 0.96, 95% CI 0.86 to 1.07; sputum RR 0.87, 95% CI 0.71 to 1.06) (<LINK REF="STD-Kamin-2010b" TYPE="STUDY">Kamin 2010b</LINK>) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
<P>One study (n = 104 adults, 103 analyzed) (<LINK REF="STD-Bachert-2009" TYPE="STUDY">Bachert 2009</LINK>) was available for the assessment of effectiveness in acute sinusitis and showed significant treatment effects for resolution of all symptoms (RR 0.43, 95% CI 0.30 to 0.62) (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>), as well as key symptoms: nasal discharge (RR 0.21, 95% CI 0.11 to 0.40) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>) and resolution of headaches (RR 0.23, 95% CI 0.12 to 0.44) (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>).</P>
<P>For the common cold, there were no or small effects at day five for all outcomes (for example, resolution of all symptoms (RR 0.96, 95% CI 0.90 to 1.03) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>) based on a single trial including 103 patients as a subpopulation of the original study collective (<LINK REF="STD-Lizogub-2007" TYPE="STUDY">Lizogub 2007</LINK>)) (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>). For this entity, results were also available for day 10. At this time point, stronger effects were demonstrated (for example, resolution of all symptoms (RR 0.41, 95% CI 0.29 to 0.60)) (<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>) (<LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>).</P>
<P>Data on days off work were only available from one study, and showed a significant and relevant reduction in mean days off of 1.3 days (95% CI -2.06 to -0.54) when <I>P. sidoides</I> was used for the common cold (<LINK REF="STD-Lizogub-2007" TYPE="STUDY">Lizogub 2007</LINK>). However, the number of days off work was still very high in the treatment group (6.9 days; control group: 8.2 days), possibly as an effect of outliers (means were reported rather than medians). Data on need for antibiotics and quality of life were inconsistently reported, if at all. Meta-analyses could therefore not be performed for these secondary outcomes. </P>
<P>There were no valid data for the treatment of sore throat, nor any other acute respiratory infections beyond acute bronchitis, sinusitis and the common cold.</P>
<P>Adverse events were rarely reported, but were slightly more common in the treatment group (RR 1.32, 95% CI 1.04 to 1.66) (<LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>). Gastrointestinal symptoms seemed to be particularly common. There were no severe adverse events. The number of adverse events leading to withdrawal was similar between the comparison groups.</P>
<P>A funnel plot showed severe asymmetry for the main outcome (complete resolution of all symptoms) (<LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>). Both large dose-finding trials using tablet preparations were close to no difference, while all small trials using alcoholic extract were strongly positive.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-10-02 07:40:12 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>On the basis of the available study data <I>P. sidoides</I> extract can be considered as effective for symptom resolution of acute bronchitis in adults and in children. Statistical heterogeneity was partly explained by the use of different preparations. Only the drops of <I>P. sidoides</I> extract showed superiority, referred to the cure rate at day seven. The tablet preparation was not effective. There was consistency across different outcomes (all symptoms, key symptoms) for the alcoholic extract. However, there were only two studies each per age group on the alcoholic extract, and one dose-finding, multi-arm study each for tablets. Overall the quality of the evidence for these outcomes is considered low (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
<P>There were only single studies available for the assessment of efficacy in sinusitis and the common cold in adults, and the overall quality for these two entities was considered very low (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>; <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>). Patients with sinusitis might benefit from <I>P. sidoides</I> extract (higher cure rate at day 21). For the treatment of the common cold there are only few data. Only half of the collected data for this condition are published. The reported results show efficacy after 10 days, but not after five days.</P>
<P>Based on a pooled analyses of all studies, there was a slightly raised risk for adverse events in the treatment group. None of the reported events were serious. Besides gastrointestinal complaints such as nausea, vomiting, diarrhea or heartburn, allergic skin reactions with pruritus and urticaria were reported in the included trials.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-09-07 01:01:32 +1000" MODIFIED_BY="[Empty name]">
<P>Although we performed a broad search for all acute respiratory infections (ARIs) in both children and adults, only a limited number of conditions were covered by clinical trials of sufficient quality. These included acute bronchitis in adults and children, and acute sinusitis and the common cold in adults only. For other frequent diseases such as rhinosinusitis, non-streptococcal pharyngitis or otitis media there were no trials, or only with high risk of bias (e.g. not blinded).</P>
<P>Very few studies reported on time to complete resolution of symptoms (preferred primary outcome), and none of the studies originally reported the number of patients free of symptoms at a prespecified point in time (alternative primary outcome). Therefore, we had to abstain from meta-analysis of the preferred primary outcome. All studies used a non-validated symptom score to show efficacy. Results of the individual studies were recalculated for this review by the investigator under the assumption that a score of 0 corresponds to complete resolution. Thus, in conclusion, although not available from the published reports, evidence could be pooled as prespecified and may thus be considered complete. However, data on quality of life and days lost from work were insufficiently reported.</P>
<P>Some concerns arose as all studies were performed based on a similar protocol, by the same investigator (i.e. the manufacturer) and in similar settings (multi-center outpatient, Ukraine or Russia). This narrow spectrum compromises the representativeness of the evidence. More studies including those from other investigators and/or other parts of the world (Germany, Bulgaria, Japan, Korea) are underway (see <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK> table and <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>). So far, results are not available from these studies.</P>
<P>With respect to the assessment of safety, the relatively small studies of short treatment duration included in this review cannot be expected to pick up rare but severe events with sufficient precision. To solve this issue, other data sources may be necessary to complement our findings.</P>
<P>Shorter duration of symptoms or of illness due to acute respiratory infection by using herbal medicines would need to be translated into fewer lost days of work and less inappropriate antibiotic use. Studies based on (often self reported) symptom improvement remain difficult to assess because of the lack of valid, responsive outcome measures (<LINK REF="REF-Linder-2003" TYPE="REFERENCE">Linder 2003</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-09-07 01:02:02 +1000" MODIFIED_BY="[Empty name]">
<P>All included studies used similar methods and all were individually considered of moderate risk of bias (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). While randomization procedures and concealment of allocation were standard for all included studies, we had some concerns about the effectiveness of the blinding, the use of unvalidated scores for outcome assessment, minor attrition problems and, in one instance (<LINK REF="STD-Lizogub-2007" TYPE="STUDY">Lizogub 2007</LINK>), selective reporting. This was reflected by downgrading (-1) for trial quality in the GRADE system for all main outcomes (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>; <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>).</P>
<P>There were also concerns with respect to positive outcome, or small study bias. While the number of studies was insufficient for formal statistical testing, the combined funnel plot based on the main outcomes for all conditions and age groups was severely asymmetrical, suggesting publication bias. This resulted in further downgrading of the overall quality of the evidence (-1 for publication bias).</P>
<P>Statistical heterogeneity was present in several instances, even when different preparations were accounted for by sub-analyses. However, the direction of the results was rather uniform.</P>
<P>Lastly, the overall quality of the results was compromised by the low number of studies. In particular, this led to further downgrading of the quality of the evidence when only small, single studies were available (common cold and acute sinusitis). The results for these two conditions should be regarded with particular caution (very low quality).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-09-07 01:03:42 +1000" MODIFIED_BY="[Empty name]">
<P>A very broad search strategy was used in this review, including tailored search strategies for a large spectrum of different sources. Also, authors and investigators were very co-operative in providing information on unpublished studies. Despite this, there is some evidence of publication bias. This resulted in downgrading the overall quality of the evidence (see above).</P>
<P>As all authors are German, there may be a bias in that studies published in German, or German journals, may have been more likely to be identified than articles in other non-English languages, even though language restrictions were not applied.</P>
<P>Some evidence is still missing from a number of studies for which results are not yet available. This will be included in the next update of this review. At this time, all unpublished data used in the first version of this review have been published.</P>
<P>Quality scoring of individual studies may have been overly restrictive. For example, there was downgrading for failure to assess the success of blinding, since we considered blinding particularly important in view of the nature of the outcome assessment (symptom scores). Differential drop-out rates led to exclusion from the analyses due to the high risk of bias of two individual studies. Both were strongly positive so inclusion would have resulted in stronger effects favoring treatment.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-10-02 07:40:12 +1000" MODIFIED_BY="[Empty name]">
<P>Reducing the duration of illness due to acute respiratory infections is, of course, desirable. These infections are very common and are a major cause of lost days of work and of inappropriate antibiotic use (<LINK REF="REF-Gonzales-2000" TYPE="REFERENCE">Gonzales 2000</LINK>; <LINK REF="REF-Wenzel-2006" TYPE="REFERENCE">Wenzel 2006</LINK>).</P>
<P>Among the different treatment options studied so far for acute bronchitis, none have been reliable or highly effective in reducing the duration of illness. The use of ß2-agonists in the treatment of acute bronchitis in people without pulmonary disease is not supported by clinical data (<LINK REF="REF-Becker-2011" TYPE="REFERENCE">Becker 2011</LINK>). Although data from clinical trials are lacking, in some countries mucolytic or antitussive agents are commonly used, often in combination with antibiotics (<LINK REF="REF-Chalumeau-2013" TYPE="REFERENCE">Chalumeau 2013</LINK>; <LINK REF="REF-Poole-2012" TYPE="REFERENCE">Poole 2012</LINK>; <LINK REF="REF-Wenzel-2006" TYPE="REFERENCE">Wenzel 2006</LINK>). Different meta-analyses of antibiotic treatment in acute bronchitis suggested that symptoms of acute bronchitis were reduced by less than a day (<LINK REF="REF-Bent-1999" TYPE="REFERENCE">Bent 1999</LINK>; <LINK REF="REF-Fahey-1998" TYPE="REFERENCE">Fahey 1998</LINK>; <LINK REF="REF-Smith-2011" TYPE="REFERENCE">Smith 2011</LINK>). A recent large study of antibiotics versus placebo for acute lower respiratory tract infection was unable to show differences in the duration of symptoms rated "moderately bad" or worse (<LINK REF="REF-Little-2013" TYPE="REFERENCE">Little 2013</LINK>). The limited effect of antibiotic treatment in acute bronchitis is accompanied by a trend toward increased adverse events and must be weighed against potential adverse event effects such as medialization of a self limited condition, the treatment costs of antibiotics and the risk of an increasing microbial resistance (<LINK REF="REF-Smith-2011" TYPE="REFERENCE">Smith 2011</LINK>). Similarly, antibiotic treatment cannot be recommended in acute laryngitis, otitis media in children and the common cold (<LINK REF="REF-Kenealy-2013" TYPE="REFERENCE">Kenealy 2013</LINK>; <LINK REF="REF-Reveiz-2013" TYPE="REFERENCE">Reveiz 2013</LINK>; <LINK REF="REF-Venekamp-2013" TYPE="REFERENCE">Venekamp 2013</LINK>).</P>
<P>The role of herbal medicines for symptom relief of acute respiratory infections is unclear. Studies with over-the-counter (OTC) medications in general did not show convincing results based on a recent Cochrane review (<LINK REF="REF-Smith-2012" TYPE="REFERENCE">Smith 2012</LINK>). According to a systematic review, the use of Chinese herbs for acute bronchitis cannot be recommended due to limitations in trial design and an unknown safety profile of Chinese herbs (<LINK REF="REF-Jiang-2012" TYPE="REFERENCE">Jiang 2012</LINK>). Some evidence for limited effects of <I>Echinacea </I>on the incidence and duration of the common cold was reported (<LINK REF="REF-Shah-2007" TYPE="REFERENCE">Shah 2007</LINK>), but the meta-analytic approach in this study can be criticized. The authors of an earlier review summarized that there is no clear evidence that <I>Echinacea </I>may prevent common cold and, if there is any effect on the duration of the illness, only preparations of <I>Echinacea purpurea</I> might have this after the onset of cold symptoms (<LINK REF="REF-Linde-2008" TYPE="REFERENCE">Linde 2008</LINK>). A recent review showed again that <I>Echinacea purpurea</I> extract cannot prevent a common cold. For treatment of the common cold the extract might be effective, but issues surrounding dose and formulation require clarification (<LINK REF="REF-Nahas-2011" TYPE="REFERENCE">Nahas 2011</LINK>). There is one study reporting that a preparation of thyme dry extract and primrose root dry extract was associated with a mean reduction in coughing fits (<LINK REF="REF-Kemmerich-2006" TYPE="REFERENCE">Kemmerich 2006</LINK>). The same was shown for a fixed combination of thyme fluid extract and ivy leaves fluid extract (<LINK REF="REF-Kemmerich-2007" TYPE="REFERENCE">Kemmerich 2007</LINK>). A further study showed higher cure rates for the fixed combination of a thyme fluid extract and primrose root tincture than placebo in adult patients with acute bronchitis (<LINK REF="REF-Gruenwald-2005" TYPE="REFERENCE">Gruenwald 2005</LINK>). None of these study results has been replicated. Treatment effects have also been reported with a preparation containing nasturtium herb and horseradish root (<LINK REF="REF-Goos-2006" TYPE="REFERENCE">Goos 2006</LINK>; <LINK REF="REF-Goos-2007" TYPE="REFERENCE">Goos 2007</LINK>). Some of these studies have methodological flaws, and interpretation of the results is difficult. Recently a study with a more sophisticated methodology evaluated the same phytotherapy combination for prevention of acute respiratory tract infections in patients with a medical history of at least two such episodes in the last cold season (<LINK REF="REF-Fintelmann-2012" TYPE="REFERENCE">Fintelmann 2012</LINK>). Compared with placebo the preparation was reported to be associated with a lower infection rate after 84 days, but the study was sponsored by the manufacturer and therefore the results have to be replicated by independent researchers.</P>
<P>For acute rhinosinusitis a study reported a higher rate of complete remission with a complex homeopathic medication versus placebo (<LINK REF="REF-Zabolotnyi-2007" TYPE="REFERENCE">Zabolotnyi 2007</LINK>), but no differences in paracetamol concomitant use in the two arms. Since the study showed a large difference in drop-outs in the two arms, the last observation carried forward analysis approach may have overestimated symptom resolution in the active treatment arm. In a systematic review, oral glucocorticoids, given as adjunctive therapy to oral antibiotics, potential effects on short-term relief of symptoms in acute sinusitis were found, but the data are limited and of minor quality (<LINK REF="REF-Venekamp-2011" TYPE="REFERENCE">Venekamp 2011</LINK>). A subsequent randomized study by the same author indicates that the anti-inflammatory effect of monotherapy with oral corticosteroids seems to be of no benefit in clinically diagnosed acute rhinosinusitis (<LINK REF="REF-Venekamp-2012" TYPE="REFERENCE">Venekamp 2012</LINK>). Antibiotics have no role in uncomplicated acute rhinosinusitis, due to lack of major benefits (<LINK REF="REF-Ah_x002d_See-2007" TYPE="REFERENCE">Ah-See 2007</LINK>; <LINK REF="REF-Lemiengre-2012" TYPE="REFERENCE">Lemiengre 2012</LINK>; <LINK REF="REF-Masood-2007" TYPE="REFERENCE">Masood 2007</LINK>; <LINK REF="REF-Williamson-2007" TYPE="REFERENCE">Williamson 2007</LINK>).</P>
<P>To date, two other systematic reviews of <I>P. sidoides</I> extract have been published (<LINK REF="REF-Agbabiaka-2008" TYPE="REFERENCE">Agbabiaka 2008</LINK>; <LINK REF="REF-Ulbricht-2010" TYPE="REFERENCE">Ulbricht 2010</LINK>). Agbabiaka et al reviewed the available data for acute bronchitis and came to conclusions similar to those presented here. The systematic review included six randomized controlled trials in adult patients with acute bronchitis. Two of the studies were unpublished at that time. The studies included by Agbabiaka were also reviewed in the present report. All but two studies (<LINK REF="STD-Blochin-1999" TYPE="STUDY">Blochin 1999</LINK>; <LINK REF="STD-Matthys-2003" TYPE="STUDY">Matthys 2003</LINK>) were eligible for the present review under the terms of our methodological requirements. In Ulbricht et al unpublished data were not reported. The authors included the results from blinded and unblinded observational study reports. They summarized that on basis of these data the positive evidence for the effects of <I>P. sidoides </I>in acute bronchitis is highly suggestive, albeit not definitive.</P>
<P>In the present analysis, adverse events were slightly more frequent with <I>P. sidoides</I>. There have been case reports of allergic reactions, liver toxicity and hemorrhage after treatment with the commercially available preparation (<LINK REF="REF-de-Boer-2007" TYPE="REFERENCE">de Boer 2007</LINK>). Recently, the Drug Commission of the German Medical Association (Arzneimittelkommission der deutschen Ärzteschaft AKDÄ) announced a possible relation between the consumption of <I>Umckaloabo®</I>, the proprietary medicinal product of <I>P. sidoides</I> on the German market, and the occurrence of hepatitis (<LINK REF="REF-AKD_x00c4_-2011" TYPE="REFERENCE">AKDÄ 2011</LINK>). On the basis of 19 case reports the commission concluded that a causal relationship between <I>Umckaloabo®</I> and very rarely occurring hepatitis cannot be ruled out. In contrast, the European Medicines Agency (<LINK REF="REF-EMA-2012" TYPE="REFERENCE">EMA 2012</LINK>) refers to a re-evaluation (<LINK REF="REF-Teschke-2012a" TYPE="REFERENCE">Teschke 2012a</LINK>; <LINK REF="REF-Teschke-2012b" TYPE="REFERENCE">Teschke 2012b</LINK>) of all available data concerning the hepatotoxic effects of <I>P. sidoides</I>. This assessment showed a lack of convincing evidence for a hepatotoxic risk associated with the treatment of <I>P. sidoides </I>when used as recommended. In none of the 15 analyzed cases could Pelargonium hepatotoxicity be confirmed as the final diagnosis.</P>
<P>A more recent report summarized the adverse events data of herbal medicines, published in systematic reviews (<LINK REF="REF-Posadzki-2013" TYPE="REFERENCE">Posadzki 2013</LINK>). The authors defined three classes of phytotherapeutics: one class comprises plant extracts, such as <I>Piper methysticum</I> and <I>Cassia senna</I>,<I> </I>which can cause serious side effects. The second class consists of plant extracts such as <I>Aloe vera</I>,<I> Viscum album</I> and <I>Cimicifuga racemosa</I>,<I> </I>with moderately severe side effects. The third class comprises phytotherapeutics with minor side effects such as <I>Crataegus</I> ssp., thyme and <I>Echinacea</I> spp. <I>P. sidoides </I>was assigned to the second class with moderate side effects, such as severe nausea or pruritus. Hepatotoxic effects of <I>P. sidoides </I>were<I> </I>not reported in this review.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Based on the limited evidence from very few clinical trials with acceptable methodology,<I> P. sidoides</I> might offer symptom relief in acute bronchitis, rhinosinusitis and the common cold. The clinical relevance of these effects remains uncertain.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>More well-designed, placebo-controlled trials in acute bronchitis, rhinosinusitis and the common cold, with endpoints such as time to complete recovery, days lost from work, use of other drugs for symptom relief and antibiotics, are recommended to provide better evidence for a clinically relevant efficacy of the preparation in acute respiratory infections. It would be desirable if the available manufacturer-initiated studies from Eastern Europe could be complemented by more evaluations from independent researchers covering a larger variety of settings and methodological approaches.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>M. Doerks (Bremen) and C. Fischer (Freiburg) participated in the screening and the retrieval and management of published articles. M. Kieser (2008 version) and T. Reineke (2013 update) of Schwabe Pharmaceuticals, Karlsruhe, provided unpublished manuscripts and information on missing data upon request. W. Kamin and H. Matthys responded to author enquiries. The review authors wish to thank the following people for commenting on the draft of this review (2008 version): Janet Wale, Rakesh Lodha, George Lewith, Mark Jones and Taixiang Wu.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-10-03 07:18:02 +1000" MODIFIED_BY="[Empty name]">
<P>Antje Timmer has received honoraria for scientific presentations from Ferring, Abbott and the Falk Foundation. She is involved in various pharmacoepidemiological research projects funded by Novartis, Sanofi Aventis, Takeda, Bayer and Celgene. All projects and presentations are unrelated to the content of this review, i.e. they neither dealt with ARI nor with cold medications.<BR/>Judith Günther's declaration of interest: "Participation in a public debate on the significance of phytotherapy in medical care as speaker for an evidence based approach. The debate was sponsored by Dr. Willmar Schwabe GmbH, Karlsruhe."<BR/>The remaining authors do not have any declarations of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Antje Timmer (AT) wrote the protocol, screened the search results, extracted the data, scored the quality, wrote the introduction, the methods and results section, the abstract and plain language summary, and compiled all entries on study description and references.<BR/>Edith Motschall (EM) devised the search strategy, carried out the searches and wrote the search strategy section of the review.<BR/>Judith Günther (JG) screened the search results, extracted the data, scored the quality and wrote the introduction section, the plain language summary and the discussion.<BR/>Winfried Kern (WK) extracted the data, scored the quality and wrote the introduction and discussion section.<BR/>Gerta Rücker (GR) advised on the review methods, was the final arbiter on study quality and cross checked all results.<BR/>Gerd Antes (GA) served as final arbiter and consulted on study selection and data extraction.<BR/>All authors contributed to the planning of the review, participated in the writing of the protocol and review, and approved the final versions.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-07-01 16:40:05 +1000" MODIFIED_BY="Liz Dooley">
<P>Title changed from 'Pelargonium sidoides extract (Umckaloabo) for acute respiratory tract infections' to include all <I>P. sidoides</I> preparations.<BR/>The heterogeneity rule was changed by request of the Contact Editor (2008 version). Double-blinding was included as an additional inclusion criterion for studies (2013 version).</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-09-07 00:39:30 +1000" MODIFIED_BY="Liz Dooley">
<STUDIES MODIFIED="2013-09-07 00:39:30 +1000" MODIFIED_BY="Liz Dooley">
<INCLUDED_STUDIES MODIFIED="2013-09-07 00:39:30 +1000" MODIFIED_BY="Liz Dooley">
<STUDY DATA_SOURCE="MIX" ID="STD-Bachert-2009" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NAME="Bachert 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20090422&lt;br&gt;IS - 0300-0729 (Print)&lt;br&gt;IS - 0300-0729 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Multicenter Study&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;RN - 0 (EPs 7630)&lt;br&gt;RN - 0 (Plant Extracts)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-09-07 00:38:41 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bachert C, Schapowal A, Funk P, Kieser M</AU>
<TI>Treatment of acute rhinosinusitis with the preparation from Pelargonium sidoides EPs 7630: a randomized, double-blind, placebo-controlled trial</TI>
<SO>Rhinology</SO>
<YR>2009</YR>
<VL>47</VL>
<NO>1</NO>
<PG>51-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Abstracts of the 13th symposium of Complementary Health Care, Exeter, 2006&lt;/p&gt;" NOTES_MODIFIED="2013-09-07 00:38:41 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bachert C, Schapowal A, Kieser M, Malek F</AU>
<TI>Treatment of acute bacterial maxillary sinusitis with EPs 7630-solution: a randomised, double-blind, placebo-controlled trial</TI>
<SO>Focus on Alternative Complementary Therapy</SO>
<YR>2006</YR>
<VL>11</VL>
<PG>4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Chuchalin-2005" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley" NAME="Chuchalin 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-03-26 08:30:06 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chuchalin AG, Berman B, Lehmacher W</AU>
<TI>Treatment of acute bronchitis in adults with a pelargonium sidoides preparation (EPs 7630): a randomized, double blind, placebo-controlled trial</TI>
<SO>Explore</SO>
<YR>2005</YR>
<VL>1</VL>
<NO>6</NO>
<PG>437-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Golovatiouk A, Chuchalin AG. Wirksamkeit eines Extraktes aus Pelargonium sidoides (EPs 7630) im Vergleich zu Placebo bei Patienten mit akuter Bronchitis. Doppelpublikation, vgl. Chuchalin 2005&lt;br&gt;Efficacy of Pelargonium Sidoides Preparation (Eps (R) 7630) in Adults with Acute Bronchitis. Phytopharmaka VII. Darmstadt: Steinkopff, 2002: 3-12&lt;/p&gt;" NOTES_MODIFIED="2013-09-07 00:38:41 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Golovatiouk A, Chuchalin AG</AU>
<TI>Efficacy of Pelargonium sidoides preparation (Eps (R) 7630) in adults with acute bronchitis</TI>
<TO>Wirksamkeit eines Extraktes aus Pelargonium sidoides (EPs 7630) im Vergleich zu Placebo bei Patienten mit akuter Bronchitis</TO>
<SO>Phytopharmaka</SO>
<YR>2002</YR>
<VL>7</VL>
<PG>3-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20070212&lt;br&gt;IS - 0944-7113 (Print)&lt;br&gt;IS - 0944-7113 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Letter&lt;br&gt;PT - Multicenter Study&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;RN - 0 (Anti-Bacterial Agents)&lt;br&gt;RN - 0 (EPs 7630)&lt;br&gt;RN - 0 (Plant Extracts)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-09-07 00:38:41 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulz V</AU>
<TI>Liquid herbal drug preparation from the root of Pelargonium sidoides is effective against acute bronchitis: results of a double-blind study with 124 patients</TI>
<SO>Phytomedicine</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>Suppl 6</NO>
<PG>74-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-01 10:59:22 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulz V</AU>
<TI>Pelargonium sidoides extract for the treatment of acute bronchitis. [German]</TI>
<TO>Pelargonium sidoides-Extrakt bei akuter Bronchitis</TO>
<SO>Komplementäre und Integrative Medizin</SO>
<YR>2007</YR>
<VL>48</VL>
<NO>4</NO>
<PG>35-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kamin-2010a" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NAME="Kamin 2010a" YEAR="2010">
<REFERENCE MODIFIED="2013-02-26 02:52:57 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Received October 11, 2007&lt;/p&gt;" NOTES_MODIFIED="2013-02-26 02:52:57 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Anonymous</AU>
<TI>Efficacy and tolerability of Pelargonium sidoides extract EPs 7630 in patients (1 to 18 years old) with acute bronchitis: a randomized, double-blind, placebo-controlled clinical trial. Study No. 701003.01.001</TI>
<SO>Summary of design, methods and results</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Prepared and after completion of analysis; received October 11, 2007&lt;/p&gt;" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Anonymous</AU>
<TI>Efficacy and tolerability of Pelargonium sidoides extract EPs 7630 in patients (1 to 18 years old) with acute bronchitis: a randomized, double-blind, placebo-controlled clinical trial. Study No. 701003.01.001</TI>
<SO>Supplement to the clinical study report (subgroup of patients less than 7 years old)</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huntley A, Kamin W</AU>
<TI>Encouraging results for herbal treatment of acute bronchitis in children and adolescents</TI>
<SO>Focus on Alternative and Complementary Therapies</SO>
<YR>2010</YR>
<VL>15</VL>
<NO>3</NO>
<PG>238-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20100303&lt;br&gt;IS - 0946-1965 (Print)&lt;br&gt;IS - 0946-1965 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Multicenter Study&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;RN - 0 (EPs 7630)&lt;br&gt;RN - 0 (Plant Extracts)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-09-07 00:38:41 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kamin W, Maydannik V, Malek FA, Kieser M</AU>
<TI>Efficacy and tolerability of EPs 7630 in children and adolescents with acute bronchitis - a randomized, double-blind, placebo-controlled multicenter trial with a herbal drug preparation from Pelargonium sidoides roots</TI>
<SO>International Journal of Clinical Pharmacology and Therapeutics</SO>
<YR>2010</YR>
<VL>48</VL>
<NO>3</NO>
<PG>184-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kamin-2010b" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Jenny Bellorini" NAME="Kamin 2010b" YEAR="2010">
<REFERENCE MODIFIED="2013-07-16 15:48:45 +1000" MODIFIED_BY="Jenny Bellorini" NOTES="&lt;p&gt;Investigator supplied, (Dr.Wilmar Schwabe K. Efficacy and tolerability of Pelargonium sidoides extract EPs 7630 in patients (6 to 18 years ol) with acute bronchitis. Study-No. 701003.01.002. Biostatistical short report of the Interim Analysis 2007;1-16.&lt;/p&gt;" NOTES_MODIFIED="2013-07-16 15:48:45 +1000" NOTES_MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Anonymous</AU>
<TI>Efficacy and tolerability of Pelargonium sidoides extract EPs 7630 in patients (6 to 18 years old) with acute bronchitis. Study No. 701003.01.002</TI>
<SO>Biostatistical Short Report of the Interim Analysis</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20100331&lt;br&gt;IS - 1651-2227 (Electronic)&lt;br&gt;IS - 0803-5253 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;RN - 0 (EPs 7630)&lt;br&gt;RN - 0 (Plant Extracts)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-09-07 00:38:41 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kamin W, Maydannik VG, Malek FA, Kieser M</AU>
<TI>Efficacy and tolerability of EPs 7630 in patients (aged 6-18 years old) with acute bronchitis</TI>
<SO>Acta Paediatrica</SO>
<YR>2010</YR>
<VL>99</VL>
<NO>4</NO>
<PG>537-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kamin-2010b-_x002d_-10-mg" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Jenny Bellorini" NAME="Kamin 2010b - 10 mg" YEAR="2010">
<REFERENCE MODIFIED="2013-07-16 15:50:52 +1000" MODIFIED_BY="Jenny Bellorini" NOTES="&lt;p&gt;3 doses; a: 3x10mg&lt;/p&gt;" NOTES_MODIFIED="2013-07-16 15:50:52 +1000" NOTES_MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Anonymous</AU>
<TI>Efficacy and tolerability of Pelargonium sidoides extract EPs 7630 in patients (6 to 18 years old) with acute bronchitis. Study No. 701003.01.002</TI>
<SO>Biostatistical short report of the Interim Analysis</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20100331&lt;br&gt;IS - 1651-2227 (Electronic)&lt;br&gt;IS - 0803-5253 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;RN - 0 (EPs 7630)&lt;br&gt;RN - 0 (Plant Extracts)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-09-07 00:38:41 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kamin W, Maydannik VG, Malek FA, Kieser M</AU>
<TI>Efficacy and tolerability of EPs 7630 in patients (aged 6-18 years old) with acute bronchitis</TI>
<SO>Acta Paediatrica</SO>
<YR>2010</YR>
<VL>99</VL>
<NO>4</NO>
<PG>537-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Kamin-2010b-_x002d_-20-mg" MODIFIED="2013-09-07 00:39:30 +1000" MODIFIED_BY="Liz Dooley" NAME="Kamin 2010b - 20 mg" YEAR="2010">
<REFERENCE MODIFIED="2013-07-16 15:52:12 +1000" MODIFIED_BY="Liz Dooley" NOTES="&lt;p&gt;b: 3x 20mg&lt;/p&gt;" NOTES_MODIFIED="2013-07-16 15:52:12 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Anonymous</AU>
<TI>Efficacy and tolerability of Pelargonium sidoides extract EPs 7630 in patients (6 to 18 years old) with acute bronchitis. Study No. 701003.01.002</TI>
<SO>Biostatistical Short Report of the Interim Analysis</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20100331&lt;br&gt;IS - 1651-2227 (Electronic)&lt;br&gt;IS - 0803-5253 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;RN - 0 (EPs 7630)&lt;br&gt;RN - 0 (Plant Extracts)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-09-07 00:38:41 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kamin W, Maydannik VG, Malek FA, Kieser M</AU>
<TI>Efficacy and tolerability of EPs 7630 in patients (aged 6-18 years old) with acute bronchitis</TI>
<SO>Acta Paediatrica</SO>
<YR>2010</YR>
<VL>99</VL>
<NO>4</NO>
<PG>537-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-09-07 00:39:30 +1000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Kamin-2010b-_x002d_-30-mg" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley" NAME="Kamin 2010b - 30 mg" YEAR="2010">
<REFERENCE MODIFIED="2013-07-16 15:52:25 +1000" MODIFIED_BY="Liz Dooley" NOTES="&lt;p&gt;b: 3x 30mg&lt;/p&gt;" NOTES_MODIFIED="2013-07-16 15:52:25 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Anonymous</AU>
<TI>Efficacy and tolerability of Pelargonium sidoides extract EPs 7630 in patients (6 to 18 years old) with acute bronchitis. Study No. 701003.01.002</TI>
<SO>Biostatistical Short Report of the Interim Analysis</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20100331&lt;br&gt;IS - 1651-2227 (Electronic)&lt;br&gt;IS - 0803-5253 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;RN - 0 (EPs 7630)&lt;br&gt;RN - 0 (Plant Extracts)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-09-07 00:38:41 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kamin W, Maydannik VG, Malek FA, Kieser M</AU>
<TI>Efficacy and tolerability of EPs 7630 in patients (aged 6-18 years old) with acute bronchitis</TI>
<SO>Acta Paediatrica</SO>
<YR>2010</YR>
<VL>99</VL>
<NO>4</NO>
<PG>537-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kamin-2012" MODIFIED="2013-07-15 22:47:57 +1000" MODIFIED_BY="Jenny Bellorini" NAME="Kamin 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-07-01 11:08:46 +1000" MODIFIED_BY="Jenny Bellorini" NOTES="&lt;p&gt;Prepared after completion of analysis. Received October 11, 2007&lt;/p&gt;" NOTES_MODIFIED="2013-07-01 11:08:46 +1000" NOTES_MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Anonymous</AU>
<TI>Efficacy and tolerability of EPs 7630, a liquid herbal drug preparation from Pelargonium sidoides in patients (1-18 years old) suffering from acute bronchitis: a randomized, double-blind, placebo-controlled trial. Study No. 701003.01.004</TI>
<SO>Summary of Design, Methods and Results</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-01 11:09:04 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Prepared after completion of analysis. Received October 11, 2007&lt;/p&gt;" NOTES_MODIFIED="2013-07-01 11:09:04 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Anonymous</AU>
<TI>Efficacy and tolerability of Pelargonium sidoides extract EPs 7630 in patients (1 to 18 years old) with acute bronchitis: a randomized, double-blind, placebo-controlled clinical trial. Study No. 701003.01.004</TI>
<SO>Supplement to the Clinical Study Report (subgroup of patients less than 7 years old)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-15 22:47:57 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kamin W, Ilyenko LI, Malek FA, Kieser M</AU>
<TI>Treatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescents</TI>
<SO>Pediatrics International: Official Journal of the Japan Pediatric Society</SO>
<YR>2012</YR>
<VL>54</VL>
<NO>2</NO>
<PG>219-26</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="22360575"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lizogub-2007" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Jenny Bellorini" NAME="Lizogub 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lizogub VG, Riley DS, Heger M</AU>
<TI>Efficacy of Pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial</TI>
<SO>Explore</SO>
<YR>2007</YR>
<VL>3</VL>
<NO>6</NO>
<PG>573-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Matthys-2007a" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NAME="Matthys 2007a" YEAR="2007">
<REFERENCE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20080529&lt;br&gt;IS - 0032-0943 (Print)&lt;br&gt;IS - 0032-0943 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Multicenter Study&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;RN - 0 (EPs 7630)&lt;br&gt;RN - 0 (Plant Extracts)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-09-07 00:38:41 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matthys H, Funk P</AU>
<TI>EPs 7630 improves acute bronchitic symptoms and shortens time to remission. Results of a randomised, double-blind, placebo-controlled, multicentre trial</TI>
<SO>Planta Medica</SO>
<YR>2008</YR>
<VL>74</VL>
<NO>6</NO>
<PG>686-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-15 22:45:13 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Checked overlap with other studies - no overlap&lt;/p&gt;" NOTES_MODIFIED="2013-07-15 22:45:13 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Matthys H, Heger M</AU>
<TI>Treatment of acute bronchitis with a liquid herbal drug preparation from Pelargonium sidoides (EPs 7630): a randomised, multicentre, double-blind, placebo-controlled study</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2007</YR>
<VL>23</VL>
<NO>2</NO>
<PG>323-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-24 22:40:08 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulz V</AU>
<TI>Pelargonium sidoides extract EPs for the treatment of 217 patients with acute bronchitis: Publication of an additional double-blind study. [German]</TI>
<TO>Pelargonium sidoides-Extrakt EPs 7630 bei 217 Patienten mit akuter Bronchitis: Weitere zulassungsrelevante Doppelblindstudie publiziert</TO>
<SO>Zeitschrift für Phytotherapie</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>4</NO>
<PG>169-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Matthys-2010" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley" NAME="Matthys 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-07-16 15:52:58 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Anonymous</AU>
<TI>Efficacy and tolerability of Pelargonium sidoides extract EPs 7630 in patients (older than 18 years) with acute bronchitis. Study No. 701003.01.003</TI>
<SO>Biostatistical Short Report of the Interim Analysis</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-01 11:12:26 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ernst E</AU>
<TI>Instead of antibiotics: Pelargonium sidoides in acute bronchitis. [German]</TI>
<TO>Statt Antibiotika: Pelargonium sidoides bei akuter Bronchitis</TO>
<SO>Munchener Medizinische Wochenschrift</SO>
<YR>2010</YR>
<VL>152</VL>
<NO>41</NO>
<PG>32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-01 11:12:46 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matthys H, Lizogub VG, Funk P, Malek FA</AU>
<TI>Health-related quality of life and patient-reported outcome in patients with acute bronchitis receiving EPs 7630 treatment</TI>
<SO>Respiration</SO>
<YR>2011</YR>
<VL>82</VL>
<NO>1</NO>
<PG>100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matthys H, Lizogub VG, Funk P, Malek FA</AU>
<TI>Pelargonium sidoides in acute bronchitis - Health-related quality of life and patient-reported outcome in adults receiving EPs 7630 treatment</TI>
<TO>Pelargonium sidoides bei akuter Bronchitis - Gesundheitsbezogene Lebensqualitat und Therapiebeurteilung aus Patientensicht unter Behandlung mit EPs 7630</TO>
<SO>Wiener Medizinische Wochenschrift</SO>
<YR>2010</YR>
<VL>160</VL>
<NO>21-2</NO>
<PG>564-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="21170697"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20100517&lt;br&gt;IS - 1473-4877 (Electronic)&lt;br&gt;IS - 0300-7995 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;RN - 0 (EPs 7630)&lt;br&gt;RN - 0 (Placebos)&lt;br&gt;RN - 0 (Plant Extracts)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-09-07 00:38:41 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Matthys H, Lizogub VG, Malek FA, Kieser M</AU>
<TI>Efficacy and tolerability of EPs 7630 tablets in patients with acute bronchitis: a randomised, double-blind, placebo-controlled dose-finding study with a herbal drug preparation from Pelargonium sidoides</TI>
<SO>Current Medical Research Opinion</SO>
<YR>2010</YR>
<VL>26</VL>
<NO>6</NO>
<PG>1413-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-25 00:15:57 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulz V</AU>
<TI>Assessment of the success of treatment from the patient's point of view: Study of Pelargonium sidoides in acute bronchitis breaks the mold. [German]</TI>
<TO>Beurteilung des Behandlungserfolges aus Patientensicht: Studie mit Pelargonium sidoides bei akuter Bronchitis geht neue Wege</TO>
<SO>Zeitschrift für Phytotherapie</SO>
<YR>2011</YR>
<VL>32</VL>
<NO>1</NO>
<PG>21-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-24 22:35:45 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulz V</AU>
<TI>Dose finding study on the efficacy of Pelargonium sidoides extract (EPs 7630 in new tablet form) in 405 adults with acute bronchitis. [German]</TI>
<TO>Dosisfindungsstudie zur Wirksamkeit von Pelargonium-sidoides-extrakt (EPs 7630 in neuer Tablettenform) bei 405 Erwachsenen mit akuter Bronchitis</TO>
<SO>Zeitschrift für Phytotherapie</SO>
<YR>2008</YR>
<VL>29</VL>
<NO>1</NO>
<PG>37-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Matthys-2010-_x002d_-10-mg" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley" NAME="Matthys 2010 - 10 mg" YEAR="2010">
<REFERENCE MODIFIED="2013-07-16 15:53:21 +1000" MODIFIED_BY="Liz Dooley" NOTES="&lt;p&gt;3x10 mg&lt;/p&gt;" NOTES_MODIFIED="2013-07-16 15:53:21 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Anonymous</AU>
<TI>Efficacy and tolerability of Pelargonium sidoides extract EPs 7630 in patients (older than 18 years) with acute bronchitis. Study No. 701003.01.003</TI>
<SO>Biostatistical Short Report of the Interim Analysis</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matthys H, Lizogub VG, Funk P, Malek FA</AU>
<TI>Pelargonium sidoides in acute bronchitis - Health-related quality of life and patient-reported outcome in adults receiving EPs 7630 treatment</TI>
<TO>Pelargonium sidoides bei akuter Bronchitis - Gesundheitsbezogene Lebensqualitat und Therapiebeurteilung aus Patientensicht unter Behandlung mit EPs 7630</TO>
<SO>Wiener Medizinische Wochenschrift</SO>
<YR>2010</YR>
<VL>160</VL>
<NO>21-2</NO>
<PG>564-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="21170697"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20100517&lt;br&gt;IS - 1473-4877 (Electronic)&lt;br&gt;IS - 0300-7995 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;RN - 0 (EPs 7630)&lt;br&gt;RN - 0 (Placebos)&lt;br&gt;RN - 0 (Plant Extracts)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-09-07 00:38:41 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Matthys H, Lizogub VG, Malek FA, Kieser M</AU>
<TI>Efficacy and tolerability of EPs 7630 tablets in patients with acute bronchitis: a randomised, double-blind, placebo-controlled dose-finding study with a herbal drug preparation from Pelargonium sidoides</TI>
<SO>Current Medical Research Opinion</SO>
<YR>2010</YR>
<VL>26</VL>
<NO>6</NO>
<PG>1413-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Matthys-2010-_x002d_-20-mg" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley" NAME="Matthys 2010 - 20 mg" YEAR="2010">
<REFERENCE MODIFIED="2013-07-16 15:53:34 +1000" MODIFIED_BY="Liz Dooley" NOTES="&lt;p&gt;3x20 mg&lt;/p&gt;" NOTES_MODIFIED="2013-07-16 15:53:34 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Anonymous</AU>
<TI>Efficacy and tolerability of Pelargonium sidoides extract EPs 7630 in patients (older than 18 years) with acute bronchitis. Study No. 701003.01.003</TI>
<SO>Biostatistical Short Report of the Interim Analysis</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matthys H, Lizogub VG, Funk P, Malek FA</AU>
<TI>Pelargonium sidoides in acute bronchitis - Health-related quality of life and patient-reported outcome in adults receiving EPs 7630 treatment</TI>
<TO>Pelargonium sidoides bei akuter Bronchitis - Gesundheitsbezogene Lebensqualitat und Therapiebeurteilung aus Patientensicht unter Behandlung mit EPs 7630</TO>
<SO>Wiener Medizinische Wochenschrift</SO>
<YR>2010</YR>
<VL>160</VL>
<NO>21-2</NO>
<PG>564-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="21170697"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20100517&lt;br&gt;IS - 1473-4877 (Electronic)&lt;br&gt;IS - 0300-7995 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;RN - 0 (EPs 7630)&lt;br&gt;RN - 0 (Placebos)&lt;br&gt;RN - 0 (Plant Extracts)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-09-07 00:38:41 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Matthys H, Lizogub VG, Malek FA, Kieser M</AU>
<TI>Efficacy and tolerability of EPs 7630 tablets in patients with acute bronchitis: a randomised, double-blind, placebo-controlled dose-finding study with a herbal drug preparation from Pelargonium sidoides</TI>
<SO>Current Medical Research Opinion</SO>
<YR>2010</YR>
<VL>26</VL>
<NO>6</NO>
<PG>1413-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Matthys-2010-_x002d_-30-mg" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley" NAME="Matthys 2010 - 30 mg" YEAR="2010">
<REFERENCE MODIFIED="2013-07-16 15:53:49 +1000" MODIFIED_BY="Liz Dooley" NOTES="&lt;p&gt;3x30 mg&lt;/p&gt;" NOTES_MODIFIED="2013-07-16 15:53:49 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Anonymous</AU>
<TI>Efficacy and tolerability of Pelargonium sidoides extract EPs 7630 in patients (older than 18 years) with acute bronchitis. Study No. 701003.01.003</TI>
<SO>Biostatistical Short Report of the Interim Analysis</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matthys H, Lizogub VG, Funk P, Malek FA</AU>
<TI>Pelargonium sidoides in acute bronchitis - Health-related quality of life and patient-reported outcome in adults receiving EPs 7630 treatment</TI>
<TO>Pelargonium sidoides bei akuter Bronchitis - Gesundheitsbezogene Lebensqualitat und Therapiebeurteilung aus Patientensicht unter Behandlung mit EPs 7630</TO>
<SO>Wiener Medizinische Wochenschrift</SO>
<YR>2010</YR>
<VL>160</VL>
<NO>21-2</NO>
<PG>564-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="21170697"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20100517&lt;br&gt;IS - 1473-4877 (Electronic)&lt;br&gt;IS - 0300-7995 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;RN - 0 (EPs 7630)&lt;br&gt;RN - 0 (Placebos)&lt;br&gt;RN - 0 (Plant Extracts)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-09-07 00:38:41 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Matthys H, Lizogub VG, Malek FA, Kieser M</AU>
<TI>Efficacy and tolerability of EPs 7630 tablets in patients with acute bronchitis: a randomised, double-blind, placebo-controlled dose-finding study with a herbal drug preparation from Pelargonium sidoides</TI>
<SO>Current Medical Research Opinion</SO>
<YR>2010</YR>
<VL>26</VL>
<NO>6</NO>
<PG>1413-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Bachert-2005" NAME="Bachert 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;One of the reported studies has been recovered as a full, unpublished manuscript from the manufacturer&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bachert C, Schapowal A</AU>
<TI>EPs 7630 (Extract from Pelargonium sidoides) is effective in the treatment of acute maxillary sinusitis - results from two randomized double blind placebo controlled trials</TI>
<TO>EPs 7630 (Extrakt aus Pelargonium sidoides) ist wirksam in der Behandlung der akuten Sinusitis maxillaris - Ergebnisse zweier doppelblinder placebokontrollierter Studien</TO>
<SO>Kongressband Phytopharmaka Phytotherapie; S4</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bereznoj-2009" MODIFIED="2013-07-01 11:29:51 +1000" MODIFIED_BY="[Empty name]" NAME="Bereznoj 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-07-01 11:29:51 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bereznoj VV, Heger M, Iljenko LJ, Tischko FA</AU>
<TI>EPs 7630 in adults and children with acute tonsillitis [German]</TI>
<TO>EPs 7630 bei Erwachsenen und Kindern mit Angina tonsillaris</TO>
<SO>Zeitschrift für Phytotherapie</SO>
<YR>2009</YR>
<VL>30</VL>
<NO>1</NO>
<PG>6-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bereznoy-2003" MODIFIED="2013-09-06 20:07:41 +1000" MODIFIED_BY="[Empty name]" NAME="Bereznoy 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-07-15 22:51:11 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Bereznoy VV, Riley DS, Wassmer G, Heger M&lt;br&gt;Efficacy of extract of pelargonium sidoides in children with acute non-group a beta-hemolytic streptococcus tonsillopharyngitis: a randomized, double blind, placebo-controlled trial&lt;br&gt;Alternative Therapies&lt;br&gt;2003&lt;br&gt;9&lt;br&gt;5&lt;br&gt;68-79&lt;/p&gt;" NOTES_MODIFIED="2013-07-15 22:51:11 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bereznoy VV, Riley DS, Wassmer G, Heger M</AU>
<TI>Efficacy of extract of pelargonium sidoides in children with acute non-group a beta-hemolytic streptococcus tonsillopharyngitis: a randomized, double blind, placebo-controlled trial</TI>
<SO>Alternative Therapies</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>5</NO>
<PG>68-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-06 20:07:41 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Heger M, Bereznoy VV. Nicht streptokokken-bedingte Tonsillopharyngitis bei Kindern: Wirksamkeit eines Extrakts aus Pelargonium sidoides (EPs 7630) im Vergleich zu Placebo [Non streptokkokkal tonsillopharyngitis in children: efficacy of an extract of Pelargonium sidoides (EPs 7630) as compared to placebo. &lt;br&gt;Phytopharmaka VII. Darmstadt: Steinkopff, 2002: 13-25&lt;/p&gt;" NOTES_MODIFIED="2013-09-06 20:07:41 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Heger M, Bereznoy VV</AU>
<TI>Non streptococcal tonsillopharyngitis in children: efficacy of an extract of Pelargonium sidoides (EPs 7630) as compared to placebo</TI>
<TO>Nicht-streptokokkenbedingte Tonsillopharyngitis bei Kindern: Wirksamkeit eines Extraktes aus Pelargonium sidoides (EPs 7630) im Vergleich zu Placebo</TO>
<SO>Phytopharmaka</SO>
<YR>2002</YR>
<VL>7</VL>
<PG>13-25</PG>
<PB>Steinkopff</PB>
<CY>Darmstadt</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blochin-1999" NAME="Blochin 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Blochin B, Haidvogl M, Heger M. Umckaloabo vs. acetylcysteine in the treatment of acute bronchitis in children [Umckaloabo im Vergleich mit Acetylcystein bei Kindern mit akuter Bronchitis]. Der Kassenarzt 1999; 49:46-49&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blochin B, Haidvogel M, Heger M</AU>
<TI>Umckaloabo vs. acetylcysteine in the treatment of acute bronchitis in children</TI>
<TO>Umckaloabo im Vergleich mit Acetylcystein bei Kindern mit akuter Bronchitis</TO>
<SO>Der Kassenarzt</SO>
<YR>1999</YR>
<VL>49</VL>
<PG>46-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blochin-2000" MODIFIED="2013-09-06 20:07:55 +1000" MODIFIED_BY="[Empty name]" NAME="Blochin 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-09-06 20:07:55 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Blochin B, Heger M. Umckaloabo vs. symptomatische Therapie in der Behandlung der akuten Angina catarrhalis. [Umckaloabo vs. symptomatic therapy for the treatment of acute non streptococcol tonsillitis]. P&amp;#228;d 2000; 6:2-8&lt;/p&gt;" NOTES_MODIFIED="2013-09-06 20:07:55 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blochin B, Heger M</AU>
<TI>Umckaloabo vs. symptomatic therapy for the treatment of acute non streptococcal tonsillitis</TI>
<TO>Umckaloabo vs. symptomatische. Therapie in der Behandlung der akuten Angina catarrhalis</TO>
<SO>Päd</SO>
<YR>2000</YR>
<VL>6</VL>
<PG>2-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dome-1996" MODIFIED="2013-07-15 22:51:32 +1000" MODIFIED_BY="[Empty name]" NAME="Dome 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;subcohort of Haidvogl 1996&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dome L, Schuster R</AU>
<TI>Umckaloabo - a phytotherapeutic alternative for acute bronchitis in childhood?</TI>
<TO>Umckaloabo - eine phytotherapeutische Alternative bei akuter Bronchitis im Kindesalter</TO>
<SO>Ärztezeitschrift für Naturheilverfahren</SO>
<YR>1996</YR>
<VL>37</VL>
<NO>3</NO>
<PG>216-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-15 22:51:32 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Haidvogl M, Heger M. Treatment effect and safety of EPs 7630-solution in acute bronchitis in childhood: report of a multicentre observational study. Phytomedicine 2007; 14 Suppl 6:60-64.&lt;/p&gt;" NOTES_MODIFIED="2013-07-15 22:51:32 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Haidvogl M, Heger M</AU>
<TI>Treatment effect and safety of EPs 7630-solution in acute bronchitis in childhood: report of a multicentre observational study</TI>
<SO>Phytomedicine</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>Suppl 6</NO>
<PG>60-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haidvogl-1996" NAME="Haidvogl 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haidvogl M, Schuster R, Heger M</AU>
<TI>Acute bronchitis in childhood. Multicenter study on the effectiveness and safety of the phytotherapeutic preparation Umckaloabo</TI>
<TO>Akute Bronchitis im Kindesalter. Multi-zenter Studie zur Wirksamkeit und Verträglichkeit des Phytotherapeutikums Umckaloabo</TO>
<SO>Zeitschrift für Phytotherapie</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>300-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koenig-1995" MODIFIED="2013-07-01 11:31:53 +1000" MODIFIED_BY="[Empty name]" NAME="Koenig 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-07-01 11:31:53 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>König I</AU>
<TI>Natural respiratory tract therapy: from Umckaloabo drug to therapy of respiratory tract infections</TI>
<TO>Naturnahe Atemwegstherapie: von der Umckaloabo-Droge zur Therapie von Atemwegsinfekten</TO>
<SO>Therapiewoche</SO>
<YR>1995</YR>
<VL>45</VL>
<NO>19</NO>
<PG>1123-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luna-2011" MODIFIED="2013-09-06 20:09:12 +1000" MODIFIED_BY="[Empty name]" NAME="Luna 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-09-06 20:09:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Luna LA Jr, Bachi AL, Novaes e Brito RR, Eid RG, Suguri VM, Oliveira PW, et al</AU>
<TI>Immune responses induced by Pelargonium sidoides extract in serum and nasal mucosa of athletes after exhaustive exercise: modulation of secretory IgA, IL-6 and IL-15</TI>
<SO>Phytomedicine</SO>
<YR>2011</YR>
<VL>18</VL>
<NO>4</NO>
<PG>303-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="20850953"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martins-Kirk-2007" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NAME="Martins Kirk 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Martins Kirk K</AU>
<TI>Post marketing surveillance of Pelargonium sidoides for treatment of presumably viral acute community acquired tonsillopharyngitis</TI>
<TO>Vigilancia Pos-Comercializacao do Pelargonium sidoides no tratamento das tonsilofaringites comunitarias agudas de origem presumidamente viral</TO>
<SO>Revista Panamericana de Infectología</SO>
<YR>2007</YR>
<VL>9</VL>
<NO>1</NO>
<PG>15-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matthys-2003" NAME="Matthys 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matthys H, Eisebitt R, Seith B, Heger M</AU>
<TI>Efficacy and safety of an extract of Pelargonium sidoides (EPs 7630) in adults with acute bronchitis. A randomised, double-blind, placebo-controlled trial</TI>
<SO>Phytomedicine</SO>
<YR>2003</YR>
<VL>10</VL>
<NO>Suppl IV</NO>
<PG>7-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Matthys-2007b" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NAME="Matthys 2007b" YEAR="2007">
<REFERENCE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20070212&lt;br&gt;IS - 0944-7113 (Print)&lt;br&gt;IS - 0944-7113 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Multicenter Study&lt;br&gt;RN - 0 (Anti-Bacterial Agents)&lt;br&gt;RN - 0 (EPs 7630)&lt;br&gt;RN - 0 (Plant Extracts)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-09-07 00:38:41 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matthys H, Heger M</AU>
<TI>EPs 7630-solution--an effective therapeutic option in acute and exacerbating bronchitis</TI>
<SO>Phytomedicine</SO>
<YR>2007</YR>
<VL>14 Suppl 6</VL>
<PG>65-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matthys-2007c" MODIFIED="2013-09-06 20:10:27 +1000" MODIFIED_BY="[Empty name]" NAME="Matthys 2007c" YEAR="2007">
<REFERENCE MODIFIED="2013-09-06 20:10:27 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matthys H, Kamin W, Funk P, Heger M</AU>
<TI>Pelargonium sidoides preparation (EPs 7630) in the treatment of acute bronchitis in adults and children</TI>
<SO>Phytomedicine</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>Suppl 6</NO>
<PG>69-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="17184981"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matthys-2013" MODIFIED="2013-04-11 23:48:47 +1000" MODIFIED_BY="[Empty name]" NAME="Matthys 2013" YEAR="2013">
<REFERENCE MODIFIED="2013-04-11 23:48:44 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matthys H, Pliskevich DA, Bondarchuk OM, Malek FA, Tribanek M, Kieser M</AU>
<TI>Randomised, double blind, placebo-controlled trials of EPs 7673 in adults with COP</TI>
<SO>Respiratory Medicine</SO>
<YR>2013</YR>
<VL>107</VL>
<PG>691-701</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patiroglu-2012" MODIFIED="2013-09-06 20:10:42 +1000" MODIFIED_BY="[Empty name]" NAME="Patiroglu 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-09-06 20:10:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patiroglu T, Tunc A, Eke Gungor H, Unal E</AU>
<TI>The efficacy of Pelargonium sidoides in the treatment of upper respiratory tract infections in children with transient hypogammaglobulinemia of infancy</TI>
<SO>Phytomedicine</SO>
<YR>2012</YR>
<VL>19</VL>
<NO>11</NO>
<PG>958-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="22809962"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perez-2011" MODIFIED="2013-09-06 20:10:50 +1000" MODIFIED_BY="[Empty name]" NAME="Perez 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-09-06 20:10:50 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Perez G, Rodriguez N, Castro H, Silva O, Pabbou D, Maestracci F, et al</AU>
<TI>Evaluation of the effectiveness of Renikan</TI>
<TO>Extracto del Pelargonium sidoides estandarizado en el tratamiento de las infecciones de las vias respiratorias superiores de etilogia viral</TO>
<SO>Archivas Venezolanos de Farmacologia y Terapeutica</SO>
<YR>2011</YR>
<VL>30</VL>
<NO>4</NO>
<PG>79-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Roots-2004" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NAME="Roots 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Roots I, Arold G, Dienel A, Meng G, Wollny A, Bauer S</AU>
<TI>Placebo controlled double blind study of interaction of Pelargonium sidoides with penicillin in healthy volunteers</TI>
<TO>Placebokontrollierte doppelblinde Interaktionsstudie mit Pelargonium sidoides Extrakt und Penicillin V bei gesunden Probanden</TO>
<SO>Phytopharmaka und Phytotherapie - Forschung und Praxis</SO>
<YR>2004</YR>
<PG>22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schapowal-2007" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NAME="Schapowal 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schapowal A, Heger M</AU>
<TI>EPs 7630 solution (Umckaloabo) in the treatment of sinusitis. [German]</TI>
<TO>EPs 7630 losung (Umckaloabo) bei sinusitis</TO>
<SO>Zeitschrift für Phytotherapie</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>2</NO>
<PG>58-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tahan-2013" MODIFIED="2013-09-06 20:11:50 +1000" MODIFIED_BY="[Empty name]" NAME="Tahan 2013" YEAR="2013">
<REFERENCE MODIFIED="2013-09-06 20:11:50 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tahan F, Yaman M</AU>
<TI>Can the Pelargonium sidoides root extract EPs(R) 7630 prevent asthma attacks during viral infections of the upper respiratory tract in children?</TI>
<SO>Phytomedicine</SO>
<YR>2013</YR>
<VL>20</VL>
<NO>2</NO>
<PG>148-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="23142309"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-05-23 01:42:38 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Bachert-2004" MODIFIED="2013-05-14 02:42:35 +1000" MODIFIED_BY="[Empty name]" NAME="Bachert 2004" YEAR="2004">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Beck-2001" MODIFIED="2013-05-14 02:40:36 +1000" MODIFIED_BY="[Empty name]" NAME="Beck 2001" YEAR="2001">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Heger-2002" MODIFIED="2013-05-14 02:39:30 +1000" MODIFIED_BY="[Empty name]" NAME="Heger 2002" YEAR="2002">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Heger-2003" MODIFIED="2013-05-14 02:44:22 +1000" MODIFIED_BY="[Empty name]" NAME="Heger 2003" YEAR="2003">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-ISRCTN86579667" MODIFIED="2013-05-23 01:42:38 +1000" MODIFIED_BY="[Empty name]" NAME="ISRCTN86579667" YEAR="9667">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Wolf-2011" MODIFIED="2013-05-14 02:43:47 +1000" MODIFIED_BY="[Empty name]" NAME="Wolf 2011" YEAR="2011">
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2013-05-23 23:28:27 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-EUCTR2007_x002d_004923_x002d_39_x002d_DE" MODIFIED="2013-05-23 01:12:52 +1000" MODIFIED_BY="[Empty name]" NAME="EUCTR2007-004923-39-DE" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-EUCTR2007_x002d_005579_x002d_33_x002d_BG" MODIFIED="2013-05-23 00:53:22 +1000" MODIFIED_BY="[Empty name]" NAME="EUCTR2007-005579-33-BG" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-EUCTR2007_x002d_005797_x002d_31_x002d_BG" MODIFIED="2013-05-23 00:44:15 +1000" MODIFIED_BY="[Empty name]" NAME="EUCTR2007-005797-31-BG" YEAR="2013">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-EUCTR2011_x002d_002652_x002d_14_x002d_DE" MODIFIED="2013-05-23 00:19:48 +1000" MODIFIED_BY="[Empty name]" NAME="EUCTR2011-002652-14-DE" YEAR="2013">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-ISRCTN77419032" MODIFIED="2013-05-23 23:28:14 +1000" MODIFIED_BY="[Empty name]" NAME="ISRCTN77419032" YEAR="2013">
<REFERENCE MODIFIED="2013-05-22 23:45:18 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>(Schwabe Pharmaceuticals)</AU>
<TI>Safety and tolerability of Pelargonium sidoides extract EPs® 7630 in children (1 to 5 years old) suffering from acute bronchitis: a randomised controlled trial</TI>
<SO>International Clinical Trials Platform (WHO - ICTRP)</SO>
<YR>2012</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-JPRN_x002d_UMIN000003815" MODIFIED="2013-05-23 23:28:19 +1000" MODIFIED_BY="[Empty name]" NAME="JPRN-UMIN000003815" YEAR="2013">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01420445" MODIFIED="2013-05-23 23:28:27 +1000" MODIFIED_BY="[Empty name]" NAME="NCT01420445" YEAR="2013">
<REFERENCE MODIFIED="2013-05-22 23:45:21 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>(Yuhan Corporation)</AU>
<TI>Safety/Tolerability and Efficacy of YHD001 in Patients With Acute and Chronic Bronchitis</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley">
<ADDITIONAL_REFERENCES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley">
<REFERENCE ID="REF-Agbabiaka-2008" MODIFIED="2013-05-16 21:14:30 +1000" MODIFIED_BY="[Empty name]" NAME="Agbabiaka 2008" TYPE="JOURNAL_ARTICLE">
<AU>Agbabiaka TB, Guo R, Ernst E</AU>
<TI>Pelargonium sidoides for acute bronchitis: a systematic review and meta-analysis</TI>
<SO>Phytomedicine</SO>
<YR>2008</YR>
<VL>15</VL>
<NO>5</NO>
<PG>378-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ah_x002d_See-2007" MODIFIED="2013-09-06 20:12:29 +1000" MODIFIED_BY="Liz Dooley" NAME="Ah-See 2007" TYPE="JOURNAL_ARTICLE">
<AU>Ah-See KW, Evans AS</AU>
<TI>Sinusitis and its management</TI>
<SO>BMJ</SO>
<YR>2007</YR>
<VL>334</VL>
<PG>358-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-AKD_x00c4_-2011" MODIFIED="2013-05-16 21:16:18 +1000" MODIFIED_BY="[Empty name]" NAME="AKDÄ 2011" TYPE="JOURNAL_ARTICLE">
<AU>Arzneimittelkommission der deutschen Ärzteschaft</AU>
<TI>Hepatitis linked to Umckaloabo ® (from the UAW database; 29.07.2011)</TI>
<SO>Deutsches Ärzteblatt</SO>
<YR>2011</YR>
<VL>108</VL>
<PG>30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Becker-2011" MODIFIED="2013-07-01 11:26:04 +1000" MODIFIED_BY="[Empty name]" NAME="Becker 2011" TYPE="COCHRANE_REVIEW">
<AU>Becker LA, Hom J, Villasis-Keever M, van der Wouden JC</AU>
<TI>Beta2-agonists for acute bronchitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2013-07-01 11:26:04 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-01 11:25:53 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001726.pub4"/>
<IDENTIFIER MODIFIED="2013-07-01 11:26:04 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21735384"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bent-1999" MODIFIED="2013-06-20 01:32:16 +1000" MODIFIED_BY="[Empty name]" NAME="Bent 1999" TYPE="JOURNAL_ARTICLE">
<AU>Bent S, Saint S, Vittinghoff E, Grady D</AU>
<TI>Antibiotics in acute bronchitis: a meta-analysis</TI>
<SO>American Journal of Medicine</SO>
<YR>1999</YR>
<VL>107</VL>
<PG>62-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bucher-2003" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NAME="Bucher 2003" TYPE="JOURNAL_ARTICLE">
<AU>Bucher HC, Tschudi P, Young J, Périat P, Welge-Lüussen A, Züst H, et al</AU>
<TI>Effect of amoxicillin-clavulanate in clinically diagnosed acute rhinosinusitis: a placebo-controlled, double-blind, randomized trial in general practice</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2003</YR>
<VL>163</VL>
<NO>15</NO>
<PG>1793-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chalumeau-2013" MODIFIED="2013-07-01 11:37:52 +1000" MODIFIED_BY="[Empty name]" NAME="Chalumeau 2013" TYPE="COCHRANE_REVIEW">
<AU>Chalumeau M, Duijvestijn YC</AU>
<TI>Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2013-07-01 11:37:52 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-01 11:37:52 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003124.pub4"/>
<IDENTIFIER TYPE="PUBMED" VALUE="23728642"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-CKS-Guideline-2009" MODIFIED="2013-09-06 20:13:53 +1000" MODIFIED_BY="[Empty name]" NAME="CKS Guideline 2009" TYPE="OTHER">
<AU>NHS</AU>
<TI>CKS-Guideline: Sinusitis</TI>
<SO>Online document. http://cks.nice.org.uk/sinusitis#!background.</SO>
<YR>Last revised March 2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CKS-Guideline-2010" MODIFIED="2013-09-06 20:14:05 +1000" MODIFIED_BY="[Empty name]" NAME="CKS Guideline 2010" TYPE="OTHER">
<AU>NHS</AU>
<TI>CKS Guideline: Cough</TI>
<SO>Online document. http://cks.nice.org.uk/cough#!backgroundsub.</SO>
<YR>Last revised September 2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CKS-Guideline-2011" MODIFIED="2013-09-06 20:14:16 +1000" MODIFIED_BY="[Empty name]" NAME="CKS Guideline 2011" TYPE="OTHER">
<AU>NHS</AU>
<TI>CKS-Guideline: Common Cold</TI>
<SO>Online document. http://cks.nice.org.uk/common-cold#!backgroundsub:6.</SO>
<YR>Last revised November 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Conrad-2007a" MODIFIED="2013-07-01 11:38:26 +1000" MODIFIED_BY="[Empty name]" NAME="Conrad 2007a" TYPE="JOURNAL_ARTICLE">
<AU>Conrad A, Jung I, Tioua D, Lallemand C, Carrapatoso F, Engels I, et al</AU>
<TI>Extract of Pelargonium sidoides (EPs((R)) 7630) inhibits the interactions of group A-streptococci and host epithelia in vitro</TI>
<SO>Phytomedicine</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>Suppl 6</NO>
<PG>52-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Conrad-2007b" MODIFIED="2013-06-20 01:30:55 +1000" MODIFIED_BY="[Empty name]" NAME="Conrad 2007b" TYPE="JOURNAL_ARTICLE">
<AU>Conrad A, Hansmann C, Engels I, Daschner FD, Frank U</AU>
<TI>Extract of Pelargonium sidoides (EPs 7630) improves phagocytosis, oxidative burst, and intracellular killing of human peripheral blood phagocytes in vitro</TI>
<SO>Phytomedicine</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>Suppl 6</NO>
<PG>46-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Conrad-2007c" MODIFIED="2013-06-20 01:30:59 +1000" MODIFIED_BY="[Empty name]" NAME="Conrad 2007c" TYPE="JOURNAL_ARTICLE">
<AU>Conrad A, Kolodziej H, Schulz V</AU>
<TI>Pelargonium sidoides-extract (EPs((R)) 7630): registration confirms efficacy and safety</TI>
<SO>Wiener Klinische Wochenschrift</SO>
<YR>2007</YR>
<VL>157</VL>
<NO>13-14</NO>
<PG>331-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Boer-2007" MODIFIED="2013-06-20 01:31:01 +1000" MODIFIED_BY="[Empty name]" NAME="de Boer 2007" TYPE="JOURNAL_ARTICLE">
<AU>de Boer HJ, Hagemann U, Bate J, Meyboom RH</AU>
<TI>Allergic reactions to medicines derived from pelargonium species</TI>
<SO>Drug Safety</SO>
<YR>2007</YR>
<VL>30</VL>
<NO>8</NO>
<PG>677-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EMA-2012" MODIFIED="2013-05-16 21:22:11 +1000" MODIFIED_BY="[Empty name]" NAME="EMA 2012" TYPE="OTHER">
<AU>European Medicines Agency (EMA). Committee on Herbal Medicinal Products (HMPC)</AU>
<TI>Assessment report on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix. 20 November 2012, EMA/HMPC/560962/2010</TI>
<SO>www.ema.europa.eu</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fahey-1998" MODIFIED="2013-09-06 20:15:18 +1000" MODIFIED_BY="Liz Dooley" NAME="Fahey 1998" TYPE="JOURNAL_ARTICLE">
<AU>Fahey T, Stocks N, Thomas T</AU>
<TI>Quantitative systematic review of randomised controlled trials comparing antibiotic with placebo for acute cough in adults</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>316</VL>
<PG>906-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fintelmann-2012" MODIFIED="2013-07-15 22:54:08 +1000" MODIFIED_BY="[Empty name]" NAME="Fintelmann 2012" TYPE="JOURNAL_ARTICLE">
<AU>Fintelmann V, Albrecht U, Schmitz G, Schnitker J</AU>
<TI>Efficacy and safety of a combination herbal medicinal product containing Tropaeoli majoris herba and Armoraciae rusticanae radix for the prophylactic treatment of patients with respiratory tract diseases: a randomised, prospective, double-blind, placebo-controlled phase III trial</TI>
<SO>Current Medical Research Opinion</SO>
<YR>2012</YR>
<VL>28</VL>
<PG>1799-807</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gonzales-2000" MODIFIED="2013-06-20 01:32:06 +1000" MODIFIED_BY="[Empty name]" NAME="Gonzales 2000" TYPE="JOURNAL_ARTICLE">
<AU>Gonzales R, Sande MA</AU>
<TI>Uncomplicated acute bronchitis</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2000</YR>
<VL>133</VL>
<PG>981-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gonzales-2001" MODIFIED="2013-09-06 20:15:41 +1000" MODIFIED_BY="Liz Dooley" NAME="Gonzales 2001" TYPE="JOURNAL_ARTICLE">
<AU>Gonzales R, Bartlett JG, Besser RE, Cooper RJ, Hickner JM, Hoffman JR, et al</AU>
<TI>Principles of appropriate antibiotic use for treatment of acute respiratory tract infections in adults: background, specific aims, and methods</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>37</VL>
<NO>6</NO>
<PG>690-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goos-2006" MODIFIED="2013-06-20 01:31:53 +1000" MODIFIED_BY="[Empty name]" NAME="Goos 2006" TYPE="JOURNAL_ARTICLE">
<AU>Goos KH, Albrecht U, Schneider B</AU>
<TI>Efficacy and safety profile of a herbal drug containing nasturtium herb and horseradish root in acute sinusitis, acute bronchitis and acute urinary tract infection in comparison with other treatments in the daily practice/results of a prospective cohort study</TI>
<SO>Arzneimittelforschung</SO>
<YR>2006</YR>
<VL>56</VL>
<NO>3</NO>
<PG>249-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goos-2007" MODIFIED="2013-06-20 01:31:56 +1000" MODIFIED_BY="[Empty name]" NAME="Goos 2007" TYPE="JOURNAL_ARTICLE">
<AU>Goos KH, Albrecht U, Schneider B</AU>
<TI>On-going investigations on efficacy and safety profile of a herbal drug containing nasturtium herb and horseradish root in acute sinusitis, acute bronchitis and acute urinary tract infection in children in comparison with other antibiotic treatments</TI>
<SO>Arzneimittelforschung</SO>
<YR>2007</YR>
<VL>57</VL>
<NO>4</NO>
<PG>238-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gruenwald-2005" MODIFIED="2013-06-20 01:31:58 +1000" MODIFIED_BY="[Empty name]" NAME="Gruenwald 2005" TYPE="JOURNAL_ARTICLE">
<AU>Gruenwald J, Graubaum HJ, Busch R</AU>
<TI>Efficacy and tolerability of a fixed combination of thyme and primrose root in patients with acute bronchitis. A double-blind, randomized, placebo-controlled clinical trial</TI>
<SO>Arzneimittelforschung</SO>
<YR>2005</YR>
<VL>55</VL>
<NO>11</NO>
<PG>669-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-09-06 20:17:45 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<PB>Wiley-Blackwell</PB>
<CY>Chichester</CY>
<IDENTIFIERS MODIFIED="2013-09-06 20:17:17 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Jiang-2012" MODIFIED="2013-07-01 11:41:37 +1000" MODIFIED_BY="[Empty name]" NAME="Jiang 2012" TYPE="COCHRANE_REVIEW">
<AU>Jiang L, Li K, Wu T</AU>
<TI>Chinese medicinal herbs for acute bronchitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-07-01 11:41:37 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-01 11:41:37 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004560.pub4"/>
<IDENTIFIER TYPE="PUBMED" VALUE="22336804"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kayser-1997" NAME="Kayser 1997" TYPE="JOURNAL_ARTICLE">
<AU>Kayser O, Kolodziej H</AU>
<TI>Antibacterial activity of extracts and constituents of Pelargonium sidoides and Pelargonium reniforme</TI>
<SO>Planta Medica</SO>
<YR>1997</YR>
<VL>63</VL>
<NO>6</NO>
<PG>508-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kayser-2001" NAME="Kayser 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kayser O, Kolodziej H, Kiderlen AF</AU>
<TI>Immunomodulatory principles of Pelargonium sidoides</TI>
<SO>Phytotherapy Research</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>2</NO>
<PG>122-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kemmerich-2006" MODIFIED="2013-07-01 11:41:59 +1000" MODIFIED_BY="[Empty name]" NAME="Kemmerich 2006" TYPE="JOURNAL_ARTICLE">
<AU>Kemmerich B, Eberhardt R, Stammer H</AU>
<TI>Efficacy and tolerability of a fluid extract combination of thyme herb and ivy leaves and matched placebo in adults suffering from acute bronchitis with productive cough. A prospective, double-blind, placebo-controlled clinical trial</TI>
<SO>Arzneimittelforschung</SO>
<YR>2006</YR>
<VL>56</VL>
<PG>652-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kemmerich-2007" MODIFIED="2013-06-20 00:45:18 +1000" MODIFIED_BY="[Empty name]" NAME="Kemmerich 2007" TYPE="JOURNAL_ARTICLE">
<AU>Kemmerich B</AU>
<TI>Evaluation of efficacy and tolerability of a fixed combination of dry extracts of thyme herb and primrose root in adults suffering from acute bronchitis with productive cough. A prospective, double-blind, placebo-controlled multicenter clinical trial</TI>
<SO>Arzneimittelforschung</SO>
<YR>2007</YR>
<VL>57</VL>
<PG>607-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kenealy-2013" MODIFIED="2013-07-01 11:43:13 +1000" MODIFIED_BY="[Empty name]" NAME="Kenealy 2013" TYPE="COCHRANE_REVIEW">
<AU>Kenealy T, Arroll B</AU>
<TI>Antibiotics for the common cold and acute purulent rhinitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2013-07-01 11:43:13 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-01 11:43:13 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000247.pub3"/>
<IDENTIFIER TYPE="PUBMED" VALUE="23733381"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kolodziej-2003" NAME="Kolodziej 2003" TYPE="JOURNAL_ARTICLE">
<AU>Kolodziej H, Kayser O, Radtke OA, Kiderlen AF, Koch E</AU>
<TI>Pharmacological profile of extracts of Pelargonium sidoides and their constituents</TI>
<SO>Phytomedicine</SO>
<YR>2003</YR>
<VL>10</VL>
<NO>Suppl 4</NO>
<PG>18-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kolodziej-2007" MODIFIED="2013-06-20 01:32:40 +1000" MODIFIED_BY="[Empty name]" NAME="Kolodziej 2007" TYPE="JOURNAL_ARTICLE">
<AU>Kolodziej H, Kiderlen AF</AU>
<TI>In vitro evaluation of antibacterial and immunomodulatory activities of Pelargonium reniforme, Pelargonium sidoides and the related herbal drug preparation EPs 7630</TI>
<SO>Phytomedicine</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>Suppl 6</NO>
<PG>18-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Latte-2000" MODIFIED="2013-09-06 20:18:46 +1000" MODIFIED_BY="[Empty name]" NAME="Latte 2000" TYPE="JOURNAL_ARTICLE">
<AU>Latte KP, Kayser O, Tan N, Kaloga M, Kolodziej H</AU>
<TI>Unusual coumarin patterns of Pelargonium species forming the origin of the traditional herbal medicine Umckaloabo</TI>
<SO>Zeitschrift für Naturforschung</SO>
<YR>2000</YR>
<VL>55c</VL>
<PG>528-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lemiengre-2012" MODIFIED="2013-06-14 18:08:23 +1000" MODIFIED_BY="[Empty name]" NAME="Lemiengre 2012" TYPE="COCHRANE_REVIEW">
<AU>Lemiengre MB, van Driel ML, Merenstein D, Young J, De Sutter AIM</AU>
<TI>Antibiotics for clinically diagnosed acute rhinosinusitis in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2013-06-14 18:07:41 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-14 18:07:41 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006089.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Linde-2008" MODIFIED="2013-07-01 11:22:14 +1000" MODIFIED_BY="[Empty name]" NAME="Linde 2008" TYPE="COCHRANE_REVIEW">
<AU>Linde K, Barrett B, Bauer R, Melchart D, Woelkart K</AU>
<TI>Echinacea for preventing and treating the common cold</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2013-07-01 11:22:14 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-01 11:20:08 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000530.pub2"/>
<IDENTIFIER MODIFIED="2013-07-01 11:22:14 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16437427"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Linder-2003" MODIFIED="2013-06-20 01:33:05 +1000" MODIFIED_BY="[Empty name]" NAME="Linder 2003" TYPE="JOURNAL_ARTICLE">
<AU>Linder JA, Singer DE, Ancker M, Atlas SJ</AU>
<TI>Measures of health-related quality of life for adults with acute sinusitis. A systematic review</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>2003</YR>
<VL>18</VL>
<PG>390-401</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Little-2013" MODIFIED="2013-07-01 11:44:01 +1000" MODIFIED_BY="[Empty name]" NAME="Little 2013" TYPE="JOURNAL_ARTICLE">
<AU>Little P, Stuart B, Moore M, Coenen S, Butler CC, Godycki-Cwirko M, et al</AU>
<TI>Amoxicillin for acute lower-respiratory-tract infection in primary care when pneumonia is not suspected: a 12-country, randomised, placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>2013</YR>
<VL>13</VL>
<NO>2</NO>
<PG>123-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Masood-2007" MODIFIED="2013-06-20 01:33:21 +1000" MODIFIED_BY="[Empty name]" NAME="Masood 2007" TYPE="JOURNAL_ARTICLE">
<AU>Masood A, Moumoulidis I, Panesar J</AU>
<TI>Acute rhinosinusitis in adults: an update on current management</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>2007</YR>
<VL>83</VL>
<NO>980</NO>
<PG>402-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2008" MODIFIED="2013-07-15 22:54:32 +1000" MODIFIED_BY="[Empty name]" NAME="Moore 2008" TYPE="JOURNAL_ARTICLE">
<AU>Moore M, Little P, Rumsby K, Kelly J, Watson L, Warner G, et al</AU>
<TI>Predicting the duration of symptoms in lower respiratory tract infection</TI>
<SO>British Journal of General Practice</SO>
<YR>2000</YR>
<VL>58</VL>
<NO>547</NO>
<PG>88-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nahas-2011" MODIFIED="2013-07-15 22:54:40 +1000" MODIFIED_BY="[Empty name]" NAME="Nahas 2011" TYPE="JOURNAL_ARTICLE">
<AU>Nahas R, Balla A</AU>
<TI>Complementary and alternative medicine for prevention and treatment of the common cold</TI>
<SO>Canadian Family Physician</SO>
<YR>2011</YR>
<VL>57</VL>
<NO>1</NO>
<PG>31-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Neugebauer-2005" MODIFIED="2008-03-14 05:25:21 +1000" MODIFIED_BY="Jenny Bellorini" NAME="Neugebauer 2005" TYPE="JOURNAL_ARTICLE">
<AU>Neugebauer P, Mickenhagen A, Siefer O, Walger M</AU>
<TI>A new approach to pharmacological effects on ciliary beat frequency in cell cultures - exemplary measurements under Pelargonium sidoides extract (EPs 7630)</TI>
<SO>Phytomedicine</SO>
<YR>2005</YR>
<VL>12</VL>
<NO>1-2</NO>
<PG>46-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poole-2012" MODIFIED="2013-07-01 14:25:50 +1000" MODIFIED_BY="[Empty name]" NAME="Poole 2012" TYPE="COCHRANE_REVIEW">
<AU>Poole PJ, Black PN, Cates CJ</AU>
<TI>Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2008-02-22 15:23:23 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-02-22 15:23:23 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001287.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Posadzki-2013" MODIFIED="2013-07-15 22:54:50 +1000" MODIFIED_BY="[Empty name]" NAME="Posadzki 2013" TYPE="JOURNAL_ARTICLE">
<AU>Posadzki P, Watson LK, Ernst E</AU>
<TI>Adverse effects of herbal medicines: an overview of systematic reviews</TI>
<SO>Clinical Medicine</SO>
<YR>2013</YR>
<VL>13</VL>
<PG>7-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reveiz-2013" MODIFIED="2013-07-01 14:27:41 +1000" MODIFIED_BY="[Empty name]" NAME="Reveiz 2013" TYPE="COCHRANE_REVIEW">
<AU>Reveiz L, Cardona AF</AU>
<TI>Antibiotics for acute laryngitis in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2013-07-01 14:27:41 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-01 14:27:41 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004783.pub4"/>
<IDENTIFIER TYPE="PUBMED" VALUE="23543536"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2013-07-01 15:35:33 +1000" MODIFIED_BY="[Empty name]" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-2003" MODIFIED="2013-06-20 01:33:50 +1000" MODIFIED_BY="[Empty name]" NAME="Schulz 2003" NOTES="&lt;p&gt;contains information on unpublished studies&lt;/p&gt;" NOTES_MODIFIED="2013-06-20 01:33:50 +1000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Schulz V, Kolodziej H</AU>
<TI>Umckaloabo</TI>
<SO>Deutsche Apotheker-Zeitung</SO>
<YR>2003</YR>
<VL>143</VL>
<NO>12</NO>
<PG>55-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shah-2007" MODIFIED="2013-06-20 01:34:00 +1000" MODIFIED_BY="[Empty name]" NAME="Shah 2007" TYPE="JOURNAL_ARTICLE">
<AU>Shah SA, Sander S, White CM, Rinaldi M, Coleman CI</AU>
<TI>Evaluation of echinacea for the prevention and treatment of the common cold: a meta-analysis</TI>
<SO>Lancet Infectious Diseases</SO>
<YR>2007</YR>
<VL>7</VL>
<NO>9</NO>
<PG>580</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-2011" MODIFIED="2013-07-01 11:21:18 +1000" MODIFIED_BY="[Empty name]" NAME="Smith 2011" TYPE="COCHRANE_REVIEW">
<AU>Smith SM, Fahey T, Smucny J, Becker LA</AU>
<TI>Antibiotics for acute bronchitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2013-07-01 11:20:53 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-01 11:20:53 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000245.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Smith-2012" MODIFIED="2013-07-01 14:28:58 +1000" MODIFIED_BY="[Empty name]" NAME="Smith 2012" TYPE="COCHRANE_REVIEW">
<AU>Smith SM, Schroeder K, Fahey T</AU>
<TI>Over-the-counter (OTC) medications for acute cough in children and adults in ambulatory settings</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2013-07-01 14:28:58 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-01 14:28:58 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001831.pub4"/>
<IDENTIFIER TYPE="PUBMED" VALUE="22895922"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Taylor-2005" MODIFIED="2013-09-06 20:19:55 +1000" MODIFIED_BY="[Empty name]" NAME="Taylor 2005" TYPE="JOURNAL_ARTICLE">
<AU>Taylor P, Maalim S, Coleman S</AU>
<TI>The strange story of Umckaloabo</TI>
<SO>Pharmaceutical Journal</SO>
<YR>2005</YR>
<VL>275</VL>
<NO>24</NO>
<PG>790-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Teschke-2012a" MODIFIED="2013-07-01 14:29:40 +1000" MODIFIED_BY="[Empty name]" NAME="Teschke 2012a" TYPE="JOURNAL_ARTICLE">
<AU>Teschke R, Frenzel C, Wolff A, Herzog J, Glass X, Schulze J, et al</AU>
<TI>Initially purported hepatotoxicity by Pelargonium sidoides: the dilemma of pharmacovigilance and proposals for improvement</TI>
<SO>Annals of Hepatology</SO>
<YR>2012</YR>
<VL>11</VL>
<NO>4</NO>
<PG>500-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="22700632"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Teschke-2012b" MODIFIED="2013-07-01 14:29:58 +1000" MODIFIED_BY="[Empty name]" NAME="Teschke 2012b" TYPE="JOURNAL_ARTICLE">
<AU>Teschke R, Frenzel C, Schulze J, Eickhoff A</AU>
<TI>Spontaneous reports of primarily suspected herbal hepatotoxicity by Pelargonium sidoides: was causality adequately ascertained?</TI>
<SO>Regulatory Toxicology and Pharmacology</SO>
<YR>2012</YR>
<VL>63</VL>
<NO>1</NO>
<PG>1-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="22381150"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ulbricht-2010" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NAME="Ulbricht 2010" TYPE="JOURNAL_ARTICLE">
<AU>Ulbricht C, Abrams TR, Conquer J, Costa D, Serrano JM, Lovin R, et al</AU>
<TI>An evidence-based systematic review of Umckaloabo (Pelargonium sidoides) by the Natural Standard Research Collaboration</TI>
<SO>Journal of Dietary Supplements</SO>
<YR>2010</YR>
<VL>7</VL>
<PG>283-302</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Venekamp-2011" MODIFIED="2013-07-01 11:29:10 +1000" MODIFIED_BY="[Empty name]" NAME="Venekamp 2011" TYPE="COCHRANE_REVIEW">
<AU>Venekamp RP, Thompson MJ, Hayward G, Heneghan CJ, Del Mar CB, Perera R, et al</AU>
<TI>Systemic corticosteroids for acute sinusitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2013-07-01 11:29:10 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-01 11:29:10 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008115.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Venekamp-2012" MODIFIED="2013-09-06 20:20:39 +1000" MODIFIED_BY="[Empty name]" NAME="Venekamp 2012" TYPE="JOURNAL_ARTICLE">
<AU>Venekamp RP, Bonten MJ, Rovers MM, Verheij TJ, Sachs AP</AU>
<TI>Systemic corticosteroid monotherapy for clinically diagnosed acute rhinosinusitis: a randomized controlled trial</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>2012</YR>
<VL>184</VL>
<NO>14</NO>
<PG>E751-7</PG>
<IDENTIFIERS MODIFIED="2013-06-14 18:06:12 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-14 18:06:12 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1503/cmaj.120430"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Venekamp-2013" MODIFIED="2013-07-01 14:32:06 +1000" MODIFIED_BY="[Empty name]" NAME="Venekamp 2013" TYPE="COCHRANE_REVIEW">
<AU>Venekamp RP, Sanders S, Glasziou PP, Del Mar CB, Rovers MM</AU>
<TI>Antibiotics for acute otitis media in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-07-01 14:32:06 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-01 14:32:06 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000219.pub3"/>
<IDENTIFIER TYPE="PUBMED" VALUE="23440776"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wenzel-2006" MODIFIED="2013-07-01 14:32:17 +1000" MODIFIED_BY="[Empty name]" NAME="Wenzel 2006" TYPE="JOURNAL_ARTICLE">
<AU>Wenzel RP, Fowler AA</AU>
<TI>Acute bronchitis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>355</VL>
<PG>2125-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Williamson-2007" MODIFIED="2013-07-01 14:32:29 +1000" MODIFIED_BY="[Empty name]" NAME="Williamson 2007" TYPE="JOURNAL_ARTICLE">
<AU>Williamson IG, Rumsby K, Benge S, Moore M, Smith PW, Cross M, et al</AU>
<TI>Antibiotics and topical nasal steroid for treatment of acute maxillary sinusitis: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2007</YR>
<VL>298</VL>
<NO>21</NO>
<PG>2487-96</PG>
<IDENTIFIERS MODIFIED="2013-05-16 21:50:05 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-16 21:50:05 +1000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="PubMed PMID: 18056902."/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zabolotnyi-2007" MODIFIED="2013-07-01 14:32:39 +1000" MODIFIED_BY="[Empty name]" NAME="Zabolotnyi 2007" TYPE="JOURNAL_ARTICLE">
<AU>Zabolotnyi DI, Kneis KC, Richardson A, Rettenberger R, Heger M, Kaszkin-Bettag M, et al</AU>
<TI>Efficacy of a complex homeopathic medication (Sinfrontal) in patients with acute maxillary sinusitis: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial</TI>
<SO>Explore (NY)</SO>
<YR>2007</YR>
<VL>3</VL>
<NO>2</NO>
<PG>98-109</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zimmermann-1965" MODIFIED="2013-09-06 20:22:24 +1000" MODIFIED_BY="[Empty name]" NAME="Zimmermann 1965" TYPE="JOURNAL_ARTICLE">
<AU>Zimmermann W</AU>
<TI>On the anticoagulant properties of the Umckaloabo drug</TI>
<TO>Über die gerinnungshemmende Wirkung der Umckaloabo Droge</TO>
<SO>Ärztliche Forschung</SO>
<YR>1965</YR>
<VL>19</VL>
<NO>5</NO>
<PG>278-80</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-07-01 11:26:54 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Timmer-2008" MODIFIED="2013-07-01 11:26:54 +1000" MODIFIED_BY="[Empty name]" NAME="Timmer 2008" TYPE="COCHRANE_REVIEW">
<AU>Timmer A, Gunther J, Rucker G, Motschall E, Antes G, Kern WV</AU>
<TI>Pelargonium sidoides extract for acute respiratory tract infections</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2013-07-01 11:26:54 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-01 11:26:54 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006323.pub2"/>
<IDENTIFIER MODIFIED="2013-07-01 11:26:11 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18646148"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2013-06-20 01:22:34 +1000" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-10-02 07:43:14 +1000" MODIFIED_BY="Liz Dooley">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-10-02 07:43:14 +1000" MODIFIED_BY="Liz Dooley" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Bachert-2009">
<CHAR_METHODS MODIFIED="2013-07-01 16:40:12 +1000" MODIFIED_BY="[Empty name]">
<P>RCT, double-blind, multi-center</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-26 02:41:21 +1000" MODIFIED_BY="[Empty name]">
<P>103 adults, acute bacterial sinusitis, diagnosis confirmed by radiography<BR/>Setting: ENT clinics and outpatient departments, Ukraine</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-30 15:37:38 +1000" MODIFIED_BY="Liz Dooley">
<P>
<I>P. sidoides</I> (alcoholic root extract) 3 x 60 drops versus placebo for 21 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-03-24 10:41:06 +1000" MODIFIED_BY="[Empty name]">
<P>Primary: difference in symptom score change at day 7<BR/>Secondary: change in individual symptom severity at day 7 and 21. Quality of life measures, physician assessment (IMOS). Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Details on blocking/treatment assignment clarified by investigator; missing data supplied by investigator<BR/>Quality assessment: Grade B (moderate risk of bias)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Chuchalin-2005">
<CHAR_METHODS MODIFIED="2013-07-01 16:40:36 +1000" MODIFIED_BY="[Empty name]">
<P>RCT, double-blind, multi-center</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-21 23:13:16 +1000" MODIFIED_BY="[Empty name]">
<P>124 adults, acute bronchitis, &lt; 48 hours past onset<BR/>Setting: GP practices, Russia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-30 15:37:40 +1000" MODIFIED_BY="Liz Dooley">
<P>
<I>P. sidoides</I> (alcoholic root extract) 3 x 30 drops versus placebo for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Primary: difference in symptom score change at day 7<BR/>Secondary: change in individual symptom severity. Patient satisfaction (IMPSS), physician assessment (IMOS). Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-01 14:46:41 +1000" MODIFIED_BY="[Empty name]">
<P>Details on treatment assignment clarified by investigator; missing data supplied by investigator</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-01 16:24:58 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Kamin-2010a">
<CHAR_METHODS MODIFIED="2013-07-01 16:24:58 +1000" MODIFIED_BY="[Empty name]">
<P>RCT, double-blind, multi-center</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-26 02:53:45 +1000" MODIFIED_BY="[Empty name]">
<P>200 children (1 to 18 years), acute bronchitis, &lt; 48 hours past onset<BR/>Setting: in- and outpatient departments, Russia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-30 15:37:12 +1000" MODIFIED_BY="Liz Dooley">
<P>
<I>P. sidoides</I> (alcoholic root extract) 3 x 10 to 30 drops (depending on age of child) versus placebo for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-03-24 10:41:04 +1000" MODIFIED_BY="[Empty name]">
<P>Primary: difference in symptom score change at day 7<BR/>Secondary: change in individual symptom severity. Patient satisfaction (IMPSS), physician assessment (IMOS). Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-01 14:47:32 +1000" MODIFIED_BY="[Empty name]">
<P>Unvalidated score used for reporting, additional information supplied (assumes score = 0 for absence of symptoms). Interim report was provided for 2008 version of review by the investigator (Schwabe Pharmaceuticals). Full paper published preceding current update</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Kamin-2010b">
<CHAR_METHODS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Dose-finding RCT (3 treatment arms), double-blind, multi-center</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-21 23:13:39 +1000" MODIFIED_BY="[Empty name]">
<P>405 children (6 to 18 years), acute bronchitis, &lt; 48 hours past onset<BR/>Setting: in- and outpatient departments, Ukraine</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-26 02:38:00 +1000" MODIFIED_BY="Liz Dooley">
<P>
<I>P. sidoides</I> 3 x 10/20/30 mg tablets versus placebo for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-03-24 10:41:04 +1000" MODIFIED_BY="[Empty name]">
<P>Primary: difference in symptom score change at day 7<BR/>Secondary: change in individual symptom severity. Patient satisfaction (IMPSS), physician assessment (IMOS). Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-26 02:34:47 +1000" MODIFIED_BY="[Empty name]">
<P>Interim report was provided for 2008 version of review by the investigator (Schwabe Pharmaceuticals). Full paper published preceding current update. For analysis, this study is divided into 3 parts (1 treatment arm, 1/3 of control numbers and control events)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Kamin-2010b-_x002d_-10-mg">
<CHAR_METHODS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Dose-finding RCT (first of 3 treatment arms), double-blind, multi-center</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children (6 to 18 years), acute bronchitis, &lt; 48 hours past onset<BR/>Setting: in- and outpatient departments, Ukraine</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-30 15:37:19 +1000" MODIFIED_BY="Liz Dooley">
<P>
<I>P. sidoides</I> 3 x 10 mg tablets versus placebo for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-03-24 10:41:05 +1000" MODIFIED_BY="[Empty name]">
<P>Primary: difference in symptom score change at day 7<BR/>Secondary: change in individual symptom severity. Patient satisfaction (IMPSS), physician assessment (IMOS). Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-26 02:36:00 +1000" MODIFIED_BY="[Empty name]">
<P>Interim report was provided for 2008 version of review by the investigator (Schwabe Pharmaceuticals). Full paper published preceding current update. For analysis, this study is divided into 3 parts (1 treatment arm, 1/3 of control numbers and control events). This trial is part of Kamin 2010, representing 1 treatment arm and 1/3 each of the number of control events and the number of controls (see methods)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Kamin-2010b-_x002d_-20-mg">
<CHAR_METHODS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Dose-finding RCT (second of 3 treatment arms), double-blind, multi-center</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-02-22 15:41:15 +1000" MODIFIED_BY="[Empty name]">
<P>Children (6 to 18 years), acute bronchitis, &lt; 48 hours past onset<BR/>Setting: in- and outpatient departments, Ukraine</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-30 15:37:21 +1000" MODIFIED_BY="Liz Dooley">
<P>
<I>P. sidoides</I> 3 x 20 mg tablets versus placebo for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-03-24 10:41:05 +1000" MODIFIED_BY="[Empty name]">
<P>Primary: difference in symptom score change at day 7<BR/>Secondary: change in individual symptom severity. Patient satisfaction (IMPSS), physician assessment (IMOS). Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-01 14:50:07 +1000" MODIFIED_BY="[Empty name]">
<P>Interim report was provided for 2008 version of review by the investigator (Schwabe Pharmaceuticals). Full paper published preceding current update. For analysis, this study is divided into 3 parts (1 treatment arm, 1/3 of control numbers and control events). This trial is part of Kamin 2010, representing 1 treatment arm and 1/3 each of the number of control events and the number of controls (see Methods)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Kamin-2010b-_x002d_-30-mg">
<CHAR_METHODS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Dose-finding RCT (third of 3 treatment arms), double-blind, multi-center</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children (6 to 18 years), acute bronchitis, &lt; 48 hours past onset<BR/>Setting: in- and outpatient departments, Ukraine</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-30 15:37:24 +1000" MODIFIED_BY="Liz Dooley">
<P>
<I>P. sidoides</I> 3 x 30 mg tablets versus placebo for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Primary: difference in symptom score change at day 7<BR/>Secondary: change in individual symptom severity. Patient satisfaction (IMPSS), physician assessment (IMOS). Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-01 14:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>Interim report was provided for 2008 version of review by the investigator (Schwabe Pharmaceuticals). Full paper published preceding current update. For analysis, this study is divided into 3 parts (1 treatment arm, 1/3 of control numbers and control events). This trial is part of Kamin 2010, representing 1 treatment arm and 1/3 each of the number of control events and the number of controls (see Methods)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Kamin-2012">
<CHAR_METHODS MODIFIED="2013-07-01 14:50:34 +1000" MODIFIED_BY="[Empty name]">
<P>RCT, double-blind, multi-center</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-16 06:10:24 +1000" MODIFIED_BY="[Empty name]">
<P>220 children (1 to 18 years), acute bronchitis, &lt; 48 hours past onset<BR/>Setting: in- and outpatient departments, Ukraine</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-30 15:37:35 +1000" MODIFIED_BY="Liz Dooley">
<P>
<I>P. sidoides</I> (alcoholic root extract) 3 x 10 to 30 drops (depending on age of child) versus placebo for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-03-24 10:41:06 +1000" MODIFIED_BY="[Empty name]">
<P>Primary: difference in symptom score change at day 7<BR/>Secondary: change in individual symptom severity. Patient satisfaction (IMPSS), physician assessment (IMOS). Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Interim report was provided for 2008 version of review by the investigator (Schwabe Pharmaceuticals). Full paper published preceding current update</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-01 14:51:21 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Lizogub-2007">
<CHAR_METHODS MODIFIED="2013-07-01 14:51:21 +1000" MODIFIED_BY="[Empty name]">
<P>RCT, double-blind, multi-center</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-16 06:18:40 +1000" MODIFIED_BY="[Empty name]">
<P>103 adults (18 to 55 years), common cold, 24 to 48 hours past onset<BR/>Setting: in- and outpatient departments, practices, Ukraine</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-30 15:37:43 +1000" MODIFIED_BY="Liz Dooley">
<P>
<I>P. sidoides</I> (alcoholic root extract) 3 x 30 drops versus placebo for 10 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-01 14:45:10 +1000" MODIFIED_BY="[Empty name]">
<P>Primary: sum of symptom severity differences of cold intensity score day 1 to 5<BR/>Secondary: complete resolution; change in individual symptom severity. Patient satisfaction (IMPSS), physician assessment (IMOS). Days off work. Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-16 06:19:41 +1000" MODIFIED_BY="Antje Timmer">
<P>Missing data supplied by investigator (2009 version, low dose only). High dose results not published (requested for 2013 version)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-01 14:51:45 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Matthys-2007a">
<CHAR_METHODS MODIFIED="2013-07-01 14:51:37 +1000" MODIFIED_BY="[Empty name]">
<P>RCT, double-blind, multi-center</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-26 02:18:33 +1000" MODIFIED_BY="[Empty name]">
<P>217 adults, acute bronchitis, &lt; 48 hours past onset<BR/>Setting: outpatient departments, Russia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-30 15:37:47 +1000" MODIFIED_BY="Liz Dooley">
<P>
<I>P. sidoides</I> (alcoholic root extract) 3 x 30 drops versus placebo for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-03-24 10:41:06 +1000" MODIFIED_BY="[Empty name]">
<P>Primary: difference in symptom score change at day 7<BR/>Secondary: change in individual symptom severity. Patient satisfaction (IMPSS), physician assessment (IMOS). Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-01 14:51:45 +1000" MODIFIED_BY="[Empty name]">
<P>Details on treatment assignment clarified by investigator; missing data supplied by investigator</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Matthys-2010">
<CHAR_METHODS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Dose-finding RCT (3 treatment arms), double-blind, multi-center</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-21 23:14:33 +1000" MODIFIED_BY="[Empty name]">
<P>399 adults, acute bronchitis, &lt; 48 hours past onset<BR/>Setting: in- and outpatient departments, Ukraine</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-30 15:37:26 +1000" MODIFIED_BY="Liz Dooley">
<P>
<I>P. sidoides</I> 3 x 10/20/30 mg tablets versus placebo for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Primary: difference in symptom score change at day 7<BR/>Secondary: change in individual symptom severity. Patient satisfaction (IMPSS), physician assessment (IMOS). Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-27 20:47:23 +1000" MODIFIED_BY="[Empty name]">
<P>Interim report was provided for 2008 version of review by the investigator (Schwabe Pharmaceuticals). Full paper published preceding current update. For analysis, this study is divided into 3 parts (1 treatment arm, 1/3 of control numbers and control events)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Matthys-2010-_x002d_-10-mg">
<CHAR_METHODS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Dose-finding RCT (first of 3 treatment arms), double-blind, multi-center</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults, acute bronchitis, &lt; 48 hours past onset<BR/>Setting: in- and outpatient departments, Ukraine</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-30 15:37:28 +1000" MODIFIED_BY="Liz Dooley">
<P>
<I>P. sidoides</I> 3 x 10 mg tablets versus placebo for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-03-24 10:41:05 +1000" MODIFIED_BY="[Empty name]">
<P>Primary: difference in symptom score change at day 7<BR/>Secondary: change in individual symptom severity. Patient satisfaction (IMPSS), physician assessment (IMOS). Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Interim report was provided for 2008 version of review by the investigator (Schwabe Pharmaceuticals). Full paper published preceding current update. For analysis, this study is divided into 3 parts (1 treatment arm, 1/3 of control numbers and control events). This trial is part of Matthys 2010, representing 1 treatment arm and 1/3 each of the number of control events and the number of controls (see Methods)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Matthys-2010-_x002d_-20-mg">
<CHAR_METHODS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Dose-finding RCT (second of 3 treatment arms), double-blind, multi-center</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults, acute bronchitis, &lt; 48 hours past onset<BR/>Setting: in- and outpatient departments, Ukraine</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-30 15:37:30 +1000" MODIFIED_BY="Liz Dooley">
<P>
<I>P. sidoides</I> 3 x 20 mg tablets versus placebo for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Primary: difference in symptom score change at day 7<BR/>Secondary: change in individual symptom severity. Patient satisfaction (IMPSS), physician assessment (IMOS). Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-01 14:52:58 +1000" MODIFIED_BY="[Empty name]">
<P>Interim report was provided for 2008 version of review by the investigator (Schwabe Pharmaceuticals). Full paper published preceding current update. For analysis, this study is divided into 3 parts (1 treatment arm, 1/3 of control numbers and control events). This trial is part of Matthys 2010, representing 1 treatment arm and 1/3 each of the number of control events and the number of controls (see Methods)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Matthys-2010-_x002d_-30-mg">
<CHAR_METHODS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Dose-finding RCT (third of 3 treatment arms), double-blind, multi-center</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults, acute bronchitis, &lt; 48 hours past onset<BR/>Setting: in- and outpatient departments, Ukraine</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-30 15:37:33 +1000" MODIFIED_BY="Liz Dooley">
<P>
<I>P. sidoides</I> 3 x 30 mg tablets versus placebo for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Primary: difference in symptom score change at day 7<BR/>Secondary: change in individual symptom severity. Patient satisfaction (IMPSS), physician assessment (IMOS). Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-01 14:53:18 +1000" MODIFIED_BY="[Empty name]">
<P>Interim report was provided for 2008 version of review by the investigator (Schwabe Pharmaceuticals). Full paper published preceding current update. For analysis, this study is divided into 3 parts (1 treatment arm, 1/3 of control numbers and control events). This trial is part of Matthys 2010, representing 1 treatment arm and 1/3 each of the number of control events and the number of controls (see Methods)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BSS: Bronchitis Severity Score<BR/>ITT: intention-to-treat analysis<BR/>RCT: randomized controlled trial<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Bachert-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley">
<P>RCT, double -blind, n = 272</P>
<P>Adults with acute maxillary sinusitis</P>
<P>Intervention: <I>P. sidoides</I> (alcoholic root extract), comparator: placebo</P>
<P>Primary outcome: difference in symptoms</P>
<P>Reason for exclusion: insufficient data - data only available in abstract form. According to manufacturer full publication not planned due to flawed design (high drop-out rates). Abstract also includes data from another study for which unpublished data were available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bereznoj-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Prospective cohort, open-label, n = 1000</P>
<P>Children and young adults with tonsillitis</P>
<P>Intervention: <I>P. sidoides</I> (alcoholic root extract)</P>
<P>Primary outcome: difference in symptoms</P>
<P>Reason for exclusion: uncontrolled design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Bereznoy-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley">
<P>RCT, double-blind, n = 144<BR/>Children with pharyngotonsillitis (non-streptococcal)</P>
<P>Primary outcome: difference in symptom score<BR/>Intervention: <I>P. sidoides</I> (alcoholic root extract), comparator: placebo</P>
<P>Reason for exclusion: high differential drop-out, problematic withdrawal criteria resulting in high risk of bias (attrition bias)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Blochin-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley">
<P>RCT, open-label, n = 60<BR/>Children with acute bronchitis</P>
<P>Intervention: <I>P. sidoides</I> (alcoholic root extract), comparator: acetylcysteine</P>
<P>Primary outcome: difference in symptom score<BR/>
</P>
<P>Reason for exclusion: open-label</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Blochin-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley">
<P>RCT, open-label, n = 60<BR/>Children with tonsillopharyngitis</P>
<P>Intervention: <I>P. sidoides</I> (alcoholic root extract), comparator: therapeutic compresses ("Priessnitz Wickel") and gargling with vinegar<BR/>Primary outcome: difference in symptom score</P>
<P>Reason for exclusion: open-label</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dome-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Prospective cohort, open-label, n = 742<BR/>Children with acute bronchitis or acute exacerbation of chronic bronchitis<BR/>Primary outcome: difference in symptom score<BR/>Intervention: <I>P. sidoides</I> (alcoholic root extract)</P>
<P>Reason for exclusion: uncontrolled design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Haidvogl-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Prospective cohort, open-label, n = 259<BR/>Adults with acute bronchitis or acute exacerbation of chronic bronchitis. Duplicate publication - subset of Dome 1996<BR/>Primary outcome: difference in symptom score<BR/>Intervention: <I>P. sidoides</I> (alcoholic root extract)</P>
<P>Reason for exclusion: uncontrolled design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 16:45:40 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koenig-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-01 16:45:40 +1000" MODIFIED_BY="[Empty name]">
<P>Narrative review including imprecise report on original study, obviously observational, n = 641</P>
<P>Children and adults with various respiratory tract infections</P>
<P>Intervention: <I>P. sidoides</I> (alcoholic root extract)</P>
<P>Primary outcome: improvement of symptoms, global assessment (self and physician)</P>
<P>Reason for exclusion: insufficient information, seems uncontrolled design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Luna-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>RCT, double-blind, n = 28</P>
<P>Marathon runners</P>
<P>Primary outcome: difference in symptom score<BR/>Intervention: <I>P. sidoides</I> (alcoholic root extract), comparator: placebo</P>
<P>Primary outcome: IgA and cytokine expression</P>
<P>Reason for exclusion: not in respiratory tract infection</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martins-Kirk-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Prospective cohort, open-label, n = 1667</P>
<P>Children and adults with pharyngotonsillitis</P>
<P>Intervention: <I>P. sidoides</I> (alcoholic root extract)</P>
<P>Primary outcome: improvement of symptoms</P>
<P>Reason for exclusion: uncontrolled design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Matthys-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Liz Dooley">
<P>RCT, double-blind, n = 468<BR/>Adults with acute bronchitis</P>
<P>Intervention: <I>P. sidoides</I> (alcoholic root extract), comparator: placebo<BR/>Primary outcome: difference in symptom score</P>
<P>Reason for exclusion: high differential drop-out, problematic withdrawal criteria resulting in high risk of bias (attrition bias)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Matthys-2007b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Prospective cohort, open-label, n = 205<BR/>Adults with acute bronchitis or acute exacerbation of chronic bronchitis<BR/>Intervention: <I>P. sidoides</I> (alcoholic root extract)</P>
<P>Primary outcome: improvement of symptoms</P>
<P>Reason for exclusion: uncontrolled design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Matthys-2007c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Prospective cohort, open-label, n = 2099</P>
<P>Children and adults with acute bronchitis</P>
<P>Intervention: <I>P. sidoides</I> (alcoholic root extract)</P>
<P>Primary outcome: improvement of symptoms</P>
<P>Reason for exclusion: uncontrolled design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Matthys-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>RCT, double-blind, n = 200</P>
<P>Adults with COPD or chronic bronchitis</P>
<P>Intervention: <I>P. sidoides</I> (alcoholic root extract), comparator: placebo</P>
<P>Primary outcome: time to acute exacerbation of COPD</P>
<P>Reason for exclusion: underlying chronic disease (COPD)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patiroglu-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>RCT, double-blind, n = 28</P>
<P>Children with immunodeficiency of infancy</P>
<P>Intervention: <I>P. sidoides</I> (alcoholic root extract), comparator: placebo</P>
<P>Primary outcome: improvement of various cold symptoms</P>
<P>Reason for exclusion: underlying immunodeficiency</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Perez-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Prospective cohort, open-label, n = 305</P>
<P>Mixed group (children and adult, bronchitis, sinusitis or tonsillitis)</P>
<P>Intervention: <I>P. sidoides</I> (alcoholic root extract)</P>
<P>Primary outcome: improvement of symptoms</P>
<P>Reason for exclusion: uncontrolled design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roots-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>RCT (phase II), open-label, n = 28</P>
<P>Healthy volunteers</P>
<P>Intervention: <I>P. sidoides</I> (alcoholic root extract), comparator: placebo</P>
<P>Primary outcome: pharmacodynamics</P>
<P>Reason for exclusion: not respiratory tract infection</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schapowal-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Prospective cohort, open-label, not controlled, n = 361</P>
<P>Children and adults with sinusitis (acute and chronic)</P>
<P>Intervention: <I>P. sidoides</I> (alcoholic root extract)</P>
<P>Primary outcome: improvement of score/symptoms</P>
<P>Reason for exclusion: uncontrolled design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tahan-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>RCT, open-label, n = 61</P>
<P>Children with upper respiratory tract infection and asthma<BR/>Intervention: <I>P. sidoides</I> (alcoholic root extract), comparator: placebo</P>
<P>Primary outcome: prevention of asthma attacks during viral infection</P>
<P>Reasons for exclusion: underlying chronic disease, open-label</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>COPD: chronic obstructive pulmonary disease<BR/>n: number of persons in study<BR/>RCT: randomized controlled trial<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2013-09-06 19:19:25 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bachert-2004">
<CHAR_METHODS MODIFIED="2013-07-01 14:55:01 +1000" MODIFIED_BY="[Empty name]">
<P>RCT, double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-14 02:45:37 +1000" MODIFIED_BY="[Empty name]">
<P>272 adults with acute maxillary sinusitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-06 19:19:25 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>P. sidoides</I> alcoholic extract versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-01 14:55:05 +1000" MODIFIED_BY="[Empty name]">
<P>Not known yet</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-14 02:48:11 +1000" MODIFIED_BY="[Empty name]">
<P>Performed in Ukraine, unpublished material only (investigator supplied)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-09-06 19:19:32 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beck-2001">
<CHAR_METHODS MODIFIED="2013-07-01 14:55:13 +1000" MODIFIED_BY="[Empty name]">
<P>RCT, double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-14 02:47:31 +1000" MODIFIED_BY="[Empty name]">
<P>124 children (age 6 to 10) with angina catarrhalis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-06 19:19:32 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>P. sidoides</I> alcoholic extract versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-01 14:55:18 +1000" MODIFIED_BY="[Empty name]">
<P>Not known yet</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-14 02:48:20 +1000" MODIFIED_BY="[Empty name]">
<P>Performed in Ukraine, unpublished material only (investigator supplied)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heger-2002">
<CHAR_METHODS MODIFIED="2013-07-01 14:55:41 +1000" MODIFIED_BY="[Empty name]">
<P>RCT, double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-14 02:49:15 +1000" MODIFIED_BY="[Empty name]">
<P>215 children (age 6 to 12) with acute bronchitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>P. sidoides</I> alcoholic extract versus acetylcysteine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-01 14:55:49 +1000" MODIFIED_BY="[Empty name]">
<P>Not known yet</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-14 02:49:57 +1000" MODIFIED_BY="[Empty name]">
<P>Performed in Russia, unpublished material only (investigator supplied)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heger-2003">
<CHAR_METHODS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>RCT, double-blind, 3 arms (2 treatment, 1 placebo)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-14 02:51:38 +1000" MODIFIED_BY="[Empty name]">
<P>637 adults with acute bronchitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-06 19:19:54 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>P. sidoides</I> alcoholic extract versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-01 14:56:02 +1000" MODIFIED_BY="[Empty name]">
<P>Not known yet</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-14 02:52:02 +1000" MODIFIED_BY="[Empty name]">
<P>Performed in Germany and Ukraine, unpublished material only (investigator supplied)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISRCTN86579667">
<CHAR_METHODS MODIFIED="2013-05-23 01:45:40 +1000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 01:44:11 +1000" MODIFIED_BY="[Empty name]">
<P>78 children with acute non-streptococcal tonsillopharyngitis (6 to 10 years)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>EPs 7630, 20 drops per hour during the first 1 to 2 days, followed by 20 drops 3 times daily versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-01 14:56:14 +1000" MODIFIED_BY="[Empty name]">
<P>Not known</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 01:47:10 +1000" MODIFIED_BY="[Empty name]">
<P>Registry information only, need to be checked for publication, ISO Arzneimittel GmbH &amp; Co KG (Germany); reported completed, started enrolment in 2003</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wolf-2011">
<CHAR_METHODS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>RCT, double-blind, 3 arms (2 treatment, 1 placebo)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-14 02:53:01 +1000" MODIFIED_BY="[Empty name]">
<P>72 adult healthy volunteers</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-06 19:20:23 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>P. sidoides</I> alcoholic extract versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-01 14:56:27 +1000" MODIFIED_BY="[Empty name]">
<P>Not known yet</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-14 02:53:30 +1000" MODIFIED_BY="[Empty name]">
<P>Performed in Germany, unpublished material only (investigator supplied)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>RCT: randomized controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EUCTR2007_x002d_004923_x002d_39_x002d_DE">
<CHAR_STUDY_NAME MODIFIED="2013-05-23 01:13:22 +1000" MODIFIED_BY="[Empty name]">
<P>Efficacy and tolerability of EPs® 7630 film-coated tablets in patients (&gt;=18 years old) with Acute Rhinopharyngitis (ARP)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-07-01 14:57:03 +1000" MODIFIED_BY="[Empty name]">
<P>RCT, double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 01:13:22 +1000" MODIFIED_BY="[Empty name]">
<P>Adults with acute rhinopharyngitis, sample/target size not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-01 14:57:09 +1000" MODIFIED_BY="[Empty name]">
<P>EPs® 7630 <U>solution</U> versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Area under the curve (AUC) of the total score of rhinopharyngitis-relevant symptoms (RPS) from baseline (day 1, visit 1) to day 5 (visit 3). Change in total score of rhinopharyngitis-relevant symptoms (RPS), number of patients who experience a reduction in total score of RPS, number of patients with complete remission of RPS, change in individual rhinopharyngitis-relevant symptoms (RPS), patient's ability to work or to attend school/college, sleep quality, health-related quality of life, patient's satisfaction with treatment (IMPSS), consumption of paracetamol tablets, treatment outcome (IMOS)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>November 2007 (first enrolment)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Not reported (Schwabe Pharmaceuticals)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Performed in Bulgaria, status not reported, potential duplicate of EUCTR2007-005579-33-BG</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EUCTR2007_x002d_005579_x002d_33_x002d_BG">
<CHAR_STUDY_NAME MODIFIED="2013-05-23 00:53:39 +1000" MODIFIED_BY="[Empty name]">
<P>Efficacy and tolerability of EPs® 7630 film-coated tablets in patients (&gt;=18 years old) with Acute Rhinopharyngitis (ARP)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-07-01 14:57:15 +1000" MODIFIED_BY="[Empty name]">
<P>RCT, double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 00:53:39 +1000" MODIFIED_BY="[Empty name]">
<P>Adults with acute rhinopharyngitis, sample/target size not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-01 14:57:22 +1000" MODIFIED_BY="[Empty name]">
<P>EPs® 7630 <U>solution</U> versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Area under the curve (AUC) of the total score of rhinopharyngitis-relevant symptoms (RPS) from baseline (day 1, visit 1) to day 5 (visit 3). Change in total score of rhinopharyngitis-relevant symptoms (RPS), number of patients who experience a reduction in total score of RPS, number of patients with complete remission of RPS, change in individual rhinopharyngitis-relevant symptoms (RPS), patient's ability to work or to attend school/college, sleep quality, health-related quality of life, patient's satisfaction with treatment (IMPSS), consumption of paracetamol tablets, treatment outcome (IMOS)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>August 2008 (first enrolment)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Not reported (Schwabe Pharmaceuticals)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Performed in Bulgaria, status not reported, potential duplicate of EUCTR2007-004923-39-DE</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EUCTR2007_x002d_005797_x002d_31_x002d_BG">
<CHAR_STUDY_NAME MODIFIED="2013-05-23 00:45:10 +1000" MODIFIED_BY="[Empty name]">
<P>Efficacy and tolerability of EPs® 7630 film-coated tablets in patients (&gt;=18 years old) with Acute Rhinopharyngitis (ARP)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-07-01 14:57:30 +1000" MODIFIED_BY="[Empty name]">
<P>RCT, double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 00:46:37 +1000" MODIFIED_BY="[Empty name]">
<P>Adults with acute rhinopharyngitis, sample/target size not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-01 14:57:36 +1000" MODIFIED_BY="[Empty name]">
<P>EPs® 7630 film-coated <U>tablets</U> versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Area under the curve (AUC) of the total score of rhinopharyngitis-relevant symptoms (RPS) from baseline (day 1, visit 1) to day 5 (visit 3). Change in total score of rhinopharyngitis-relevant symptoms (RPS), number of patients who experience a reduction in total score of RPS, number of patients with complete remission of RPS, change in individual rhinopharyngitis-relevant symptoms (RPS), patient's ability to work or to attend school/college, sleep quality, health-related quality of life, patient's satisfaction with treatment (IMPSS), consumption of paracetamol tablets, treatment outcome (IMOS)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>August 2008 (first enrolment)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-07-01 14:57:43 +1000" MODIFIED_BY="[Empty name]">
<P>Not reported (Schwabe Pharmaceuticals)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-05-23 00:55:05 +1000" MODIFIED_BY="[Empty name]">
<P>Performed in Bulgaria, status not reported</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EUCTR2011_x002d_002652_x002d_14_x002d_DE">
<CHAR_STUDY_NAME MODIFIED="2013-07-02 07:21:31 +1000" MODIFIED_BY="[Empty name]">
<P>Safety and tolerability of Pelargonium sidoides extract EPs® 7630 in children (1 to 5 years old) suffering from acute bronchitis: a randomized controlled trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>RCT, open-label, multi-center</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-01 14:57:51 +1000" MODIFIED_BY="[Empty name]">
<P>600 (target) children with acute bronchitis (1 to 5 years)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 00:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>2.5 ml EPs® 7630 syrup 3 times/day or 10 drops EPs® 7630 solution 3 times/day for 7 consecutive days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Adverse events, changes in individual respiratory tract infection symptoms as well as the total symptoms score</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>1 October 2011 (first enrolment)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-05-23 00:20:02 +1000" MODIFIED_BY="[Empty name]">
<P>FA Malek; Dr. Willmar Schwabe GmbH &amp; Co KG (Germany)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Potential duplicate of ISRCTN77419032</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISRCTN77419032">
<CHAR_STUDY_NAME MODIFIED="2013-07-02 07:21:32 +1000" MODIFIED_BY="[Empty name]">
<P>Safety and tolerability of Pelargonium sidoides extract EPs® 7630 in children (1 to 5 years old) suffering from acute bronchitis: a randomized controlled trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>RCT, open-label, multi-center</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-01 14:58:04 +1000" MODIFIED_BY="[Empty name]">
<P>600 (target) children with acute bronchitis (1 to 5 years)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 00:10:17 +1000" MODIFIED_BY="[Empty name]">
<P>2.5 ml EPs® 7630 syrup 3 times/day or 10 drops EPs® 7630 solution 3 times/day for 7 consecutive days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Adverse events, changes in individual respiratory tract infection symptoms as well as the total symptoms score</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>1 October 2011 (first enrolment)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-05-22 23:47:24 +1000" MODIFIED_BY="[Empty name]">
<P>FA Malek; Dr. Willmar Schwabe GmbH &amp; Co KG (Germany)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Registry information only, reported recruiting, last entry February 2012</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-JPRN_x002d_UMIN000003815">
<CHAR_STUDY_NAME MODIFIED="2013-05-23 00:26:44 +1000" MODIFIED_BY="[Empty name]">
<P>Efficacy of a Pelargonium sidoides preparation in patients with the upper respiratory infection</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-05-23 00:30:33 +1000" MODIFIED_BY="[Empty name]">
<P>RCT, 2 arms</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 00:30:57 +1000" MODIFIED_BY="[Empty name]">
<P>200 children and adults (target), acute upper respiratory tract infection (cold)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-06 19:24:52 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>P. sidoides </I>alcoholic extract versus placebo (10 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Cold intensity score (CIS), General Well-Being Index</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-05-23 00:27:20 +1000" MODIFIED_BY="[Empty name]">
<P>July 2010 (first enrolment)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-05-23 00:29:20 +1000" MODIFIED_BY="[Empty name]">
<P>K Nakayama, University of Tokyo Department of Infectious disease, Japan </P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Public recruitment in Japan, public sponsor; registry information only, reported recruiting, last entry April 2013. Contact person contacted by email 22 May 2013.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01420445">
<CHAR_STUDY_NAME MODIFIED="2013-05-23 00:12:03 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, Double-blind, Placebo/Active-controlled, Multi-center, Phase 3 Clinical Trial to Investigate the Safety/Tolerability and Efficacy of YHD001 After Oral Administration in Patients With Acute or Chronic Bronchitis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>RCT, double-blind, 4 arms (2 YHD001, 1 <I>Pelargonium sidoides</I>, 1 placebo)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-22 23:45:21 +1000" MODIFIED_BY="[Empty name]">
<P>116 adults with acute bronchitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>YHD001 (dose-finding) versus <I>P</I>
<I>elargonium sidoides</I> versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-06 19:26:36 +1000" MODIFIED_BY="[Empty name]">
<P>Change of total symptom score from baseline to the end of treatment (time frame: 7 days); safety assessment (time frame: 7 days); time to response (time frame: 7 days)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>September 2011 (first enrolment)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-05-22 23:46:35 +1000" MODIFIED_BY="[Empty name]">
<P>Yuhan Corporation, Korea</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>Performed in Korea, registry information only, reported ongoing (recruitment closed), last entry February 2012. No contact person provided. 2 physicians in the recruitment center approached by email for more information 22 May 2013</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>RCT: randomized controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bachert-2009">
<DESCRIPTION>
<P>Computer-generated randomization list with balanced block randomization, p.53</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 14:46:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chuchalin-2005">
<DESCRIPTION>
<P>List generated on a computer, p.438</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kamin-2010a">
<DESCRIPTION>
<P>Computer-generated random list, p.185</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kamin-2010b">
<DESCRIPTION>
<P>Computer-generated random list, p.538</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2010b-_x002d_-10-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2010b-_x002d_-20-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2010b-_x002d_-30-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kamin-2012">
<DESCRIPTION>
<P>Computer-generated random list, balanced block randomization, stratified by age group (p.220)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lizogub-2007">
<DESCRIPTION>
<P>Computer-generated randomization list (p.575)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Matthys-2007a">
<DESCRIPTION>
<P>Randomization schedules were prepared centrally, p.325</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Matthys-2010">
<DESCRIPTION>
<P>Computer-generated random list, p.1414</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Matthys-2010-_x002d_-10-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Matthys-2010-_x002d_-20-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Matthys-2010-_x002d_-30-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-06 19:07:35 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bachert-2009">
<DESCRIPTION>
<P>The block length was not known to the investigator. Each investigator received a set of blocks with correspondingly numbered study medication. Eligible patients were sequentially allocated to a patient number in ascending order on entry in the trial, p.53</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 14:46:59 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chuchalin-2005">
<DESCRIPTION>
<P>Research staff blinded to treatment allocation, p.438</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 02:56:05 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kamin-2010a">
<DESCRIPTION>
<P>Concealed block size, concealed allocation, p.185</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kamin-2010b">
<DESCRIPTION>
<P>Investigator supplied information, p.538</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 01:42:53 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2010b-_x002d_-10-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 01:42:59 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2010b-_x002d_-20-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 01:43:08 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2010b-_x002d_-30-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 16:41:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kamin-2012">
<DESCRIPTION>
<P>Length of blocks withheld from study centers (p.220)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lizogub-2007">
<DESCRIPTION>
<P>Blocks of study medication, block size not revealed (p.575)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 16:42:25 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Matthys-2007a">
<DESCRIPTION>
<P>Central randomization, p.325 and investigator information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Matthys-2010">
<DESCRIPTION>
<P>Central randomization, block length withheld, p.1414 and investigator information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 01:24:46 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Matthys-2010-_x002d_-10-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 01:25:16 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Matthys-2010-_x002d_-20-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-26 01:25:03 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Matthys-2010-_x002d_-30-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-01 16:24:46 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bachert-2009">
<DESCRIPTION>
<P>Double-blinding, integrity of blinding not assessed, p.53</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-01 14:47:07 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chuchalin-2005">
<DESCRIPTION>
<P>Double-blinding, integrity of blinding not assessed, p.438 and investigator information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-01 14:47:45 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2010a">
<DESCRIPTION>
<P>Double-blinding, integrity of blinding not assessed, p.185 and investigator information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-01 14:49:05 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2010b">
<DESCRIPTION>
<P>Double-blinding, integrity of blinding not assessed, p.537, and investigator supplied</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2010b-_x002d_-10-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2010b-_x002d_-20-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2010b-_x002d_-30-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-01 14:51:06 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2012">
<DESCRIPTION>
<P>Double-blinding, integrity of blinding not assessed (p.220)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lizogub-2007">
<DESCRIPTION>
<P>Double-blinding, integrity of blinding not assessed (p.575, investigator information)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Matthys-2007a">
<DESCRIPTION>
<P>Double-blinding, integrity of blinding not assessed, p.325</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Matthys-2010">
<DESCRIPTION>
<P>Double-blinding, integrity of blinding not assessed, p.1414 and investigator information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Matthys-2010-_x002d_-10-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Matthys-2010-_x002d_-20-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Matthys-2010-_x002d_-30-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-02-16 06:09:31 +1000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-02-26 01:36:43 +1000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-17 23:35:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bachert-2009">
<DESCRIPTION>
<P>Flow chart provided, minimal withdrawal (0/51, 1/52), ITT, p.53</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chuchalin-2005">
<DESCRIPTION>
<P>Flow chart provided, low non-differential withdrawal (3/64, 4/60), ITT analysis, p.439</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-17 23:36:04 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kamin-2010a">
<DESCRIPTION>
<P>Flow chart provided, low withdrawal (0/103, 3/97), ITT analysis, p.186</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2010b">
<DESCRIPTION>
<P>Overall 1 drop-out (?), no flow chart</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2010b-_x002d_-10-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2010b-_x002d_-20-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2010b-_x002d_-30-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kamin-2012">
<DESCRIPTION>
<P>Flow chart provided (p.221), low attrition (2/111; 2/107), non-differential, ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lizogub-2007">
<DESCRIPTION>
<P>Flow chart provided (p.576), low attrition (1/52; 1/51), non-differential, ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Matthys-2007a">
<DESCRIPTION>
<P>Flowchart provided, some differential loss to follow-up (withdrawals 6/108 and 13/109), ITT analysis, p.326</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Matthys-2010">
<DESCRIPTION>
<P>Flowchart provided, minimal loss to follow-up (withdrawals 1/102, 2/102, 0/101, 1/101), ITT analysis, p.1416</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Matthys-2010-_x002d_-10-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Matthys-2010-_x002d_-20-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Matthys-2010-_x002d_-30-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-17 23:59:42 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bachert-2009">
<DESCRIPTION>
<P>Primary outcome reported but not relevant to review, additional outcome information provided as requested</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-17 23:59:53 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chuchalin-2005">
<DESCRIPTION>
<P>Primary outcome reported but not relevant to review, additional outcome information provided as requested</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-17 23:59:59 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2010a">
<DESCRIPTION>
<P>Primary outcome reported but not relevant to review, additional outcome information provided as requested</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2010b">
<DESCRIPTION>
<P>Primary outcome reported but not relevant to review, additional outcome information provided as requested, p.435 and 560</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2010b-_x002d_-10-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2010b-_x002d_-20-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2010b-_x002d_-30-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-01 14:51:13 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2012">
<DESCRIPTION>
<P>Primary outcome reported, additional outcome information provided as requested</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-18 00:01:39 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lizogub-2007">
<DESCRIPTION>
<P>Results for low dose only reported, some additional outcome information provided as requested</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-18 00:01:07 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Matthys-2007a">
<DESCRIPTION>
<P>All main results reported, not all relevant to study question</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-27 20:09:35 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Matthys-2010">
<DESCRIPTION>
<P>All main results reported, not all relevant to study question</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Matthys-2010-_x002d_-10-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Matthys-2010-_x002d_-20-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Matthys-2010-_x002d_-30-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-06-26 07:05:55 +1000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="GROUP" MODIFIED="2013-07-01 16:45:23 +1000" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Validated outcome assessment</NAME>
<DESCRIPTION>
<P>Use of a validated instrument for outcome assessment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-09.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-03-07 22:19:56 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bachert-2009">
<DESCRIPTION>
<P>Unvalidated score used for reporting, additional information supplied (assumes score = 0 for absence of symptoms)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-04-18 00:05:13 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chuchalin-2005">
<DESCRIPTION>
<P>Unvalidated score used for reporting, additional information supplied (assumes score = 0 for absence of symptoms)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-07-01 16:45:23 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2010a">
<DESCRIPTION>
<P>Unvalidated score used for reporting, additional information supplied (assumes score = 0 for absence of symptoms) score used for reporting, additional information supplied but assumes BSS = 0 for absence of symptoms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-04-18 00:03:18 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2010b">
<DESCRIPTION>
<P>Unvalidated score used for reporting, additional information supplied (assumes score = 0 for absence of symptoms)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2010b-_x002d_-10-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2010b-_x002d_-20-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2010b-_x002d_-30-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-04-18 00:05:47 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kamin-2012">
<DESCRIPTION>
<P>Unvalidated score used for reporting, additional information supplied but assumes BSS = 0 for absence of symptoms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-03-07 20:28:47 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lizogub-2007">
<DESCRIPTION>
<P>Unvalidated score used for reporting, additional information supplied but assumes BSS = 0 for absence of symptoms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-03-07 20:30:07 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Matthys-2007a">
<DESCRIPTION>
<P>Unvalidated score used for reporting, additional information supplied but assumes BSS = 0 for absence of symptoms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-03-07 20:35:26 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Matthys-2010">
<DESCRIPTION>
<P>Unvalidated score used for reporting, additional information supplied but assumes BSS = 0 for absence of symptoms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" RESULT="UNKNOWN" STUDY_ID="STD-Matthys-2010-_x002d_-10-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" RESULT="UNKNOWN" STUDY_ID="STD-Matthys-2010-_x002d_-20-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" RESULT="UNKNOWN" STUDY_ID="STD-Matthys-2010-_x002d_-30-mg">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-09-21 01:51:49 +1000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-09-07 00:38:41 +1000" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2013-09-06 19:27:11 +1000" MODIFIED_BY="Grade Profiler">
<I>P. sidoides</I> for the treatment of acute bronchitis in adults</TITLE>
<TABLE COLS="7" ROWS="15">
<TR>
<TD COLSPAN="7">
<P>
<B>
<I>P. sidoides</I> for the treatment of acute bronchitis in adults</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> adults with acute bronchitis<BR/>
<B>Settings: </B>in- and outpatient departments, GP practices; Ukraine and Russia<BR/>
<B>Intervention:</B> <I>P. sidoides</I> versus placebo<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No. of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>
<I>P. sidoides</I>
</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Failure to recover by day 7 (complete resolution of all symptoms) - liquid preparation</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.66 </B>
<BR/>(0.52 to 0.83)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>341<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>953 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>629 per 1000</B>
<BR/>(495 to 791)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>960 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>634 per 1000</B>
<BR/>(499 to 797)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Failure to recover by day 7 (complete resolution of all symptoms) - tablet preparation</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.95 </B>
<BR/>(0.91 to 0.99)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>405<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>990 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>941 per 1000</B>
<BR/>(901 to 980)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>1000 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>950 per 1000</B>
<BR/>(910 to 990)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Outcome on request only, investigator-initiated studies only, minor attrition problems, success of blinding not assessed.<BR/>
<SUP>2</SUP>Relevant statistical heterogeneity, not completely solved by subgroup analyses, but both studies and all outcomes clearly in same direction.<BR/>
<SUP>3</SUP>Insufficient number of studies to perform statistical testing, but funnel plot across all conditions strongly suggests small study bias.<BR/>
<SUP>4</SUP>1 study only.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2013-09-21 01:50:43 +1000" MODIFIED_BY="Grade Profiler" NO="2" READONLY="YES">
<TITLE MODIFIED="2013-09-06 19:29:34 +1000" MODIFIED_BY="Grade Profiler">
<I>P. sidoides</I> for treating acute bronchitis in children</TITLE>
<TABLE COLS="7" ROWS="15">
<TR>
<TD COLSPAN="7">
<P>
<B>
<I>P. sidoides</I> for treating acute bronchitis in children</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> children with acute bronchitis<BR/>
<B>Settings:</B> in- and outpatient departments, GP practices; Ukraine and Russia<BR/>
<B>Intervention:</B> <I>P. sidoides </I>versus placebo<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No. of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>
<I>P. sidoides</I> </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Failure to recover by day 7 (complete resolution of all symptoms) - liquid preparation</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.82 </B>
<BR/>(0.77 to 0.88)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>420<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>971 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>796 per 1000</B>
<BR/>(748 to 854)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>971 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>796 per 1000</B>
<BR/>(748 to 854)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Failure to recover by day 7 (complete resolution of all symptoms) - tablet preparation</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.96 </B>
<BR/>(0.89 to 1.03)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>399<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>911 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>874 per 1000</B>
<BR/>(811 to 938)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>912 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>876 per 1000</B>
<BR/>(812 to 939)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Outcome on request only, investigator-initiated studies only, minor attrition problems, success of blinding not assessed.<BR/>
<SUP>2</SUP>Insufficient number of studies to perform statistical testing, but funnel plot across all conditions strongly suggests small study bias.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2013-09-21 01:51:49 +1000" MODIFIED_BY="Grade Profiler" NO="3" READONLY="YES">
<TITLE MODIFIED="2013-09-06 19:32:03 +1000" MODIFIED_BY="Grade Profiler">
<I>P. sidoides</I> versus placebo for treating acute sinusitis in adults</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>
<I>P. sidoides</I> for treating acute sinusitis in adults</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> adults with acute sinusitis<BR/>
<B>Settings: </B>in- and outpatient departments, ENT practices; Ukraine<BR/>
<B>Intervention:</B> <I>P. sidoides</I> versus placebo<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No. of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>
<I>P. sidoides</I>
</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Failure to recover by day 21 (complete resolution of all symptoms)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.43 </B>
<BR/>(0.3 to 0.62)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>103<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>904 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>389 per 1000</B>
<BR/>(271 to 560)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>904 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>389 per 1000</B>
<BR/>(271 to 560)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Outcome on request only, investigator-initiated studies only, minor attrition problems, success of blinding not assessed.<BR/>
<SUP>2</SUP>1 small study only, very wide confidence interval.<BR/>
<SUP>3</SUP>Insufficient number of studies to perform statistical testing, but funnel plot across all conditions strongly suggests small study bias.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2013-09-21 01:51:01 +1000" MODIFIED_BY="Grade Profiler" NO="4" READONLY="YES">
<TITLE MODIFIED="2013-09-06 19:34:37 +1000" MODIFIED_BY="Grade Profiler">
<I>P. sidoides</I> for common cold in adults</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>
<I>P. sidoides </I>for common cold in adults</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> adults with common cold<BR/>
<B>Settings: </B>in- and outpatient departments, GP practices; Ukraine<BR/>
<B>Intervention:</B> <I>P. sidoides </I>versus placebo<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No. of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>
<I>P. sidoides</I>
</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Failure to recover by day 5 (complete resolution of all symptoms)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.96 </B>
<BR/>(0.9 to 1.03)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>103<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>1000 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>960 per 1000</B>
<BR/>(900 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>1000 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>960 per 1000</B>
<BR/>(900 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Outcome on request only, investigator-initiated studies only, minor attrition problems, success of blinding not assessed.<BR/>
<SUP>2</SUP>1 small study only.<BR/>
<SUP>3</SUP>Insufficient number of studies to perform statistical testing, but funnel plot across all conditions strongly suggests small study bias.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-09-09 10:13:33 +1000" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-09-06 20:24:08 +1000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-09-06 20:23:15 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>
<I>P. sidoides</I> versus placebo, acute bronchitis in adults</NAME>
<DICH_OUTCOME CHI2="98.3864777378258" CI_END="0.9760178855363669" CI_START="0.9023946197119297" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9384845702783992" ESTIMABLE="YES" EVENTS_1="386" EVENTS_2="262" I2="95.93440064938706" I2_Q="89.4239747237335" ID="CMP-001.01" LOG_CI_END="-0.010542223810173938" LOG_CI_START="-0.04460350271842989" LOG_EFFECT_SIZE="-0.02757286326430192" METHOD="MH" MODIFIED="2013-06-20 02:34:32 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.1102230246251565E-16" P_Q="0.0021053583851103896" P_Z="0.0015076271538307531" Q="9.45534805258157" RANDOM="YES" SCALE="2.41" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.05019848491022175" TOTALS="SUB" TOTAL_1="475" TOTAL_2="271" WEIGHT="200.0" Z="3.1732113814188163">
<NAME>Failure to recover by day seven (complete resolution of all symptoms)</NAME>
<GROUP_LABEL_1>P. sidoides</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors P. sidoides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.807496013323361" CI_END="0.8268476651162543" CI_START="0.5200635015870233" DF="1" EFFECT_SIZE="0.6557539874064158" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="161" I2="73.7360197751815" ID="CMP-001.01.01" LOG_CI_END="-0.08257449563897691" LOG_CI_START="-0.2839436242400883" LOG_EFFECT_SIZE="-0.18325905993953256" NO="1" P_CHI2="0.05102371867992228" P_Z="3.6055398024070306E-4" STUDIES="2" TAU2="0.02065772304280334" TOTAL_1="172" TOTAL_2="169" WEIGHT="100.0" Z="3.5673904914555865">
<NAME>Liquid preparation</NAME>
<DICH_DATA CI_END="0.8549785443344743" CI_START="0.6248833839078249" EFFECT_SIZE="0.7309322033898306" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="59" LOG_CI_END="-0.06804478374441315" LOG_CI_START="-0.2042010233772141" LOG_EFFECT_SIZE="-0.13612290356081364" ORDER="1" O_E="0.0" SE="0.07997884914456334" STUDY_ID="STD-Chuchalin-2005" TOTAL_1="64" TOTAL_2="60" VAR="0.0063966163104888195" WEIGHT="51.71589585586514"/>
<DICH_DATA CI_END="0.6980616661042219" CI_START="0.48821978506909797" EFFECT_SIZE="0.5837872185911401" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="102" LOG_CI_END="-0.15610621052034293" LOG_CI_START="-0.3113846248118559" LOG_EFFECT_SIZE="-0.23374541766609946" ORDER="2" O_E="0.0" SE="0.09121130919538195" STUDY_ID="STD-Matthys-2007a" TOTAL_1="108" TOTAL_2="109" VAR="0.008319502925135568" WEIGHT="48.284104144134865"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2395291527937107" CI_END="0.9869435964564335" CI_START="0.9114504756309" DF="2" EFFECT_SIZE="0.9484462084963423" ESTIMABLE="YES" EVENTS_1="281" EVENTS_2="101" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-0.0057076664262901925" LOG_CI_START="-0.04026692409571974" LOG_EFFECT_SIZE="-0.022987295261004986" NO="2" P_CHI2="0.5380714091299732" P_Z="0.009124248307382234" STUDIES="3" TAU2="0.0" TOTAL_1="303" TOTAL_2="102" WEIGHT="100.00000000000001" Z="2.607363343536867">
<NAME>Tablet preparation</NAME>
<DICH_DATA CI_END="1.0274852439349704" CI_START="0.9160523994079752" EFFECT_SIZE="0.970170254678486" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="34" LOG_CI_END="0.011775593542137091" LOG_CI_START="-0.03807968340325501" LOG_EFFECT_SIZE="-0.013152044930558934" ORDER="3" O_E="0.0" SE="0.02928523646532434" STUDY_ID="STD-Matthys-2010-_x002d_-10-mg" TOTAL_1="102" TOTAL_2="34" VAR="8.576250748299624E-4" WEIGHT="48.05145519089693"/>
<DICH_DATA CI_END="1.0128712596743632" CI_START="0.8507770051399705" EFFECT_SIZE="0.9282928292829283" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="33" LOG_CI_END="0.005554248157762495" LOG_CI_START="-0.07018425675212506" LOG_EFFECT_SIZE="-0.03231500429718131" ORDER="4" O_E="0.0" SE="0.04448917269571373" STUDY_ID="STD-Matthys-2010-_x002d_-20-mg" TOTAL_1="101" TOTAL_2="34" VAR="0.00197928648714904" WEIGHT="20.82070135947856"/>
<DICH_DATA CI_END="0.9977934320605795" CI_START="0.8651630750549744" EFFECT_SIZE="0.9291146505954944" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="34" LOG_CI_END="-9.593591152534113E-4" LOG_CI_START="-0.06290202441796347" LOG_EFFECT_SIZE="-0.03193069176660844" ORDER="5" O_E="0.0" SE="0.03638542821995027" STUDY_ID="STD-Matthys-2010-_x002d_-30-mg" TOTAL_1="100" TOTAL_2="34" VAR="0.0013238993867491534" WEIGHT="31.127843449624525"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="104.6345190136519" CI_END="0.9740933324303375" CI_START="0.8926072174638803" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9324605830869003" ESTIMABLE="YES" EVENTS_1="374" EVENTS_2="254" I2="96.17716979281177" I2_Q="85.78144400588334" ID="CMP-001.02" LOG_CI_END="-0.011399429345663957" LOG_CI_START="-0.04933960585302469" LOG_EFFECT_SIZE="-0.030369517599344323" METHOD="MH" MODIFIED="2013-06-20 02:34:32 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.008001853941413062" P_Z="0.0017025717363340145" Q="7.033062994679484" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.059044624114049024" TOTALS="SUB" TOTAL_1="475" TOTAL_2="271" WEIGHT="200.0" Z="3.137737680847225">
<NAME>Failure to resolve key symptom by day seven: cough</NAME>
<GROUP_LABEL_1>P. sidoides</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors P. sidoides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.583541937958954" CI_END="0.8453381184307154" CI_START="0.47285945264750656" DF="1" EFFECT_SIZE="0.6322389737933127" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="153" I2="78.18281116360203" ID="CMP-001.02.01" LOG_CI_END="-0.07296954714777495" LOG_CI_START="-0.32526792482243083" LOG_EFFECT_SIZE="-0.19911873598510288" NO="1" P_CHI2="0.03228048325765709" P_Z="0.0019768885388524284" STUDIES="2" TAU2="0.03439005224691598" TOTAL_1="172" TOTAL_2="169" WEIGHT="100.0" Z="3.0936826052936186">
<NAME>Liquid preparation</NAME>
<DICH_DATA CI_END="0.862154512019131" CI_START="0.607453570403023" EFFECT_SIZE="0.7236842105263158" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="57" LOG_CI_END="-0.06441489461159594" LOG_CI_START="-0.21648691096149897" LOG_EFFECT_SIZE="-0.14045090278654748" ORDER="6" O_E="0.0" SE="0.08932785517255448" STUDY_ID="STD-Chuchalin-2005" TOTAL_1="64" TOTAL_2="60" VAR="0.007979465709728868" WEIGHT="51.83828163863472"/>
<DICH_DATA CI_END="0.6727803483167197" CI_START="0.44421826210935184" EFFECT_SIZE="0.5466820987654321" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="96" LOG_CI_END="-0.17212670261777524" LOG_CI_START="-0.35240359128441545" LOG_EFFECT_SIZE="-0.2622651469510954" ORDER="7" O_E="0.0" SE="0.10589553678777558" STUDY_ID="STD-Matthys-2007a" TOTAL_1="108" TOTAL_2="109" VAR="0.011213864711571132" WEIGHT="48.16171836136529"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.283640910484724" CI_END="0.9833838872801843" CI_START="0.9002155573153338" DF="2" EFFECT_SIZE="0.9408812221225645" ESTIMABLE="YES" EVENTS_1="278" EVENTS_2="101" I2="12.42055654119976" ID="CMP-001.02.02" LOG_CI_END="-0.007276911891527787" LOG_CI_START="-0.04565348595672609" LOG_EFFECT_SIZE="-0.02646519892412691" NO="2" P_CHI2="0.3192377045951543" P_Z="0.0068664005054088345" STUDIES="3" TAU2="1.991777811639541E-4" TOTAL_1="303" TOTAL_2="102" WEIGHT="100.0" Z="2.7032552018245877">
<NAME>Tablet preparation</NAME>
<DICH_DATA CI_END="1.0274852439349704" CI_START="0.9160523994079752" EFFECT_SIZE="0.970170254678486" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="34" LOG_CI_END="0.011775593542137091" LOG_CI_START="-0.03807968340325501" LOG_EFFECT_SIZE="-0.013152044930558934" ORDER="8" O_E="0.0" SE="0.02928523646532434" STUDY_ID="STD-Matthys-2010-_x002d_-10-mg" TOTAL_1="102" TOTAL_2="34" VAR="8.576250748299624E-4" WEIGHT="48.08544391933239"/>
<DICH_DATA CI_END="0.9958543114219089" CI_START="0.8276970591385121" EFFECT_SIZE="0.9078907890789079" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="33" LOG_CI_END="-0.001804192071771029" LOG_CI_START="-0.08212858787495325" LOG_EFFECT_SIZE="-0.04196638997336216" ORDER="9" O_E="0.0" SE="0.047182947706961076" STUDY_ID="STD-Matthys-2010-_x002d_-20-mg" TOTAL_1="101" TOTAL_2="34" VAR="0.0022262305543178235" WEIGHT="20.951867659674566"/>
<DICH_DATA CI_END="0.9900850080152156" CI_START="0.853148938384561" EFFECT_SIZE="0.9190701678863539" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="34" LOG_CI_END="-0.004327515577216401" LOG_CI_START="-0.06897514530116913" LOG_EFFECT_SIZE="-0.036651330439192775" ORDER="10" O_E="0.0" SE="0.03797433771077805" STUDY_ID="STD-Matthys-2010-_x002d_-30-mg" TOTAL_1="100" TOTAL_2="34" VAR="0.00144205032457222" WEIGHT="30.962688420993036"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.146589413775902" CI_END="0.8166914249285696" CI_START="0.5959856684393955" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.697664951674352" ESTIMABLE="YES" EVENTS_1="248" EVENTS_2="199" I2="44.02924572258868" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.08794200437936248" LOG_CI_START="-0.2247641835358074" LOG_EFFECT_SIZE="-0.15635309395758493" METHOD="MH" MODIFIED="2013-06-20 02:34:32 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.1283415203023357" P_Q="0.46493964267582777" P_Z="7.4823432690111415E-6" Q="0.5339771557783749" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.014168473219018781" TOTALS="YES" TOTAL_1="475" TOTAL_2="271" WEIGHT="100.0" Z="4.479484757772749">
<NAME>Failure to resolve key symptom by day seven: sputum</NAME>
<GROUP_LABEL_1>P. sidoides</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors P. sidoides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8759559002960002" CI_END="0.7826312174792773" CI_START="0.5442783754458579" DF="1" EFFECT_SIZE="0.6526631961608031" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="123" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-0.1064428330152082" LOG_CI_START="-0.2641789201585811" LOG_EFFECT_SIZE="-0.18531087658689463" NO="1" P_CHI2="0.3493118224763768" P_Z="4.120814431859595E-6" STUDIES="2" TAU2="0.0" TOTAL_1="172" TOTAL_2="169" WEIGHT="40.746301862019926" Z="4.605194038111649">
<NAME>Liquid preparation</NAME>
<DICH_DATA CI_END="0.7829710414539871" CI_START="0.43848716712267577" EFFECT_SIZE="0.5859375" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="48" LOG_CI_END="-0.10625430022725327" LOG_CI_START="-0.35804311228508345" LOG_EFFECT_SIZE="-0.23214870625616832" ORDER="11" O_E="0.0" SE="0.1479019945774904" STUDY_ID="STD-Chuchalin-2005" TOTAL_1="64" TOTAL_2="60" VAR="0.021875000000000002" WEIGHT="17.92097262724371"/>
<DICH_DATA CI_END="0.8833417907768123" CI_START="0.5543204080986224" EFFECT_SIZE="0.6997530864197531" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="75" LOG_CI_END="-0.05387122266574089" LOG_CI_START="-0.25623913194071296" LOG_EFFECT_SIZE="-0.15505517730322696" ORDER="12" O_E="0.0" SE="0.11887191164542532" STUDY_ID="STD-Matthys-2007a" TOTAL_1="108" TOTAL_2="109" VAR="0.014130531378237804" WEIGHT="22.825329234776216"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.076656000073094" CI_END="0.9352067720835956" CI_START="0.5720463883578143" DF="2" EFFECT_SIZE="0.7314244023398389" ESTIMABLE="YES" EVENTS_1="166" EVENTS_2="76" I2="60.60398813764014" ID="CMP-001.03.02" LOG_CI_END="-0.029092356991759546" LOG_CI_START="-0.24256875199202202" LOG_EFFECT_SIZE="-0.13583055449189077" NO="2" P_CHI2="0.07899845855540155" P_Z="0.012625277880178296" STUDIES="3" TAU2="0.02856140417531906" TOTAL_1="303" TOTAL_2="102" WEIGHT="59.25369813798008" Z="2.494167983339647">
<NAME>Tablet preparation</NAME>
<DICH_DATA CI_END="1.1721864794768646" CI_START="0.7220694103021391" EFFECT_SIZE="0.92" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="25" LOG_CI_END="0.06899670772768969" LOG_CI_START="-0.1414210530365791" LOG_EFFECT_SIZE="-0.036212172654444715" ORDER="13" O_E="0.0" SE="0.12360043425764573" STUDY_ID="STD-Matthys-2010-_x002d_-10-mg" TOTAL_1="102" TOTAL_2="34" VAR="0.015277067348678605" WEIGHT="21.936567795852785"/>
<DICH_DATA CI_END="0.863635604086496" CI_START="0.5048684183536138" EFFECT_SIZE="0.6603198781416603" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="26" LOG_CI_END="-0.06366946182233248" LOG_CI_START="-0.29682179540420567" LOG_EFFECT_SIZE="-0.1802456286132691" ORDER="14" O_E="0.0" SE="0.136954834868657" STUDY_ID="STD-Matthys-2010-_x002d_-20-mg" TOTAL_1="101" TOTAL_2="34" VAR="0.01875662679390111" WEIGHT="19.618288074914307"/>
<DICH_DATA CI_END="0.8384674478724238" CI_START="0.4667746625025202" EFFECT_SIZE="0.6256" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="25" LOG_CI_END="-0.07651379350369633" LOG_CI_START="-0.33089272639272044" LOG_EFFECT_SIZE="-0.20370325994820837" ORDER="15" O_E="0.0" SE="0.1494234443750386" STUDY_ID="STD-Matthys-2010-_x002d_-30-mg" TOTAL_1="100" TOTAL_2="34" VAR="0.022327365728900254" WEIGHT="17.698842267212985"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-09-06 20:23:31 +1000" MODIFIED_BY="Antje Timmer" NO="2">
<NAME>
<I>P. sidoides</I> versus placebo, acute bronchitis in children</NAME>
<DICH_OUTCOME CHI2="9.821217396827004" CI_END="0.9240289467491559" CI_START="0.8330168858292231" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8773435562178814" ESTIMABLE="YES" EVENTS_1="431" EVENTS_2="292" I2="59.271851559947116" I2_Q="87.99996303331818" ID="CMP-002.01" LOG_CI_END="-0.03431442356721458" LOG_CI_START="-0.07934619505404475" LOG_EFFECT_SIZE="-0.05683030931062967" METHOD="MH" MODIFIED="2013-06-20 02:34:36 +1000" MODIFIED_BY="Antje Timmer" NO="1" P_CHI2="0.043549437558048965" P_Q="0.003892515861561252" P_Z="7.537847887966543E-7" Q="8.333307662105597" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="512" TOTAL_2="307" WEIGHT="200.0" Z="4.946967698647201">
<NAME>Failure to recover by day seven (complete resolution of all symptoms)</NAME>
<GROUP_LABEL_1>P. sidoides</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors P. sidoides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.178693260080055E-5" CI_END="0.8836349712863633" CI_START="0.7663325819546758" DF="1" EFFECT_SIZE="0.8228962687066484" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="200" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="-0.05372710455236023" LOG_CI_START="-0.11558270926999814" LOG_EFFECT_SIZE="-0.08465490691117919" NO="1" P_CHI2="0.9972606999311984" P_Z="8.10521079059074E-8" STUDIES="2" TAU2="0.0" TOTAL_1="214" TOTAL_2="206" WEIGHT="100.0" Z="5.364770724266817">
<NAME>Liquid preparation</NAME>
<DICH_DATA CI_END="0.9085048524632104" CI_START="0.7451620726498586" EFFECT_SIZE="0.8227899846704139" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="95" LOG_CI_END="-0.041672748716576544" LOG_CI_START="-0.12774925798682593" LOG_EFFECT_SIZE="-0.08471100335170123" ORDER="16" O_E="0.0" SE="0.05056176763093722" STUDY_ID="STD-Kamin-2010a" TOTAL_1="103" TOTAL_2="97" VAR="0.002556492345964891" WEIGHT="48.011686776546156"/>
<DICH_DATA CI_END="0.9112979538645939" CI_START="0.7432473840279943" EFFECT_SIZE="0.822994422994423" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="105" LOG_CI_END="-0.0403396048459095" LOG_CI_START="-0.128866610685697" LOG_EFFECT_SIZE="-0.08460310776580322" ORDER="17" O_E="0.0" SE="0.052001201446037516" STUDY_ID="STD-Kamin-2012" TOTAL_1="111" TOTAL_2="109" VAR="0.0027041249518313746" WEIGHT="51.988313223453844"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9373350678348535" CI_END="1.0325083143905407" CI_START="0.8890422457761483" DF="2" EFFECT_SIZE="0.958093685715709" ESTIMABLE="YES" EVENTS_1="260" EVENTS_2="92" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.013893557548190306" LOG_CI_START="-0.051077601603974884" LOG_EFFECT_SIZE="-0.01859202202789229" NO="2" P_CHI2="0.6258356557910434" P_Z="0.26198193093903666" STUDIES="3" TAU2="0.0" TOTAL_1="298" TOTAL_2="101" WEIGHT="100.0" Z="1.121719053498828">
<NAME>Tablet preparation</NAME>
<DICH_DATA CI_END="1.1268689961568943" CI_START="0.8839827715139192" EFFECT_SIZE="0.9980645161290322" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="31" LOG_CI_END="0.05187343019592624" LOG_CI_START="-0.053556199137774096" LOG_EFFECT_SIZE="-8.413844709239629E-4" ORDER="18" O_E="0.0" SE="0.061929886155697625" STUDY_ID="STD-Kamin-2010b-_x002d_-10-mg" TOTAL_1="100" TOTAL_2="34" VAR="0.0038353107992576685" WEIGHT="33.66975870958996"/>
<DICH_DATA CI_END="1.04834594867133" CI_START="0.7918411454179024" EFFECT_SIZE="0.9111111111111111" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="30" LOG_CI_END="0.020504621203483415" LOG_CI_START="-0.10136193531469977" LOG_EFFECT_SIZE="-0.04042865705560819" ORDER="19" O_E="0.0" SE="0.07158501854796465" STUDY_ID="STD-Kamin-2010b-_x002d_-20-mg" TOTAL_1="99" TOTAL_2="33" VAR="0.0051244148805124415" WEIGHT="32.74655564819798"/>
<DICH_DATA CI_END="1.0950262249132865" CI_START="0.8483558172585728" EFFECT_SIZE="0.9638318670576735" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="31" LOG_CI_END="0.03942452027088176" LOG_CI_START="-0.07142195781277962" LOG_EFFECT_SIZE="-0.015998718770948932" ORDER="20" O_E="0.0" SE="0.06511176992525847" STUDY_ID="STD-Kamin-2010b-_x002d_-30-mg" TOTAL_1="99" TOTAL_2="34" VAR="0.0042395425827997935" WEIGHT="33.58368564221207"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.428115494046624" CI_END="0.9174985029351489" CI_START="0.8144378765063149" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8644336483665045" ESTIMABLE="YES" EVENTS_1="429" EVENTS_2="290" I2="64.99860364481121" I2_Q="82.46721111726637" ID="CMP-002.02" LOG_CI_END="-0.03739463570533825" LOG_CI_START="-0.08914203710066587" LOG_EFFECT_SIZE="-0.06326833640300208" METHOD="MH" MODIFIED="2013-06-20 02:34:36 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.02215145021257181" P_Q="0.016930187267734542" P_Z="1.645904339900315E-6" Q="5.703599163193054" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.006962856814100004" TOTALS="SUB" TOTAL_1="512" TOTAL_2="307" WEIGHT="200.0" Z="4.792652669235098">
<NAME>Failure to resolve key symptom by day seven: cough</NAME>
<GROUP_LABEL_1>P. sidoides</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors P. sidoides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.7819188111694757E-4" CI_END="0.8839039352925399" CI_START="0.7647518713618098" DF="1" EFFECT_SIZE="0.8221722378060682" ESTIMABLE="YES" EVENTS_1="170" EVENTS_2="199" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="-0.05359493254281645" LOG_CI_START="-0.11647945161544683" LOG_EFFECT_SIZE="-0.08503719207913163" NO="1" P_CHI2="0.9825535711994157" P_Z="1.1528218918004173E-7" STUDIES="2" TAU2="0.0" TOTAL_1="214" TOTAL_2="206" WEIGHT="100.0" Z="5.30082240524134">
<NAME>Liquid preparation</NAME>
<DICH_DATA CI_END="0.9085048524632104" CI_START="0.7451620726498586" EFFECT_SIZE="0.8227899846704139" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="95" LOG_CI_END="-0.041672748716576544" LOG_CI_START="-0.12774925798682593" LOG_EFFECT_SIZE="-0.08471100335170123" ORDER="21" O_E="0.0" SE="0.05056176763093722" STUDY_ID="STD-Kamin-2010a" TOTAL_1="103" TOTAL_2="97" VAR="0.002556492345964891" WEIGHT="53.37257976851761"/>
<DICH_DATA CI_END="0.913346468493649" CI_START="0.7388279407077645" EFFECT_SIZE="0.8214656964656964" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="104" LOG_CI_END="-0.0393644461109996" LOG_CI_START="-0.13145668894139165" LOG_EFFECT_SIZE="-0.08541056752619564" ORDER="22" O_E="0.0" SE="0.05409543930252642" STUDY_ID="STD-Kamin-2012" TOTAL_1="111" TOTAL_2="109" VAR="0.00292631655333332" WEIGHT="46.62742023148239"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.5889646552481946" CI_END="1.0664201900131447" CI_START="0.864678446330185" DF="2" EFFECT_SIZE="0.9602658762216362" ESTIMABLE="YES" EVENTS_1="259" EVENTS_2="91" I2="44.27362228058247" ID="CMP-002.02.02" LOG_CI_END="0.02792835876916902" LOG_CI_START="-0.06314536646271429" LOG_EFFECT_SIZE="-0.017608503846772615" NO="2" P_CHI2="0.16621353537716477" P_Z="0.44851552144520346" STUDIES="3" TAU2="0.00380260780005066" TOTAL_1="298" TOTAL_2="101" WEIGHT="100.0" Z="0.7578922081739395">
<NAME>Tablet preparation</NAME>
<DICH_DATA CI_END="1.1831708250541237" CI_START="0.8989812983224874" EFFECT_SIZE="1.0313333333333334" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="30" LOG_CI_END="0.07304745217019241" LOG_CI_START="-0.04624934288281971" LOG_EFFECT_SIZE="0.013399054643686329" ORDER="23" O_E="0.0" SE="0.07007552794279877" STUDY_ID="STD-Kamin-2010b-_x002d_-10-mg" TOTAL_1="100" TOTAL_2="34" VAR="0.00491057961646197" WEIGHT="32.846140829756294"/>
<DICH_DATA CI_END="0.988927116580484" CI_START="0.767078579172986" EFFECT_SIZE="0.8709677419354839" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="31" LOG_CI_END="-0.004835714503214292" LOG_CI_START="-0.11516014484735644" LOG_EFFECT_SIZE="-0.05999792967528537" ORDER="24" O_E="0.0" SE="0.0648051164988869" STUDY_ID="STD-Kamin-2010b-_x002d_-20-mg" TOTAL_1="99" TOTAL_2="33" VAR="0.004199703124434302" WEIGHT="35.763991634360806"/>
<DICH_DATA CI_END="1.1489381658490143" CI_START="0.8633497835377462" EFFECT_SIZE="0.9959595959595959" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="30" LOG_CI_END="0.0602966562312088" LOG_CI_START="-0.06381321554388622" LOG_EFFECT_SIZE="-0.0017582796563387155" ORDER="25" O_E="0.0" SE="0.07290275303446431" STUDY_ID="STD-Kamin-2010b-_x002d_-30-mg" TOTAL_1="99" TOTAL_2="34" VAR="0.005314811400004095" WEIGHT="31.389867535882907"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.872550512339416" CI_END="0.981539555774525" CI_START="0.672153378061216" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8122469625148205" ESTIMABLE="YES" EVENTS_1="208" EVENTS_2="146" I2="66.30883990897568" I2_Q="62.64071956654824" ID="CMP-002.03" LOG_CI_END="-0.00809219376295878" LOG_CI_START="-0.17253161437910103" LOG_EFFECT_SIZE="-0.09031190407102992" METHOD="MH" MODIFIED="2013-06-20 02:34:36 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.018324630065936764" P_Q="0.10182589211885995" P_Z="0.03132915342588289" Q="2.676711083291082" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.05855910999712696" TOTALS="SUB" TOTAL_1="438" TOTAL_2="233" WEIGHT="200.0" Z="2.152866735861983">
<NAME>Failure to resolve key symptom by day seven: sputum</NAME>
<GROUP_LABEL_1>P. sidoides</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors P. sidoides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.4978958849701085" CI_END="0.9107348804283976" CI_START="0.3300554371785797" DF="1" EFFECT_SIZE="0.5482636219133787" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="84" I2="71.41138464707203" ID="CMP-002.03.01" LOG_CI_END="-0.04060802996913296" LOG_CI_START="-0.4814131084897194" LOG_EFFECT_SIZE="-0.26101056922942617" NO="1" P_CHI2="0.06144697874194793" P_Z="0.02028267606679194" STUDIES="2" TAU2="0.09722349662434353" TOTAL_1="140" TOTAL_2="132" WEIGHT="100.0" Z="2.321077229830883">
<NAME>Liquid preparation</NAME>
<DICH_DATA CI_END="0.9157080673018632" CI_START="0.5106590583557822" EFFECT_SIZE="0.6838235294117647" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="44" LOG_CI_END="-0.03824295970286486" LOG_CI_START="-0.2918689599296999" LOG_EFFECT_SIZE="-0.16505595981628238" ORDER="26" O_E="0.0" SE="0.14898116800219197" STUDY_ID="STD-Kamin-2010a" TOTAL_1="68" TOTAL_2="62" VAR="0.022195388419297343" WEIGHT="56.14296836634938"/>
<DICH_DATA CI_END="0.6560744535610388" CI_START="0.26022907612553303" EFFECT_SIZE="0.4131944444444444" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="40" LOG_CI_END="-0.1830468726122698" LOG_CI_START="-0.5846441801211305" LOG_EFFECT_SIZE="-0.3838455263667001" ORDER="27" O_E="0.0" SE="0.235900246369438" STUDY_ID="STD-Kamin-2012" TOTAL_1="72" TOTAL_2="70" VAR="0.055648926237161535" WEIGHT="43.85703163365062"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.3406351350697516" CI_END="1.061449854258195" CI_START="0.7057750276868695" DF="2" EFFECT_SIZE="0.865531513162462" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="62" I2="14.553106973659121" ID="CMP-002.03.02" LOG_CI_END="0.025899481748956055" LOG_CI_START="-0.15133371226913547" LOG_EFFECT_SIZE="-0.0627171152600897" NO="2" P_CHI2="0.31026844299069045" P_Z="0.16540024404041132" STUDIES="3" TAU2="0.004751138061403014" TOTAL_1="298" TOTAL_2="101" WEIGHT="100.0" Z="1.387136171697899">
<NAME>Tablet preparation</NAME>
<DICH_DATA CI_END="1.4023150830579731" CI_START="0.7656558186670079" EFFECT_SIZE="1.036190476190476" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="21" LOG_CI_END="0.14684560525636084" LOG_CI_START="-0.11596641267191485" LOG_EFFECT_SIZE="0.015439596292222992" ORDER="28" O_E="0.0" SE="0.1543770802715392" STUDY_ID="STD-Kamin-2010b-_x002d_-10-mg" TOTAL_1="100" TOTAL_2="34" VAR="0.023832282913165262" WEIGHT="37.91849806977799"/>
<DICH_DATA CI_END="1.1467992283619681" CI_START="0.5815703638003622" EFFECT_SIZE="0.8166666666666667" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="20" LOG_CI_END="0.059487392054136445" LOG_CI_START="-0.23539773276439638" LOG_EFFECT_SIZE="-0.08795517035512998" ORDER="29" O_E="0.0" SE="0.1732169820233158" STUDY_ID="STD-Kamin-2010b-_x002d_-20-mg" TOTAL_1="99" TOTAL_2="33" VAR="0.030004122861265713" WEIGHT="31.184930404159218"/>
<DICH_DATA CI_END="1.035319410251589" CI_START="0.523117834674754" EFFECT_SIZE="0.7359307359307359" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="21" LOG_CI_END="0.015074356275358707" LOG_CI_START="-0.2814004733030995" LOG_EFFECT_SIZE="-0.13316305851387042" ORDER="30" O_E="0.0" SE="0.17415078246846147" STUDY_ID="STD-Kamin-2010b-_x002d_-30-mg" TOTAL_1="99" TOTAL_2="34" VAR="0.030328495034377387" WEIGHT="30.89657152606279"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-09-06 20:23:42 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>
<I>P. sidoides</I> versus placebo, acute sinusitis in adults</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.617548919923421" CI_START="0.3048310794927935" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4338756779307468" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="47" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-0.20932863351562633" LOG_CI_START="-0.5159407559541206" LOG_EFFECT_SIZE="-0.3626346947348735" METHOD="MH" MODIFIED="2013-06-20 02:34:39 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="3.549467203006655E-6" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="52" WEIGHT="100.0" Z="4.636156819713504">
<NAME>Failure to recover by day 21 (complete resolution of all symptoms)</NAME>
<GROUP_LABEL_1>P. sidoides</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors P. sidoides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6175489199234211" CI_START="0.3048310794927934" EFFECT_SIZE="0.4338756779307468" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="47" LOG_CI_END="-0.20932863351562625" LOG_CI_START="-0.5159407559541207" LOG_EFFECT_SIZE="-0.3626346947348735" ORDER="31" O_E="0.0" SE="0.18010547847485572" STUDY_ID="STD-Bachert-2009" TOTAL_1="51" TOTAL_2="52" VAR="0.03243798337665672" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.40278536544989973" CI_START="0.10860339761995214" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.20915032679738563" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.39492631721428445" LOG_CI_START="-0.9641565877811012" LOG_EFFECT_SIZE="-0.6795414524976928" METHOD="MH" MODIFIED="2013-06-20 02:34:40 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="2.87475601350657E-6" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="52" WEIGHT="100.0" Z="4.679571139360822">
<NAME>Failure to resolve key symptom by day 21: nasal discharge</NAME>
<GROUP_LABEL_1>P. sidoides</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors P. sidoides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.40278536544989973" CI_START="0.10860339761995214" EFFECT_SIZE="0.20915032679738563" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="39" LOG_CI_END="-0.39492631721428445" LOG_CI_START="-0.9641565877811012" LOG_EFFECT_SIZE="-0.6795414524976928" ORDER="32" O_E="0.0" SE="0.3343686786662314" STUDY_ID="STD-Bachert-2009" TOTAL_1="51" TOTAL_2="52" VAR="0.11180241327300149" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.43907901293325785" CI_START="0.11692264418741855" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.22657952069716775" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-0.3574573207756001" LOG_CI_START="-0.9321013717013618" LOG_EFFECT_SIZE="-0.6447793462384809" METHOD="MH" MODIFIED="2013-06-20 02:34:40 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="1.0907441080476157E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="52" WEIGHT="100.0" Z="4.398355101968915">
<NAME>Failure to resolve key symptom by day 21: headache</NAME>
<GROUP_LABEL_1>P. sidoides</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors P. sidoides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.4390790129332579" CI_START="0.11692264418741855" EFFECT_SIZE="0.22657952069716775" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="36" LOG_CI_END="-0.35745732077560005" LOG_CI_START="-0.9321013717013618" LOG_EFFECT_SIZE="-0.6447793462384809" ORDER="33" O_E="0.0" SE="0.3375487600477206" STUDY_ID="STD-Bachert-2009" TOTAL_1="51" TOTAL_2="52" VAR="0.11393916540975367" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2013-09-06 20:23:52 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>
<I>P. sidoides</I> versus placebo, the common cold in adults</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0273252591353526" CI_START="0.9009802681645095" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9620809672101117" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="51" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.011707966366104052" LOG_CI_START="-0.04528472014314307" LOG_EFFECT_SIZE="-0.01678837688851953" METHOD="MH" MODIFIED="2013-06-20 02:35:01 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.24821495081509637" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="51" WEIGHT="100.0" Z="1.1546960171826297">
<NAME>Failure to recover by day 5 (complete resolution of all symptoms)</NAME>
<GROUP_LABEL_1>P. sidoides</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors P. sidoides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0273252591353523" CI_START="0.9009802681645096" EFFECT_SIZE="0.9620809672101117" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="51" LOG_CI_END="0.011707966366103958" LOG_CI_START="-0.04528472014314301" LOG_EFFECT_SIZE="-0.01678837688851953" MODIFIED="2008-02-14 22:53:11 +1000" MODIFIED_BY="Antje Timmer" ORDER="51" O_E="0.0" SE="0.03347778617387982" STUDY_ID="STD-Lizogub-2007" TOTAL_1="52" TOTAL_2="51" VAR="0.001120762167104019" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.106110385307827" CI_START="0.6558369503432973" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8517206477732794" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.04379846995050406" LOG_CI_START="-0.18320411850207496" LOG_EFFECT_SIZE="-0.06970282427578546" METHOD="MH" MODIFIED="2013-06-20 02:35:01 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.22872765859840238" Q="0.0" RANDOM="NO" SCALE="853.84" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="51" WEIGHT="100.0" Z="1.2036428847136484">
<NAME>Failure to resolve key symptom by day 5: sore throat</NAME>
<GROUP_LABEL_1>P. sidoides</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors P. sidoides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.106110385307827" CI_START="0.6558369503432973" EFFECT_SIZE="0.8517206477732794" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="38" LOG_CI_END="0.04379846995050406" LOG_CI_START="-0.18320411850207496" LOG_EFFECT_SIZE="-0.06970282427578546" MODIFIED="2008-02-14 22:54:06 +1000" MODIFIED_BY="Antje Timmer" ORDER="52" O_E="0.0" SE="0.13334244413798024" STUDY_ID="STD-Lizogub-2007" TOTAL_1="52" TOTAL_2="51" VAR="0.01778020740869038" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.874400031166518E-30" CI_END="0.9459317881679657" CI_START="0.7175173661534487" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.823846153846154" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="50" I2="100.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-0.024140179761349155" LOG_CI_START="-0.14416758318861297" LOG_EFFECT_SIZE="-0.08415388147498105" METHOD="MH" MODIFIED="2013-06-20 02:35:01 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="1.0" P_Z="0.0059896278296525446" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="51" WEIGHT="100.0" Z="2.7483486627312987">
<NAME>Failure to resolve key symptom by day 5: nasal drainage</NAME>
<GROUP_LABEL_1>P. sidoides</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors P. sidoides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9459317881679656" CI_START="0.7175173661534486" EFFECT_SIZE="0.8238461538461539" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="50" LOG_CI_END="-0.024140179761349204" LOG_CI_START="-0.14416758318861306" LOG_EFFECT_SIZE="-0.08415388147498111" MODIFIED="2008-02-14 22:54:59 +1000" MODIFIED_BY="Antje Timmer" ORDER="53" O_E="0.0" SE="0.07050469091840399" STUDY_ID="STD-Lizogub-2007" TOTAL_1="52" TOTAL_2="51" VAR="0.0049709114414996786" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.874400031166518E-30" CI_END="0.9459317881679657" CI_START="0.7175173661534487" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.823846153846154" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="50" I2="100.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="-0.024140179761349155" LOG_CI_START="-0.14416758318861297" LOG_EFFECT_SIZE="-0.08415388147498105" METHOD="MH" MODIFIED="2013-06-20 02:35:01 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="1.0" P_Z="0.0059896278296525446" Q="0.0" RANDOM="NO" SCALE="4.477445588112261" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="51" WEIGHT="100.0" Z="2.7483486627312987">
<NAME>Failure to resolve key symptom by day 5: nasal congestion</NAME>
<GROUP_LABEL_1>P. sidoides</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors P. sidoides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9459317881679656" CI_START="0.7175173661534486" EFFECT_SIZE="0.8238461538461539" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="50" LOG_CI_END="-0.024140179761349204" LOG_CI_START="-0.14416758318861306" LOG_EFFECT_SIZE="-0.08415388147498111" MODIFIED="2008-02-14 22:56:16 +1000" MODIFIED_BY="Antje Timmer" ORDER="54" O_E="0.0" SE="0.07050469091840399" STUDY_ID="STD-Lizogub-2007" TOTAL_1="52" TOTAL_2="51" VAR="0.0049709114414996786" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6006840824455041" CI_START="0.285476074042424" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.41410256410256413" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="-0.22135387628916026" LOG_CI_START="-0.5444302844295947" LOG_EFFECT_SIZE="-0.3828920803593775" METHOD="MH" MODIFIED="2013-06-20 02:35:01 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="3.3895925948328694E-6" Q="0.0" RANDOM="NO" SCALE="19.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="51" WEIGHT="100.0" Z="4.6456792793349955">
<NAME>Failure to recover by day 10 (complete resolution of all symptoms)</NAME>
<GROUP_LABEL_1>P. sidoides</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors P. sidoides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6006840824455041" CI_START="0.285476074042424" EFFECT_SIZE="0.41410256410256413" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="45" LOG_CI_END="-0.22135387628916026" LOG_CI_START="-0.5444302844295947" LOG_EFFECT_SIZE="-0.3828920803593775" MODIFIED="2008-02-14 23:09:09 +1000" MODIFIED_BY="Antje Timmer" ORDER="55" O_E="0.0" SE="0.18977668139570392" STUDY_ID="STD-Lizogub-2007" TOTAL_1="52" TOTAL_2="51" VAR="0.03601518880156651" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9744995577638726" CI_START="0.006018841245141441" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.1090146750524109" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="0.29545704080199764" LOG_CI_START="-2.2204871116126275" LOG_EFFECT_SIZE="-0.9625150354053148" METHOD="MH" MODIFIED="2013-06-20 02:35:01 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.13370983139007722" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="51" WEIGHT="100.0" Z="1.4996317006179873">
<NAME>Failure to resolve key symptom by day 10: sore throat</NAME>
<GROUP_LABEL_1>P. sidoides</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors P. sidoides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9744995577638726" CI_START="0.006018841245141441" EFFECT_SIZE="0.1090146750524109" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.29545704080199764" LOG_CI_START="-2.2204871116126275" LOG_EFFECT_SIZE="-0.9625150354053148" MODIFIED="2008-02-14 23:09:50 +1000" MODIFIED_BY="Antje Timmer" ORDER="56" O_E="0.0" SE="1.4778780492527626" STUDY_ID="STD-Lizogub-2007" TOTAL_1="52" TOTAL_2="51" VAR="2.184123528463151" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7649960499185134" CI_START="0.04156703941523262" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.17832167832167833" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" I2="0.0" I2_Q="100.0" ID="CMP-004.07" LOG_CI_END="-0.11634080733399244" LOG_CI_START="-1.381250906728221" LOG_EFFECT_SIZE="-0.7487958570311066" METHOD="MH" MODIFIED="2013-06-20 02:35:01 +1000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.020313762157574522" Q="8.93070875780323E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="51" WEIGHT="100.0" Z="2.320501531700347">
<NAME>Failure to resolve key symptom by day 10: nasal drainage</NAME>
<GROUP_LABEL_1>P. sidoides</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors P. sidoides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7649960499185134" CI_START="0.04156703941523262" EFFECT_SIZE="0.17832167832167833" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.11634080733399244" LOG_CI_START="-1.381250906728221" LOG_EFFECT_SIZE="-0.7487958570311066" MODIFIED="2008-02-14 23:10:28 +1000" MODIFIED_BY="Antje Timmer" ORDER="57" O_E="0.0" SE="0.7430144537901444" STUDY_ID="STD-Lizogub-2007" TOTAL_1="52" TOTAL_2="51" VAR="0.5520704785410667" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0076685115078405" CI_START="0.08591292133619144" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.29423076923076924" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-004.08" LOG_CI_END="0.003317687565936712" LOG_CI_START="-1.0659415132003371" LOG_EFFECT_SIZE="-0.5313119128172004" METHOD="MH" MODIFIED="2013-06-20 02:35:01 +1000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.0514387469865364" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="51" WEIGHT="100.0" Z="1.9478012682659602">
<NAME>Failure to resolve key symptom by day 10: nasal congestion</NAME>
<GROUP_LABEL_1>P. sidoides</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors P. sidoides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0076685115078408" CI_START="0.0859129213361914" EFFECT_SIZE="0.29423076923076924" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.003317687565936808" LOG_CI_START="-1.0659415132003374" LOG_EFFECT_SIZE="-0.5313119128172004" MODIFIED="2008-02-14 23:11:21 +1000" MODIFIED_BY="Antje Timmer" ORDER="58" O_E="0.0" SE="0.6280881474485164" STUDY_ID="STD-Lizogub-2007" TOTAL_1="52" TOTAL_2="51" VAR="0.39449472096530924" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.5440068531265895" CI_START="-2.0559931468734085" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.299999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.09" MODIFIED="2013-06-20 02:35:01 +1000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="7.507576478428259E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="51" UNITS="" WEIGHT="100.0" Z="3.370338991087073">
<NAME>Days off work</NAME>
<GROUP_LABEL_1>P. sidoides</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors P. sidoides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.5440068531265895" CI_START="-2.0559931468734085" EFFECT_SIZE="-1.299999999999999" ESTIMABLE="YES" MEAN_1="6.9" MEAN_2="8.2" ORDER="34" SD_1="1.8" SD_2="2.1" SE="0.3857178768776299" STUDY_ID="STD-Lizogub-2007" TOTAL_1="52" TOTAL_2="51" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2013-09-06 20:24:08 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>
<I>P. sidoides </I>versus placebo, any indication</NAME>
<DICH_OUTCOME CHI2="5.4524383378692045" CI_END="1.660826213228076" CI_START="1.0444184675028738" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3170412174295336" ESTIMABLE="YES" EVENTS_1="200" EVENTS_2="90" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.22032419079894278" LOG_CI_START="0.018874542453553387" LOG_EFFECT_SIZE="0.11959936662624805" METHOD="MH" MODIFIED="2008-03-24 11:01:44 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6049268214486663" P_Q="1.0" P_Z="0.019952700431632088" Q="0.0" RANDOM="NO" SCALE="77.03737850730055" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1090" TOTAL_2="681" WEIGHT="100.0" Z="2.327236141503177">
<NAME>Patients with adverse events</NAME>
<GROUP_LABEL_1>P. sidoides</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors P. sidoides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.4547000782431" CI_START="0.6472912847334753" EFFECT_SIZE="3.0588235294117645" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1600090848883546" LOG_CI_START="-0.18890024037530434" LOG_EFFECT_SIZE="0.4855544222565252" ORDER="39" O_E="0.0" SE="0.792356014868722" STUDY_ID="STD-Bachert-2009" TOTAL_1="51" TOTAL_2="52" VAR="0.6278280542986424" WEIGHT="1.872479513893519"/>
<DICH_DATA CI_END="2.8846235937528077" CI_START="0.6855449240527363" EFFECT_SIZE="1.40625" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.46008915134925926" LOG_CI_START="-0.16396408043838392" LOG_EFFECT_SIZE="0.1480625354554377" ORDER="40" O_E="0.0" SE="0.3665719574653795" STUDY_ID="STD-Chuchalin-2005" TOTAL_1="64" TOTAL_2="60" VAR="0.13437500000000002" WEIGHT="9.75915951580177"/>
<DICH_DATA CI_END="1.9174118228148325" CI_START="0.7717107009547142" EFFECT_SIZE="1.2164239482200647" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="24" LOG_CI_END="0.2827154009154232" LOG_CI_START="-0.11254547754794461" LOG_EFFECT_SIZE="0.0850849616837393" ORDER="35" O_E="0.0" SE="0.23217819658228583" STUDY_ID="STD-Kamin-2010a" TOTAL_1="103" TOTAL_2="97" VAR="0.05390671496820256" WEIGHT="23.370747250466287"/>
<DICH_DATA CI_END="3.4596979655178615" CI_START="1.0405786451432502" EFFECT_SIZE="1.8973897389738974" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="11" LOG_CI_END="0.5390381861816557" LOG_CI_START="0.01727490901762721" LOG_EFFECT_SIZE="0.27815654759964137" ORDER="36" O_E="0.0" SE="0.30648633177602663" STUDY_ID="STD-Kamin-2010b" TOTAL_1="303" TOTAL_2="102" VAR="0.09393387156552468" WEIGHT="15.560889485357812"/>
<DICH_DATA CI_END="101.12550754721117" CI_START="0.2384671818300646" EFFECT_SIZE="4.910714285714286" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0048607143424544" LOG_CI_START="-0.6225713806943298" LOG_EFFECT_SIZE="0.6911446668240622" ORDER="38" O_E="0.0" SE="1.5433666186232353" STUDY_ID="STD-Kamin-2012" TOTAL_1="111" TOTAL_2="109" VAR="2.381980519480519" WEIGHT="0.4769679312903117"/>
<DICH_DATA CI_END="20.966047238879877" CI_START="0.1835173360174226" EFFECT_SIZE="1.9615384615384615" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3215165599763081" LOG_CI_START="-0.7363229037220715" LOG_EFFECT_SIZE="0.2925968281271184" ORDER="41" O_E="0.0" SE="1.2087850874460588" STUDY_ID="STD-Lizogub-2007" TOTAL_1="52" TOTAL_2="51" VAR="1.461161387631976" WEIGHT="0.9545973992398333"/>
<DICH_DATA CI_END="1.6046202988337686" CI_START="0.5829970962855389" EFFECT_SIZE="0.9672067901234568" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="24" LOG_CI_END="0.20537228183116168" LOG_CI_START="-0.23433360831184005" LOG_EFFECT_SIZE="-0.014480663240339215" ORDER="42" O_E="0.0" SE="0.2582854164492589" STUDY_ID="STD-Matthys-2007a" TOTAL_1="108" TOTAL_2="109" VAR="0.06671135635036711" WEIGHT="22.585483450855524"/>
<DICH_DATA CI_END="1.7900899675945456" CI_START="0.68943666173258" EFFECT_SIZE="1.110924683072334" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="18" LOG_CI_END="0.252874858604463" LOG_CI_START="-0.16150562611401215" LOG_EFFECT_SIZE="0.04568461624522545" ORDER="37" O_E="0.0" SE="0.24340914794011329" STUDY_ID="STD-Matthys-2010" TOTAL_1="298" TOTAL_2="101" VAR="0.059248013300931955" WEIGHT="25.419675453094946"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.072077040541284" CI_END="2.270315317226143" CI_START="0.34554242533155255" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8857145482499961" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.3560861792289354" LOG_CI_START="-0.46149862280140774" LOG_EFFECT_SIZE="-0.0527062217862362" METHOD="MH" MODIFIED="2008-02-25 08:13:59 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8390846697130159" P_Q="1.0" P_Z="0.8004991846986963" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="USER" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1090" TOTAL_2="681" WEIGHT="99.99999999999999" Z="0.25270111725577177">
<NAME>Adverse events leading to withdrawal</NAME>
<GROUP_LABEL_1>P. sidoides</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors P. sidoides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.6190824906136205" CI_START="0.012949120960082898" EFFECT_SIZE="0.3141025641025641" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8819026756368473" LOG_CI_START="-1.8877597122887428" LOG_EFFECT_SIZE="-0.502928518325948" ORDER="1" O_E="0.0" SE="1.6269133967174247" STUDY_ID="STD-Kamin-2010a" TOTAL_1="103" TOTAL_2="97" VAR="2.646847200418629" WEIGHT="17.611991447991674"/>
<DICH_DATA CI_END="5.280560959816223" CI_START="0.02104153554075779" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.7226800605664246" LOG_CI_START="-1.6769225700057495" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="2" O_E="0.0" SE="1.409538463422686" STUDY_ID="STD-Kamin-2010b" TOTAL_1="303" TOTAL_2="101" VAR="1.9867986798679869" WEIGHT="17.10395323314576"/>
<DICH_DATA CI_END="25.170242886115517" CI_START="0.04243138187661329" EFFECT_SIZE="1.0334448160535117" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.4008874063942407" LOG_CI_START="-1.3723128241934308" LOG_EFFECT_SIZE="0.014287291100404985" ORDER="3" O_E="0.0" SE="1.628991543009735" STUDY_ID="STD-Matthys-2010" TOTAL_1="298" TOTAL_2="102" VAR="2.6536134471972375" WEIGHT="8.481064704329324"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4" O_E="0.0" SE="0.0" STUDY_ID="STD-Kamin-2012" TOTAL_1="111" TOTAL_2="109" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="73.35586484045308" CI_START="0.12745377985598785" EFFECT_SIZE="3.0576923076923075" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8654348416424724" LOG_CI_START="-0.8946472802711679" LOG_EFFECT_SIZE="0.4853937806856523" ORDER="5" O_E="0.0" SE="1.6212859010389238" STUDY_ID="STD-Bachert-2009" TOTAL_1="51" TOTAL_2="52" VAR="2.6285679729075953" WEIGHT="5.647019480149711"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6" O_E="0.0" SE="0.0" STUDY_ID="STD-Chuchalin-2005" TOTAL_1="64" TOTAL_2="60" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="70.613833580842" CI_START="0.12268957662178398" EFFECT_SIZE="2.943396226415094" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8488897897104928" LOG_CI_START="-0.9111923322031477" LOG_EFFECT_SIZE="0.4688487287536725" ORDER="7" O_E="0.0" SE="1.6212859010389238" STUDY_ID="STD-Lizogub-2007" TOTAL_1="52" TOTAL_2="51" VAR="2.6285679729075953" WEIGHT="5.755616008614129"/>
<DICH_DATA CI_END="3.302368259309432" CI_START="0.17350121094463375" EFFECT_SIZE="0.7569444444444444" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5188255014126333" LOG_CI_START="-0.7606974897218852" LOG_EFFECT_SIZE="-0.12093599415462604" ORDER="8" O_E="0.0" SE="0.7515981387333716" STUDY_ID="STD-Matthys-2007a" TOTAL_1="108" TOTAL_2="109" VAR="0.5648997621474685" WEIGHT="45.400355125769394"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="855" EVENTS_2="645" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-03-24 11:01:56 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="7.0871189361159415" SORT_BY="USER" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="1090" TOTAL_2="681" WEIGHT="0.0" Z="0.0">
<NAME>Failure to resolve all symptoms at prespecified day - publication bias</NAME>
<GROUP_LABEL_1>P. sidoides</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors P. sidoides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6980616661042219" CI_START="0.48821978506909797" EFFECT_SIZE="0.5837872185911401" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="102" LOG_CI_END="-0.15610621052034293" LOG_CI_START="-0.3113846248118559" LOG_EFFECT_SIZE="-0.23374541766609946" MODIFIED="2008-02-14 23:14:15 +1000" MODIFIED_BY="Antje Timmer" ORDER="117" O_E="0.0" SE="0.09121130919538195" STUDY_ID="STD-Matthys-2007a" TOTAL_1="108" TOTAL_2="109" VAR="0.008319502925135568" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.6006840824455041" CI_START="0.285476074042424" EFFECT_SIZE="0.41410256410256413" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="45" LOG_CI_END="-0.22135387628916026" LOG_CI_START="-0.5444302844295947" LOG_EFFECT_SIZE="-0.3828920803593775" MODIFIED="2008-02-14 23:13:16 +1000" MODIFIED_BY="Antje Timmer" ORDER="118" O_E="0.0" SE="0.18977668139570392" STUDY_ID="STD-Lizogub-2007" TOTAL_1="52" TOTAL_2="51" VAR="0.03601518880156651" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.6175489199234211" CI_START="0.3048310794927934" EFFECT_SIZE="0.4338756779307468" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="47" LOG_CI_END="-0.20932863351562625" LOG_CI_START="-0.5159407559541207" LOG_EFFECT_SIZE="-0.3626346947348735" MODIFIED="2008-02-14 23:18:44 +1000" MODIFIED_BY="Antje Timmer" ORDER="119" O_E="0.0" SE="0.18010547847485572" STUDY_ID="STD-Bachert-2009" TOTAL_1="51" TOTAL_2="52" VAR="0.03243798337665672" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.0431347038204069" CI_START="0.8920446005839227" EFFECT_SIZE="0.9646360351058337" ESTIMABLE="YES" EVENTS_1="259" EVENTS_2="91" LOG_CI_END="0.018340394091438464" LOG_CI_START="-0.049613431158347356" LOG_EFFECT_SIZE="-0.015636518533454446" MODIFIED="2008-02-14 23:18:22 +1000" MODIFIED_BY="Antje Timmer" ORDER="120" O_E="0.0" SE="0.039916413328584185" STUDY_ID="STD-Kamin-2010b" TOTAL_1="298" TOTAL_2="101" VAR="0.0015933200530183732" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.8549785443344743" CI_START="0.6248833839078249" EFFECT_SIZE="0.7309322033898306" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="59" LOG_CI_END="-0.06804478374441315" LOG_CI_START="-0.2042010233772141" LOG_EFFECT_SIZE="-0.13612290356081364" MODIFIED="2008-02-14 23:14:28 +1000" MODIFIED_BY="Antje Timmer" ORDER="121" O_E="0.0" SE="0.07997884914456334" STUDY_ID="STD-Chuchalin-2005" TOTAL_1="64" TOTAL_2="60" VAR="0.0063966163104888195" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9085048524632104" CI_START="0.7451620726498586" EFFECT_SIZE="0.8227899846704139" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="95" LOG_CI_END="-0.041672748716576544" LOG_CI_START="-0.12774925798682593" LOG_EFFECT_SIZE="-0.08471100335170123" MODIFIED="2008-02-14 23:17:39 +1000" MODIFIED_BY="Antje Timmer" ORDER="122" O_E="0.0" SE="0.05056176763093722" STUDY_ID="STD-Kamin-2010a" TOTAL_1="103" TOTAL_2="97" VAR="0.002556492345964891" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9112979538645939" CI_START="0.7432473840279943" EFFECT_SIZE="0.822994422994423" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="105" LOG_CI_END="-0.0403396048459095" LOG_CI_START="-0.128866610685697" LOG_EFFECT_SIZE="-0.08460310776580322" MODIFIED="2008-02-14 23:17:51 +1000" MODIFIED_BY="Antje Timmer" ORDER="123" O_E="0.0" SE="0.052001201446037516" STUDY_ID="STD-Kamin-2012" TOTAL_1="111" TOTAL_2="109" VAR="0.0027041249518313746" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9718308539815222" CI_START="0.9025978521090035" EFFECT_SIZE="0.9365748456033722" ESTIMABLE="YES" EVENTS_1="281" EVENTS_2="101" LOG_CI_END="-0.012409316940836686" LOG_CI_START="-0.04450570429506356" LOG_EFFECT_SIZE="-0.028457510617950127" MODIFIED="2008-02-14 23:15:41 +1000" MODIFIED_BY="Antje Timmer" ORDER="124" O_E="0.0" SE="0.018853576811552628" STUDY_ID="STD-Matthys-2010" TOTAL_1="303" TOTAL_2="102" VAR="3.55457358589115E-4" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-09-07 00:38:45 +1000" MODIFIED_BY="Liz Dooley">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-06-20 01:50:30 +1000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAMuCAYAAAAzFYXdAABRGUlEQVR42u2df4RWzf//3yRJkkiy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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-09-07 00:38:45 +1000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-09-07 00:38:45 +1000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUQAAAK+CAIAAABVafBzAAAdm0lEQVR42u3dvW4kRdvGcUtIiMDB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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-06-20 02:34:33 +1000" MODIFIED_BY="Liz Dooley" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 <I>P. sidoides</I> versus placebo, acute bronchitis in adults, outcome: 1.2 Failure to recover by day seven (complete resolution of all symptoms).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAswAAAFgCAMAAACYOd8gAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2013-06-20 02:34:37 +1000" MODIFIED_BY="Liz Dooley" NO="5" REF_ID="CMP-002.01" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 <I>P. sidoides</I> versus placebo, acute bronchitis in children, outcome: 2.2 Failure to recover by day seven (complete resolution of all symptoms).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAr0AAAFgCAMAAACBsjGGAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2013-09-06 20:26:43 +1000" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-003.01" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 <I>P. sidoides</I> versus placebo, acute sinusitis in adults, outcome: 3.1 Failure to recover by day 21 (complete resolution of all symptoms).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArEAAACQCAMAAAAoa8OlAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2013-09-06 20:26:47 +1000" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-004.01" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 <I>P. sidoides</I> versus placebo, the common cold in adults, outcome: 4.1 Failure to recover by day 5 (complete resolution of all symptoms).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArEAAACQCAMAAAAoa8OlAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2013-09-06 20:26:51 +1000" MODIFIED_BY="[Empty name]" NO="8" REF_ID="CMP-004.05" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 <I>P. sidoides</I> versus placebo, the common cold in adults, outcome: 4.5 Failure to recover by day 10 (complete resolution of all symptoms).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArEAAACQCAMAAAAoa8OlAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2013-06-20 01:50:42 +1000" MODIFIED_BY="Liz Dooley" NO="9" REF_ID="CMP-005.01" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 5 <I>P. sidoides</I> versus placebo, any indication, outcome: 5.1 Patients with adverse events.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAq8AAAEACAMAAACqHW8JAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2013-06-20 02:31:40 +1000" MODIFIED_BY="Liz Dooley" NO="10" REF_ID="CMP-005.03" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:NO;SHOW_CI_LINES:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 5 <I>P. sidoides</I> versus placebo, any indication, outcome: 5.3 Failure to resolve all symptoms at prespecified day - publication bias.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-09-09 10:29:28 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-09-09 10:08:23 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-09-09 10:04:12 +1000" MODIFIED_BY="[Empty name]">Electronic databases searched</TITLE>
<APPENDIX_BODY MODIFIED="2013-09-09 10:07:02 +1000" MODIFIED_BY="[Empty name]">
<TABLE COLS="4" ROWS="34">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Database (host)</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Update status</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Hits 2013</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Search date</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>MEDLINE</B> (via OvidSP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1946 to April Week 2 2013</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>117</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="22" VALIGN="TOP">
<P>24 April 2013</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>MEDLINE Daily Update</B> (via OvidSP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>23 April 2013</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>MEDLINE</B> <B>in Process &amp; Other Non-Indexed Citations</B> (via OvidSP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>23 April 2013<BR/>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Journals@Ovid</B>
</P>
<P>(via OvidSP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>23 April 2013</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>82</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>The Cochrane Library</I>
</P>
<P>(via Wiley Online Library):</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>    - Cochrane Reviews</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Issue 3 of 12, March 2013</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>24</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>    - Other Reviews</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Issue 1 of 4, January 2013</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>    - Clinical Trials</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Issue 3 of 12, March 2013</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Biosis Previews</B>
</P>
<P>(via Web of Knowledge, Thomson Reuters)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1926 to 23 April 2013</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>188</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Web of Science</B> (Thomson Reuters)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Present = 21 April 2013</P>
<P>Databases:</P>
<P>- SCI-EXP: 1945 to present</P>
<P>- SSCI: 1975 to present</P>
<P>- A&amp;HCI: 1975 to present</P>
<P>- CPCI-S: 1990 to present</P>
<P>- CPCI-SSH: 1990 to present</P>
<P>- BKCI-S: 2005 to present</P>
<P>- BKCI-SSH: 2005 to present</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>253</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>CINAHL</B> (via EBSCOhost)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1981 to present</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>51</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>CCMed</B>
</P>
<P>(via DIMDI www.dimdi.de)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 January 2000 to 19 February 2013</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>89</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>XToxline</B>
</P>
<P>(via DIMDI www.dimdi.de)</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 January 1965 to 19 April 2013</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Global Health</B>
</P>
<P>(via DIMDI www.dimdi.de)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 January 1972 to 24 April 2013</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>81</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>AMED</B>
</P>
<P>(via DIMDI www.dimdi.de)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 January 1985 to 8 April 2013</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>39</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Derwent Drug File</B>
</P>
<P>(via DIMDI www.dimdi.de)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 January 1983 to 23 April 2013</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>35</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Derwent Drug Backfile</B>
</P>
<P>(via DIMDI www.dimdi.de)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 January 1960 to 31 December 1982</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>IPA</B>
</P>
<P>(via DIMDI www.dimdi.de)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 January 1970 to 18 April 2013</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>72</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>ISTPB + ISTP/ISSHP</B>
</P>
<P>(via DIMDI www.dimdi.de)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 January 1978 to 21 April 2013</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>38</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>EMBASE </B>(via DIMDI www.dimdi.de)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 January 1974 to 24 April 2013</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>170</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>EMBASE Alert </B>(via DIMDI www.dimdi.de)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>22 February 2013 to 24 April 2013</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Deutsches Ärzteblatt</B> (via www.dimdi.de)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 January 1996 to 22 April 2013</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Thieme-Verlag</B> (via DIMDI)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 August 2002 to 27 April 2012</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>28</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27 April 2012</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Thieme-Verlag</B> (via <A HREF="http://www.thieme-connect">www.thieme-connect</A>)</P>
<P>Not available via DIMDI any more</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Publication year</P>
<P>2012 to 2013</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>25 April 2013</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Springer</B> (via SpringerLink www.springerlink.com)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Search date 25 April 2013</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Cambase</B>
</P>
<P>(via www.cambase.de)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Update status/time span unknown</P>
<P>Search date 25 April 2013</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>35</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>LILACS</B>
</P>
<P>
<A HREF="http://lilacs.bvsalud.org/en/">http://lilacs.bvsalud.org/en/</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Last update 1 March 2013</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>29 April 2013</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>TRIPdatabase </B>(via <A HREF="http://www.tripdatabase.com/">www.tripdatabase.com</A>)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
<P>?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>50</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>PubMed</B>
</P>
<P>(component &#8220;Supplied by Publisher&#8221;)</P>
<P>via <A HREF="http://www.pubmed.gov">www.pubmed.gov</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Search date 30 April 2013</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>30 April 2013</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>ScienceDirect</B>
</P>
<P>
<A HREF="http://www.sciencedirect.com">www.sciencedirect.com</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Search date 30 April 2013</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>68</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Web of Science: Cited Reference Search </B>
</P>
<P>of included articles for update 2013</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Updated 26 April 2013</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>71</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 May 2013</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Total including duplicates</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>1565</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Total without duplicates</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>844</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-09-09 10:08:33 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2013-09-09 10:04:51 +1000" MODIFIED_BY="[Empty name]">Medline (Ovid) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-09-09 10:07:45 +1000" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="33">
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>#</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Searches</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Results</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>exp Pelargonium/</P>
</TD>
<TD>
<P>150</P>
</TD>
</TR>
<TR>
<TD>
<P>2</P>
</TD>
<TD>
<P>(umcka* or pelargoni* or eps 7630 or eps7630).mp.</P>
</TD>
<TD>
<P>663</P>
</TD>
</TR>
<TR>
<TD>
<P>3</P>
</TD>
<TD>
<P>(Gerani* adj3 (afri* or south* or sud* or root?)).mp.</P>
</TD>
<TD>
<P>10</P>
</TD>
</TR>
<TR>
<TD>
<P>4</P>
</TD>
<TD>
<P>(Ikhubalo or Icwayiba or iYeza lezikali or Yeza lezikali or kaloba? or Kalwerbossi or (Khoaara adj2 Nyenyane) or Rabassam or Uvendle).mp.</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>5</P>
</TD>
<TD>
<P>or/1-4                           <I>
<B>facet intervention  (I)</B>
</I>
</P>
</TD>
<TD>
<P>669</P>
</TD>
</TR>
<TR>
<TD>
<P>6</P>
</TD>
<TD>
<P>exp Respiratory Tract Infections/</P>
</TD>
<TD>
<P>276791</P>
</TD>
</TR>
<TR>
<TD>
<P>7</P>
</TD>
<TD>
<P>exp Cough/</P>
</TD>
<TD>
<P>11377</P>
</TD>
</TR>
<TR>
<TD>
<P>8</P>
</TD>
<TD>
<P>exp Otorhinolaryngologic Diseases/</P>
</TD>
<TD>
<P>285325</P>
</TD>
</TR>
<TR>
<TD>
<P>9</P>
</TD>
<TD>
<P>exp Paramyxoviridae/</P>
</TD>
<TD>
<P>27160</P>
</TD>
</TR>
<TR>
<TD>
<P>10</P>
</TD>
<TD>
<P>exp Respiratory Syncytial Viruses/</P>
</TD>
<TD>
<P>6310</P>
</TD>
</TR>
<TR>
<TD>
<P>11</P>
</TD>
<TD>
<P>exp Haemophilus/</P>
</TD>
<TD>
<P>14912</P>
</TD>
</TR>
<TR>
<TD>
<P>12</P>
</TD>
<TD>
<P>exp Haemophilus Infections/</P>
</TD>
<TD>
<P>9251</P>
</TD>
</TR>
<TR>
<TD>
<P>13</P>
</TD>
<TD>
<P>exp Respiratory Syncytial Virus Infections/</P>
</TD>
<TD>
<P>4316</P>
</TD>
</TR>
<TR>
<TD>
<P>14</P>
</TD>
<TD>
<P>exp Respirovirus/</P>
</TD>
<TD>
<P>6208</P>
</TD>
</TR>
<TR>
<TD>
<P>15</P>
</TD>
<TD>
<P>exp Respirovirus Infections/</P>
</TD>
<TD>
<P>2267</P>
</TD>
</TR>
<TR>
<TD>
<P>16</P>
</TD>
<TD>
<P>Orthomyxoviridae Infections/</P>
</TD>
<TD>
<P>6719</P>
</TD>
</TR>
<TR>
<TD>
<P>17</P>
</TD>
<TD>
<P>Adenoviridae Infections/</P>
</TD>
<TD>
<P>4483</P>
</TD>
</TR>
<TR>
<TD>
<P>18</P>
</TD>
<TD>
<P>Adenovirus Infections, Human/</P>
</TD>
<TD>
<P>1875</P>
</TD>
</TR>
<TR>
<TD>
<P>19</P>
</TD>
<TD>
<P>(respirat* or URTI* or cold* or cough* or naso* or nasal* or nose or sinus* or ear* or otalg* or otit* or oto* or laryn* or pharyn* or retro-pharyn* or retropharyn* or throat* or tonsil* or trach* or epiglot* or rhin* or bronch* or whoop* or pertuss* or pulmo* or lung* or pneumo* or pleur* or paramyxovir* or respiratory syncytial virus* or rsv or haemophilus* or hemophilus* or influenza* or parainfluenza* or para-influenza*).mp.</P>
</TD>
<TD>
<P>3077662</P>
</TD>
</TR>
<TR>
<TD>
<P>20</P>
</TD>
<TD>
<P>or/6-19                         <I>
<B>facet population/disease (P)</B>
</I>
</P>
</TD>
<TD>
<P>3161448</P>
</TD>
</TR>
<TR>
<TD>
<P>21</P>
</TD>
<TD>
<P>5 and 20                      <I>
<B>facet P + I</B>
</I>
</P>
</TD>
<TD>
<P>106</P>
</TD>
</TR>
<TR>
<TD>
<P>22</P>
</TD>
<TD>
<P>randomized controlled trial.pt.</P>
</TD>
<TD>
<P>346442</P>
</TD>
</TR>
<TR>
<TD>
<P>23</P>
</TD>
<TD>
<P>controlled clinical trial.pt.</P>
</TD>
<TD>
<P>85736</P>
</TD>
</TR>
<TR>
<TD>
<P>24</P>
</TD>
<TD>
<P>random*.ab.</P>
</TD>
<TD>
<P>580401</P>
</TD>
</TR>
<TR>
<TD>
<P>25</P>
</TD>
<TD>
<P>clinical trials as topic.sh.</P>
</TD>
<TD>
<P>163995</P>
</TD>
</TR>
<TR>
<TD>
<P>26</P>
</TD>
<TD>
<P>trial.ti.</P>
</TD>
<TD>
<P>106747</P>
</TD>
</TR>
<TR>
<TD>
<P>27</P>
</TD>
<TD>
<P>or/22-26           <I>
<B>modified Cochrane-filter for random. trials (RCT)</B>
</I>
</P>
</TD>
<TD>
<P>909459</P>
</TD>
</TR>
<TR>
<TD>
<P>28</P>
</TD>
<TD>
<P>5 and 27          <I>
<B>facet</B> <B>I + RCT</B>
</I>
</P>
</TD>
<TD>
<P>43</P>
</TD>
</TR>
<TR>
<TD>
<P>29</P>
</TD>
<TD>
<P>21 or 28           <I>
<B>facet I + (P or RCT)</B>
</I>
</P>
</TD>
<TD>
<P>128</P>
</TD>
</TR>
<TR>
<TD>
<P>30</P>
</TD>
<TD>
<P>exp animals/ not humans/</P>
</TD>
<TD>
<P>3802336</P>
</TD>
</TR>
<TR>
<TD>
<P>31</P>
</TD>
<TD>
<P>29 not 30         <I>
<B>exclusion of animals</B>
</I>
</P>
</TD>
<TD>
<P>107</P>
</TD>
</TR>
<TR>
<TD>
<P>32</P>
</TD>
<TD>
<P>remove duplicates from 31</P>
</TD>
<TD>
<P>105</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2013-09-09 10:29:28 +1000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2013-05-29 01:45:15 +1000" MODIFIED_BY="[Empty name]">Search strategies (all databases)</TITLE>
<APPENDIX_BODY MODIFIED="2013-09-09 10:29:28 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>MEDLINE</B> <B>(via OvidSP) 1946 to April Week 2 2013</B>
</P>
<P>Search date: 24 April 2013</P>
<TABLE COLS="3" ROWS="33">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>#</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Searches</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Results</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>exp Pelargonium/</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>150</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(umcka* or pelargoni* or eps 7630 or eps7630).mp.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>663</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(Gerani* adj3 (afri* or south* or sud* or root?)).mp.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(Ikhubalo or Icwayiba or iYeza lezikali or Yeza lezikali or kaloba? or Kalwerbossi or (Khoaara adj2 Nyenyane) or Rabassam or Uvendle).mp.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>or/1-4                           <I>
<B>facet intervention  (I)</B>
</I>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>669</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>exp Respiratory Tract Infections/</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>276791</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>exp Cough/</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11377</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>exp Otorhinolaryngologic Diseases/</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>285325</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>exp Paramyxoviridae/</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27160</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>exp Respiratory Syncytial Viruses/</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6310</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>exp Haemophilus/</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14912</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>exp Haemophilus Infections/</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9251</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>exp Respiratory Syncytial Virus Infections/</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4316</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>exp Respirovirus/</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6208</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>exp Respirovirus Infections/</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2267</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Orthomyxoviridae Infections/</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6719</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adenoviridae Infections/</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4483</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adenovirus Infections, Human/</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1875</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>19</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(respirat* or URTI* or cold* or cough* or naso* or nasal* or nose or sinus* or ear* or otalg* or otit* or oto* or laryn* or pharyn* or retro-pharyn* or retropharyn* or throat* or tonsil* or trach* or epiglot* or rhin* or bronch* or whoop* or pertuss* or pulmo* or lung* or pneumo* or pleur* or paramyxovir* or respiratory syncytial virus* or rsv or haemophilus* or hemophilus* or influenza* or parainfluenza* or para-influenza*).mp.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3077662</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>or/6-19                         <I>
<B>facet population/disease (P)</B>
</I>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3161448</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 and 20                      <I>
<B>facet P + I</B>
</I>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>106</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>22</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>randomized controlled trial.pt.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>346442</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>23</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>controlled clinical trial.pt.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>85736</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>24</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>random*.ab.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>580401</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>clinical trials as topic.sh.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>163995</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>26</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>trial.ti.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>106747</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>or/22-26           <I>
<B>modified Cochrane-filter for random. trials (RCT)</B>
</I>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>909459</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>28</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 and 27          <I>
<B>facet</B> <B>I + RCT</B>
</I>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>43</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>29</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21 or 28           <I>
<B>facet I + (P or RCT)</B>
</I>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>128</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>exp animals/ not humans/</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3802336</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>31</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>29 not 30         <I>
<B>exclusion of animals</B>
</I>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>107</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>32</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>remove duplicates from 31</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>105</P>
</TD>
</TR>
</TABLE>
<P>Legend:</P>
<P>.ab. = abstract<BR/>Adj3 = within 3 words in any order<BR/>Exp = explode<BR/>.mp. = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier<BR/>.pt. = publication type<BR/>.sh. or / = Medical Subject Heading (MeSH)<BR/>.ti. = title<BR/>? or * = wildcard, truncation</P>
<P>
<B>MEDLINE Daily Update</B> <B>(via OvidSP) 23 April 2013</B>
</P>
<P>Search date: 24 April 2013 </P>
<TABLE COLS="3" ROWS="6">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>#</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Searches</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Results</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>exp Pelargonium/</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(umcka* or pelargoni* or eps 7630 or eps7630).mp.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(Gerani* adj3 (afri* or south* or sud* or root?)).mp.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(Ikhubalo or Icwayiba or iYeza lezikali or Yeza lezikali or kaloba? or Kalwerbossi or (Khoaara adj2 Nyenyane) or Rabassam or Uvendle).mp.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>or/1-4               <I>
<B>facet intervention(I)</B>
</I>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
</TR>
</TABLE>
<P>Legend:</P>
<P>Exp = explode<BR/>Adj3 = within 3 words in any order<BR/>.mp. = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier</P>
<P>
<B>MEDLINE In-Process &amp; Other Non-Indexed Citations</B> <B>(via OvidSP) 23 April 2013</B>
</P>
<P>Search date: 24 April 2013<BR/>
</P>
<TABLE COLS="3" ROWS="10">
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>#</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Searches</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Results</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>(umcka* or pelargoni* or eps 7630 or eps7630).mp.</P>
</TD>
<TD VALIGN="TOP">
<P>69</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>(Gerani* adj3 (afri* or south* or sud* or root?)).mp.</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>(Ikhubalo or Icwayiba or iYeza lezikali or Yeza lezikali or kaloba? or Kalwerbossi or (Khoaara adj2 Nyenyane) or Rabassam or Uvendle).mp.</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>or/1-3               <I>
<B>facet intervention  (I)</B>
</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>70</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>(respirat* or URTI* or cold* or cough* or naso* or nasal* or nose or sinus* or ear* or otalg* or otit* or oto* or laryn* or pharyn* or retro-pharyn* or retropharyn* or throat* or tonsil* or trach* or epiglot* or rhin* or bronch* or whoop* or pertuss* or pulmo* or lung* or pneumo* or pleur* or paramyxovir* or respiratory syncytial virus* or rsv or haemophilus* or hemophilus* or influenza* or parainfluenza* or para-influenza*).mp.                <I>
<B>facet population/disease (P)</B>
</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>153005</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>4 and 5                        <I>
<B>facet I + P</B>
</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>(rando* or trial* or placebo*).mp.                  <I>
<B>facet RCT</B>
</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>73454</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>4 and 7                        <I>
<B>facet I + RCT</B>
</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>6 or 8               <I>
<B>facet I + (P or RCT)</B>
</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
</TR>
</TABLE>
<P>Legend:</P>
<P>Adj3 = within 3 words in any order<BR/>.mp. = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier<BR/>? or * = wildcard, truncation</P>
<P>
<B>Journals@Ovid</B> <B>Full Text (via OvidSP) </B>
</P>
<P>Update status: 23 April 2013<BR/>Search date: 24 April 2013 </P>
<TABLE COLS="3" ROWS="15">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>#</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Searches</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Results</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(umckaloabo* or umcka or pelargonium* or pelargonie* or eps* 7630* or eps7630*).mp.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>248</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(Gerani* adj3 (afri* or south* or sud* or root?)).mp.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>23</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(Ikhubalo or Icwayiba or iYeza lezikali or Yeza lezikali or kaloba? or Kalwerbossi or (Khoaara adj2 Nyenyane) or Rabassam or Uvendle).mp.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(respirat* or URTI* or cold* or cough* or naso* or nasal* or nose or sinus* or ear* or otalg* or otit* or oto* or laryn* or pharyn* or retro-pharyn* or retropharyn* or throat* or tonsil* or trach* or epiglot* or rhin* or bronch* or whoop* or pertuss* or pulmo* or lung* or pneumo* or pleur* or paramyxovir* or respiratory syncytial virus* or rsv or haemophilus* or hemophilus* or influenza* or parainfluenza* or para-influenza).mp.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2593193</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(1 or 2 or 3) and 4     <I>
<B>facet Intervention (I) + Disease (P) (in fulltext)</B>
</I>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>155</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(rando* or placebo*).mp. or trial*.ti,ab.    </P>
<P>
<I>
<B>Facet rando contr. trials (RCT)</B>
</I>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1187891</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>((systematic* adj3 (review* or overview*)) or meta-analy* or metaanaly*).mp.   <I>
<B>facet syst. Rev.  (SR)</B>
</I>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>232243</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 and (6 or 7)             </P>
<P>
<I>
<B>facet I + P + (RCT or SR)  (in fulltext)</B>
</I>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>75</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(umckaloabo* or umcka or pelargonium* or pelargonie* or eps* 7630* or eps7630*).ti,ab.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>92</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(Gerani* adj3 (afri* or south* or sud* or root?)).ti,ab.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(Ikhubalo or Icwayiba or iYeza lezikali or Yeza lezikali or kaloba? or Kalwerbossi or (Khoaara adj2 Nyenyane) or Rabassam or Uvendle).ti,ab.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(respirat* or URTI* or cold* or cough* or naso* or nasal* or nose or sinus* or ear* or otalg* or otit* or oto* or laryn* or pharyn* or retro-pharyn* or retropharyn* or throat* or tonsil* or trach* or epiglot* or rhin* or bronch* or whoop* or pertuss* or pulmo* or lung* or pneumo* or pleur* or paramyxovir* or respiratory syncytial virus* or rsv or haemophilus* or hemophilus* or influenza* or parainfluenza* or para-influenza).ti,ab.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>713671</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(9 or 10 or 11) and 12  <I>
<B>facet I + P (in title or abstract)</B>
</I>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>19</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8 or 13 </P>
<P>
<I>
<B>facet I + P + (RCT or SR)  (in fulltext) OR</B>
</I>
</P>
<P>
<I>
<B>facet I + P (in title or abstract)</B>
</I>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>82</P>
</TD>
</TR>
</TABLE>
<P>Legend:</P>
<P>.ti,ab. = title, abstract<BR/>.mp. = title, abstract, full text, caption text<BR/>?, * = Wildcard, truncation</P>
<P>
<I>
<B>The Cochrane Library</B>
</I>
<B> (via Wiley Online Library)</B> (<A HREF="http://www.thecochranelibrary.org">www.thecochranelibrary.org</A>)</P>
<P>Update status:</P>
<UL>
<LI>Cochrane Database of Systematic Reviews (CDSR): Issue 3 of 12, March 2013</LI>
<LI>Other Reviews (DARE):  Issue 1 of 4, January 2013</LI>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL): Issue 3 of 12, March 2013</LI>
</UL>
<P>Search date: 24 April 2013</P>
<TABLE COLS="3" ROWS="5">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>ID</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Search</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Hits</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>umcka* or pelargonium* or eps7630 or eps next 7630</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>24</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Gerani* near (afri* or south* or sud* or root*)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Ikhubalo or Icwayiba or (iYeza next lezikali) or (Yeza next lezikali) or kaloba* or Kalwerbossi or (Khoaara near Nyenyane) or Rabassam or Uvendle</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(#1 OR #2 OR #3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>24</P>
<P>CDSR: 2</P>
<P>DARE: 2</P>
<P>CENTRAL: 20</P>
</TD>
</TR>
</TABLE>
<P>
<B>Biosis Previews</B> <B>(via Web of Knowledge, Thomson Reuters)</B>
</P>
<P>Update status: 1926 to present, updated 23 April 2013<BR/>Time span = all years</P>
<TABLE COLS="1" ROWS="1">
<TR>
<TD>
<P>DocType=All document types; Language=All languages</P>
<P> </P>
<P>Search date: 24 April 2013</P>
</TD>
</TR>
</TABLE>
<P>  </P>
<TABLE COLS="3" ROWS="16">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Set</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Results</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Query</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=BIOSIS&amp;doc=1&amp;qid=15&amp;SID=S2F1JcCmK4GdA259Cc3&amp;search_mode=CombineSearches">188</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#14 OR #11 OR #10           </P>
<P>
<I>
<B>facet (I + P) or (I+humans) or (I+(RCT or SR))</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 14</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=BIOSIS&amp;doc=1&amp;qid=14&amp;SID=S2F1JcCmK4GdA259Cc3&amp;search_mode=AdvancedSearch">32</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#4 and (#12 or #13)                  <I>
<B>facet I + (RCT or SR)</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=BIOSIS&amp;doc=1&amp;qid=13&amp;SID=S2F1JcCmK4GdA259Cc3&amp;search_mode=AdvancedSearch">46,491</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ts=("meta-analy*" or metaanaly* or (systematic near/3 (review or overview)))                     <I>
<B>facet syst. Rev (SR)</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=BIOSIS&amp;doc=1&amp;qid=12&amp;SID=S2F1JcCmK4GdA259Cc3&amp;search_mode=AdvancedSearch">401,718</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ts=(randomi$ed or randomly or placebo*)     </P>
<P>
<I>
<B>                                      facet random. contr. Trials (RCTs)</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 11</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=BIOSIS&amp;doc=1&amp;qid=11&amp;SID=S2F1JcCmK4GdA259Cc3&amp;search_mode=AdvancedSearch">100</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(#4) AND Taxa Notes=(Humans)           <I>
<B>facet I + humans</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=BIOSIS&amp;doc=1&amp;qid=10&amp;SID=S2F1JcCmK4GdA259Cc3&amp;search_mode=CombineSearches">118</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#9 AND #4                                 <I>
<B>facet P + I</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=BIOSIS&amp;doc=1&amp;qid=9&amp;SID=S2F1JcCmK4GdA259Cc3&amp;search_mode=CombineSearches">1,352,337</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#8 OR #7 OR #6 OR #5          <I>
<B>facet patient/disease (P)</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=BIOSIS&amp;doc=1&amp;qid=8&amp;SID=S2F1JcCmK4GdA259Cc3&amp;search_mode=AdvancedSearch">1,045,738</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ti=(respirat* or URTI* or cold* or cough* or naso* or nasal* or nose or sinus* or ear* or otalg* or otit* or oto* or laryn* or pharyn* or "retro-pharyn*" or retropharyn* or throat* or tonsil* or trach* or epiglot* or rhin* or bronch* or whoop* or pertuss* or pulmo* or lung* or pneumo* or pleur* or paramyxovir* or "respiratory syncytial virus*" or rsv or haemophilus* or hemophilus* or influenza* or parainfluenza* or "para-influenza")</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=BIOSIS&amp;doc=1&amp;qid=7&amp;SID=S2F1JcCmK4GdA259Cc3&amp;search_mode=AdvancedSearch">215,298</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>psd=respiratory system</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=BIOSIS&amp;doc=1&amp;qid=6&amp;SID=S2F1JcCmK4GdA259Cc3&amp;search_mode=AdvancedSearch">112,317</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CC=(Pharmacology - Respiratory system)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=BIOSIS&amp;doc=1&amp;qid=5&amp;SID=S2F1JcCmK4GdA259Cc3&amp;search_mode=AdvancedSearch">363,118</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ds=respiratory system disease</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=BIOSIS&amp;doc=1&amp;qid=4&amp;SID=S2F1JcCmK4GdA259Cc3&amp;search_mode=CombineSearches">2,923</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#3 OR #2 OR #1                     <I>
<B>facet intervention (I)</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ts=(Ikhubalo or Icwayiba or "iYeza lezikali" or "Yeza lezikali" or kaloba$ or Kalwerbossi or (Khoaara near/2 Nyenyane) or Rabassam or Uvendle)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=BIOSIS&amp;doc=1&amp;qid=2&amp;SID=S2F1JcCmK4GdA259Cc3&amp;search_mode=AdvancedSearch">163</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ts=(Gerani* near/3 (afri* or south* or sud* or root$))</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=BIOSIS&amp;doc=1&amp;qid=1&amp;SID=S2F1JcCmK4GdA259Cc3&amp;search_mode=AdvancedSearch">2,838</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ts=(umckaloabo* or umcka or pelargonium* or pelargonie* or (eps* near/3 7630*) or eps7630*)</P>
</TD>
</TR>
</TABLE>
<P>Legend:</P>
<P>$ or * = Wildcard, truncation<BR/>CC = Concept Codes<BR/>DS = Disease Data<BR/>PSD = Parts &amp; Structures Data<BR/>TA = Taxonomic Data<BR/>TI =Title<BR/>TS =Topic:<BR/>Searches in the following fields:<BR/>    Title field<BR/>    Foreign Title field<BR/>    Abstract field<BR/>    Major Concepts field<BR/>    Concept Code(s) field<BR/>    Taxonomic Data table<BR/>    Disease Data table<BR/>    Chemical Data table<BR/>    Gene Name Data table<BR/>    Sequence Data table<BR/>    Geographic Data table<BR/>    Geologic Time Data table<BR/>    Methods and Equipment Data table<BR/>    Parts &amp; Structure Data table<BR/>    Miscellaneous Descriptors field</P>
<P>
<B>Web of Science</B> <B>(Thomson Reuters)</B>
</P>
<P>Update status: last updated 21 April 2013</P>
<P>Databases:</P>
<UL>
<LI>Science Citation Index Expanded (SCI-EXPANDED): 1945 to present</LI>
<LI>Social Sciences Citation Index (SSCI): 1975 to present</LI>
<LI>Arts &amp; Humanities Citation Index (A&amp;HCI): 1975 to present</LI>
<LI>Conference Proceedings Citation Index - Science (CPCI-S): 1990 to present</LI>
<LI>Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH): 1990 to present</LI>
<LI>Book Citation Index&#8211; Science (BKCI-S) 2005 to present</LI>
<LI>Book Citation Index&#8211; Social Sciences &amp; Humanities (BKCI-SSH) 2005 to present </LI>
</UL>
<P>Search date: 24 April 2013</P>
<TABLE COLS="3" ROWS="11">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Set</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Results</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>   Query</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=10&amp;SID=V18eL8jF8k2mBe7feC6&amp;search_mode=CombineSearches">253</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#9 OR #6                 <I>
<B>facet (I + P) or (I+(RCT or SR))</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=9&amp;SID=V18eL8jF8k2mBe7feC6&amp;search_mode=AdvancedSearch">86</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#4 and (#7 or #8)                     <I>
<B>facet I + (RCT or SR)</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=8&amp;SID=V18eL8jF8k2mBe7feC6&amp;search_mode=AdvancedSearch">150,192</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ts=(systematic* near/3 (review* or overview*) or metaanaly* or meta-analy*)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=7&amp;SID=V18eL8jF8k2mBe7feC6&amp;search_mode=AdvancedSearch">1,631,845</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ts=(rando* or trial* or placebo*)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=6&amp;SID=V18eL8jF8k2mBe7feC6&amp;search_mode=CombineSearches">211</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#5 AND #4                           <I>
<B>facet P + I</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=5&amp;SID=V18eL8jF8k2mBe7feC6&amp;search_mode=AdvancedSearch">3,671,971</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ts=(respirat* or URTI* or cold* or cough* or naso* or nasal* or nose or sinus* or ear* or otalg* or otit* or oto* or laryn* or pharyn* or "retro-pharyn*" or retropharyn* or throat* or tonsil* or trach* or epiglot* or rhin* or bronch* or whoop* or pertuss* or pulmo* or lung* or pneumo* or pleur* or paramyxovir* or "respiratory syncytial virus*" or rsv or haemophilus* or hemophilus* or influenza* or parainfluenza* or "para-influenza")</P>
<P>
<I>
<B>facet patient/disease (P)</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=4&amp;SID=V18eL8jF8k2mBe7feC6&amp;search_mode=CombineSearches">1,606</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#3 OR #2 OR #1                     <I>
<B>facet Intervention (I)</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ts=(Ikhubalo or Icwayiba or "iYeza lezikali" or "Yeza lezikali" or kaloba$ or Kalwerbossi or (Khoaara near/2 Nyenyane) or Rabassam or Uvendle)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=2&amp;SID=V18eL8jF8k2mBe7feC6&amp;search_mode=AdvancedSearch">97</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ts=(Gerani* near/3 (afri* or south* or sud* or root$)) </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=1&amp;SID=V18eL8jF8k2mBe7feC6&amp;search_mode=AdvancedSearch">1,557</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ts=(umckaloabo* or umcka or pelargonium* or pelargonie* or (eps* near/3 7630*) or eps7630*)</P>
</TD>
</TR>
</TABLE>
<P>Legend:</P>
<P>$ or * = wildcard, truncation<BR/>TS=Topic: searches in the following fields: Title, Abstract, Author Keywords, Keywords Plus®<BR/>near/3 = within 3 words in any order</P>
<P>
<B>CINAHL (EBSCOhost)</B>
</P>
<P>Update status: 1981 to present<BR/>Search date: 24 April 2013</P>
<TABLE COLS="3" ROWS="5">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B># </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Query </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Results </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>S4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>S1 or S2 or S3                                 <B>facet intervention (I)</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>51</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>S3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>TX (Ikhubalo or Icwayiba or iYeza lezikali or Yeza lezikali or kaloba# or Kalwerbossi or (Khoaara N2 Nyenyane) or Rabassam or Uvendle)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>S2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>TX (Gerani* N3 (afri* or south* or sud* or root* or wurzel*))</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>S1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>TX umcka* or pelargonium* or pelargonie* or (eps* W3 7630*) or eps7630*</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>50</P>
</TD>
</TR>
</TABLE>
<P>Legend:</P>
<P>TX = all text<BR/>W3 = within 3 words in this order<BR/># , * = wildcard, truncation</P>
<P>
<B>Current Contents Medizin</B> <B>(CCMed), vie DIMDI</B> (<A HREF="http://www.dimdi.de">www.dimdi.de</A>)</P>
<P>Update status: 1 January 2000 to 19 February 2013<BR/>Search date: 24 April 2013 </P>
<TABLE COLS="3" ROWS="6">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>No </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Hits  </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Query</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>770327 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CC00</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>88 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>UMCKA* OR PELARGONI* OR (EPS* # # 7630*) OR EPS7630*</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>GERANI*, # # # (*AFRI* OR SOUTH* OR SUD* OR SUED* OR SÜD* OR ROOT* OR *WURZEL*)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IKHUBALO OR ICWAYIBA OR *YEZA LEZIKALI OR KALOBA* OR KALWERBOSSI OR (KHOAARA AND NYENYANE) OR RABASSAM OR UVENDLE</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>89 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 TO 4             <B>facet intervention (I)</B>
</P>
</TD>
</TR>
</TABLE>
<P>Legend:</P>
<P>CC00 = Database CCMed<BR/>Text word search in the fields: Document Type, Title<BR/># # # = within 3 words in any order</P>
<P>
<B>XTOXLINE</B> <B>(via DIMDI)</B> (<A HREF="http://www.dimdi.de">www.dimdi.de</A>)</P>
<P>Update status 1 January 1965 to 19 April 2013<BR/>Search date: 24 April 2013 </P>
<TABLE COLS="3" ROWS="15">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>No </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Hits  </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Query</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3754759 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>T165</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>65 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>UMCKA* OR PELARGONIUM* OR PELARGONIE* OR (EPS* # # 7630*) OR EPS7630*</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>GERANI*, # # # (*AFRI* OR SOUTH* OR SUD* OR SUED* OR SÜD* OR ROOT* OR *WURZEL*)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IKHUBALO OR ICWAYIBA OR *YEZA LEZIKALI OR KALOBA* OR KALWERBOSSI OR (KHOAARA AND NYENYANE) OR RABASSAM OR UVENDLE</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>71 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 OR 3 OR 4               <I>
<B>facet intervention (I)</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>443748 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RESPIRAT* OR URTI* OR COLD* OR COUGH* OR NASO* OR NASAL* OR NOSE OR SINUS* OR EAR* OR OTALG* OR OTIT* OR OTO* OR LARYN* OR PHARYN* OR RETRO-PHARYN* OR RETROPHARYN* OR THROAT* OR TONSIL* OR TRACH* OR EPIGLOT* OR RHIN* OR BRONCH*</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>262219 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>WHOOP* OR PERTUSS* OR PULMO* OR LUNG* OR PNEUMO* OR PLEUR* OR PARAMYXOVIR* OR RESPIRATORY SYNCYTIAL VIRUS* OR RSV OR HAEMOPHILUS* OR HEMOPHILUS* OR INFLUENZA* OR PARAINFLUENZA* OR PARA-INFLUENZA*</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>621326 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 OR 7            <I>
<B>facet patient/disease (P)</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 AND 8         <I>
<B>facet I + P</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>211202 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RANDO* OR PLACEBO* OR BLIND* OR (CONTROLLED # # # TRIAL*)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16521 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(SYSTEMATI* # # # *REVIEW*) OR META-ANALY* OR METAANALY*</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>219397 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10 OR 11        <I>
<B>facet RCT or syst rev. (SR)</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 AND 12       <I>
<B>facet I + (RCT or SR)</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9 OR 13    <I>
<B>facet I + (P or RCT or SR)</B>
</I>
</P>
</TD>
</TR>
</TABLE>
<P>Legend:</P>
<P>T165 = Database XTOXLINE</P>
<P># # # = within 3 words in any order<BR/>Text word search in the fields: Abstract, Controlled Terms, Document Type, Gene Symbol, Index Term, Personal Name as Subject, Section Headings, Terminology, Title, Uncontrolled Terms</P>
<P>
<B>Global Health</B> <B>(via DIMDI) </B>(<A HREF="http://www.dimdi.de">www.dimdi.de</A>)</P>
<P>Update status: 1 January 1972 to 24 April 2013<BR/>Search date: 24 April 2013 </P>
<TABLE COLS="3" ROWS="15">
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>No </B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Hits</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Search expression </B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>2113089 </P>
</TD>
<TD>
<P>AZ72   </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>264 </P>
</TD>
<TD>
<P>UMCKA* OR PELARGONIUM* OR PELARGONIE* OR (EPS* # # 7630*) OR EPS7630*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>23 </P>
</TD>
<TD>
<P>GERANI*, # # # (*AFRI* OR SOUTH* OR SUD* OR SUED* OR SÜD* OR ROOT* OR *WURZEL*)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>0 </P>
</TD>
<TD>
<P>IKHUBALO OR ICWAYIBA OR *YEZA LEZIKALI OR KALOBA* OR KALWERBOSSI OR (KHOAARA AND NYENYANE) OR RABASSAM OR UVENDLE</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>277 </P>
</TD>
<TD>
<P>2 TO 4                       <I>
<B>facet intervention (I)</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>256716 </P>
</TD>
<TD>
<P>RESPIRAT* OR URTI* OR COLD* OR COUGH* OR NASO* OR NASAL* OR NOSE OR SINUS* OR EAR* OR OTALG* OR OTIT* OR OTO* OR LARYN* OR PHARYN* OR RETRO-PHARYN* OR RETROPHARYN* OR THROAT* OR TONSIL* OR TRACH* OR EPIGLOT* OR RHIN* OR BRONCH*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>154210 </P>
</TD>
<TD>
<P>WHOOP* OR PERTUSS* OR PULMO* OR LUNG* OR PNEUMO* OR PLEUR* OR PARAMYXOVIR* OR RESPIRATORY SYNCYTIAL VIRUS* OR RSV OR HAEMOPHILUS* OR HEMOPHILUS* OR INFLUENZA* OR PARAINFLUENZA* OR PARA-INFLUENZA*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>341718 </P>
</TD>
<TD>
<P>6 OR 7                            <I>
<B>facet disease (P)</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>73 </P>
</TD>
<TD>
<P>5 AND 8                              <I>
<B>facet I + P</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>128083 </P>
</TD>
<TD>
<P>RANDO* OR PLACEBO* OR BLIND* OR (CONTROLLED # # # TRIAL*)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>16730 </P>
</TD>
<TD>
<P>(SYSTEMATI* # # # *REVIEW*) OR META-ANALY* OR METAANALY*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>138748 </P>
</TD>
<TD>
<P>10 OR 11                   <I>
<B>facet rando (RCT) or syst. Rev. (SR)</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>21 </P>
</TD>
<TD>
<P>5 AND 12                          <I>
<B>facet I + (RCT or SR)</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>81 </P>
</TD>
<TD>
<P>9 OR 13                         <I>
<B>facet I + (P or  RCT or SR)</B>
</I>
</P>
</TD>
</TR>
</TABLE>
<P>Legend:</P>
<P>AZ72 = Database GLOBAL HEALTH<BR/># # # = within 3 words in any order<BR/>Text word search in the fields: Abstract, Broader Term, Controlled Term, Document Type, Section Heading, Title, Uncontrolled Term</P>
<P>
<B>AMED</B> <B>Allied and Complementary Medicine Database</B> <B>(via DIMDI)</B> (<A HREF="http://www.dimdi.de">www.dimdi.de</A>)</P>
<P>Update status: 1 January 1985 to 8 April 2013<BR/>Search date: 24 April 2013</P>
<TABLE COLS="3" ROWS="6">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>No </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Hits  </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Search expression </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>273314 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CB85</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>35 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>UMCKA* OR PELARGONIUM* OR PELARGONIE* OR (EPS* # # 7630*) OR EPS7630*</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>GERANI*, # # # (*AFRI* OR SOUTH* OR SUD* OR SUED* OR SÜD* OR ROOT* OR *WURZEL*)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IKHUBALO OR ICWAYIBA OR *YEZA LEZIKALI OR KALOBA* OR KALWERBOSSI OR (KHOAARA AND NYENYANE) OR RABASSAM OR UVENDLE</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>39 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 TO 4             <I>
<B>facet intervention (I)</B>
</I>
</P>
</TD>
</TR>
</TABLE>
<P>Legend:</P>
<P>CB85 = Database AMED<BR/># # # = within 3 words in any order<BR/>Text word search in the fields: Abstract, Controlled Term, Document Type, Title, Uncontrolled Term</P>
<P>
<B>Derwent Drug File</B> <B>(via DIMDI)</B> (<A HREF="http://www.dimdi.de">www.dimdi.de</A>)</P>
<P>Update status: 1 January 1983 to 23 April 2013<BR/>Search date: 24 April 2013 </P>
<TABLE COLS="3" ROWS="6">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>No </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Hits  </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Search expression </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1466135 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DD83</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>31 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>UMCKA* OR PELARGONIUM* OR PELARGONIE* OR (EPS* # # 7630*) OR EPS7630*</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>GERANI*, # # # (*AFRI* OR SOUTH* OR SUD* OR SUED* OR SÜD* OR ROOT* OR *WURZEL*)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IKHUBALO OR ICWAYIBA OR *YEZA LEZIKALI OR KALOBA* OR KALWERBOSSI OR (KHOAARA AND NYENYANE) OR RABASSAM OR UVENDLE</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>35 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 TO 4             <I>
<B>facet intervention (I)</B>
</I>
</P>
</TD>
</TR>
</TABLE>
<P>Legend:</P>
<P>DD83 = Derwent Drug File<BR/># # # = within 3 words in any order<BR/>Text word search in the fields: Abstract, Extension Abstract (ABEX) in Vers. DW, Controlled Term, Index Term, Section Heading, Title</P>
<P>
<B>Derwent Drug Backfile</B> <B>(via DIMDI) </B>(<A HREF="http://www.dimdi.de">www.dimdi.de</A>)</P>
<P>Update status: 1 January 1960 to 31 December 1982<BR/>Search date: 24 April 2013 </P>
<TABLE COLS="3" ROWS="6">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>No </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Hits  </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Search expression </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>805789 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DH64</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>UMCKA* OR PELARGONIUM* OR PELARGONIE* OR (EPS* # # 7630*) OR EPS7630*</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>GERANI*, # # # (*AFRI* OR SOUTH* OR SUD* OR SUED* OR SÜD* OR ROOT* OR *WURZEL*)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IKHUBALO OR ICWAYIBA OR *YEZA LEZIKALI OR KALOBA* OR KALWERBOSSI OR (KHOAARA AND NYENYANE) OR RABASSAM OR UVENDLE</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 TO 4             <I>
<B>facet intervention (I)</B>
</I>
</P>
</TD>
</TR>
</TABLE>
<P>Legend:</P>
<P>DH64 = Derwent Drug Backfile<BR/># # # = within 3 words in any order<BR/>Text word search in the fields: Controlled Term, Index Term, Section Heading, Title</P>
<P>
<B>IPA International Pharmaceutical Abstracts (via DIMDI)</B> (<A HREF="http://www.dimdi.de">www.dimdi.de</A>)</P>
<P>Update status: 1 January 1970 to 18 April 2013<BR/>Search date: 24 April 2013<B> </B>
</P>
<TABLE COLS="3" ROWS="6">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>No </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Hits  </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Search expression </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>567686 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IA70</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>67 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>UMCKA* OR PELARGONIUM* OR PELARGONIE* OR (EPS* # # 7630*) OR EPS7630*</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>GERANI*, # # # (*AFRI* OR SOUTH* OR SUD* OR SUED* OR SÜD* OR ROOT* OR *WURZEL*)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IKHUBALO OR ICWAYIBA OR *YEZA LEZIKALI OR KALOBA* OR KALWERBOSSI OR (KHOAARA AND NYENYANE) OR RABASSAM OR UVENDLE</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>72 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 TO 4             <I>
<B>facet intervention (I)</B>
</I>
</P>
</TD>
</TR>
</TABLE>
<P>Legend:</P>
<P>IA70 = IPA International Pharmaceutical Abstracts<B> </B>
<BR/># # # = within 3 words in any order<BR/>Text word search in the fields: Abstract, Controlled Term, Drug Name, Document Type, Group of Compound, Section Heading, Terminology, Title, Uncontrolled Term</P>
<P>
<B>ISTP (Index to Scientific and Technical Proceedings) and ISSHP (Index to Social Sciences &amp; Humanities Proceedings)</B> (via DIMDI) (<A HREF="http://www.dimdi.de">www.dimdi.de</A>)</P>
<P>Update status: 1 January 1978 to 21 April 2013 <BR/>Search date: 24 April 2013</P>
<TABLE COLS="3" ROWS="17">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>No </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Hits  </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Search expression </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9484576 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>II78</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>180 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>UMCKA* OR PELARGONIUM* OR PELARGONIE* OR (EPS* # # 7630*) OR EPS7630*</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>GERANI*, # # # (*AFRI* OR SOUTH* OR SUD* OR SUED* OR SÜD* OR ROOT* OR *WURZEL*)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IKHUBALO OR ICWAYIBA OR *YEZA LEZIKALI OR KALOBA* OR KALWERBOSSI OR (KHOAARA AND NYENYANE) OR RABASSAM OR UVENDLE</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>184 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 TO 4             <I>
<B>facet intervention (I)</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>478460 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RESPIRAT* OR URTI* OR COLD* OR COUGH* OR NASO* OR NASAL* OR NOSE OR SINUS* OR EAR* OR OTALG* OR OTIT* OR OTO* OR LARYN* OR PHARYN* OR RETRO-PHARYN* OR RETROPHARYN* OR THROAT* OR TONSIL* OR TRACH* OR EPIGLOT* OR RHIN* OR BRONCH*</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>109110 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>WHOOP* OR PERTUSS* OR PULMO* OR LUNG* OR PNEUMO* OR PLEUR* OR PARAMYXOVIR* OR RESPIRATORY SYNCYTIAL VIRUS* OR RSV OR HAEMOPHILUS* OR HEMOPHILUS* OR INFLUENZA* OR PARAINFLUENZA* OR PARA-INFLUENZA*</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>556424 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 OR 7                <I>
<B>facet disease (P)</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 AND 8          <I>
<B>facet I + P</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>183144 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RANDO* OR PLACEBO* OR BLIND* OR (CONTROLLED # # # TRIAL*)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12383 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(SYSTEMATI* # # # *REVIEW*) OR META-ANALY* OR METAANALY*</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>192421 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10 OR 11            <I>
<B>facet rando (RCT) or syst. Rev. (SR)</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 AND 12          <I>
<B>facet I + (RCT or SR)</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9 OR 13           <I>
<B>facet I + (P or  RCT or SR)</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>26 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>TI=(UMCKALOABO* OR UMCKA OR PELARGONIUM* SIDOID* OR PELARGONIE* OR (EPS* # # 7630*) OR EPS7630*)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>38 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14 OR 15             <I>
<B>facet I in title or  I + (P or  RCT or SR)</B>
</I>
</P>
</TD>
</TR>
</TABLE>
<P>Legend:</P>
<P>II78 = Database ISTP + ISSHP<BR/># # # = within 3 words in any order<BR/>TI = Title<BR/>Text word search in the fields: Abstract, Book Title -  only to 1998, Conference, Document Type, Index Terms, Series, Section Headings, Title, Uncontrolled Term from 2001 on</P>
<P>
<B>EMBASE</B> <B>(via DIMDI)</B>
</P>
<P>Update status: 1 January 1974 to 24 April 2013<BR/>Search date: 24 April 2013 </P>
<TABLE COLS="3" ROWS="19">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>No </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Hits  </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Search expression </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21808651 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EM74</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>288 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CT = PELARGONIUM OR CT = PELARGONIUM SIDOIDES EXTRACT</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>546 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>UMCKA* OR PELARGONIUM* OR EPS 7630 OR EPS7630</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>546 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 OR 3            <I>
<B>facet intervention (I)</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>230268 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CT D RESPIRATORY TRACT INFECTION</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>52289 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CT D COUGHING</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>46002 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CT D PARAMYXOVIRUS OR CT D PARAMYXOVIRUS INFECTION</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>26054 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CT D HAEMOPHILUS</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>677 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CT=HAEMOPHILUS INFECTION</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1161 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CT=RESPIRATORY SYNCYTIAL VIRUS INFECTION</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10866 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CT D RESPIROVIRUS INFECTION OR CT=RESPIRATORY SYNCYTIAL PNEUMOVIRUS</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1700 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CT=ORTHOMYXOVIRIDAE INFECTION</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1069 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CT=ADENOVIRUS INFECTION OR CT=HUMAN ADENOVIRUS INFECTION</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2911192 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RESPIRAT* OR URTI* OR COLD* OR COUGH* OR NASO* OR NASAL* OR NOSE OR SINUS* OR EAR* OR OTALG* OR OTIT* OR OTO* OR LARYN* OR PHARYN* OR RETRO-PHARYN* OR RETROPHARYN* OR THROAT* OR TONSIL* OR TRACH* OR EPIGLOT* OR RHIN* OR BRONCH*</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1352547 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>WHOOP* OR PERTUSS* OR PULMO* OR LUNG* OR PNEUMO* OR PLEUR* OR PARAMYXOVIR* OR RESPIRATORY SYNCYTIAL VIRUS* OR RSV OR HAEMOPHILUS* OR HEMOPHILUS* OR INFLUENZA* OR PARAINFLUENZA*</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3746054 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 TO 15           <I>
<B>facet disease (P)</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>191 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 AND 16       <I>
<B>facet I + P</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>169 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17 NOT SU=MEDLINE        <I>
<B>(without unique medline citations)</B>
</I>
</P>
</TD>
</TR>
</TABLE>
<P>Legend:</P>
<P>EM74 = EMBASE 1974 to present<BR/>CT = controlled term (EMTREE)<BR/>CT D = explode controlled term<BR/>* = Truncation<BR/>Text word search in the fields: Abstract, Book Title, Common Device Name, Controlled Term, Device Manufacturer&#8217;s Name, Document Type, Drug Trade Name, Drug Manufacturer's Name, EMCLAS Term, Terminology, Title, Uncontrolled Term</P>
<P>
<B>EMBASE Alert</B> <B>(via DIMDI)</B>
</P>
<P>Update status: 22 February 2013 to 24 April 2013<BR/>Search date: 24 April 2013 </P>
<TABLE COLS="3" ROWS="3">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>No </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Hits  </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Search expression </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>121963 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EA08</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>UMCKA* OR PELARGONIUM* OR PELARGONIE* OR EPS 7630 OR EPS7630</P>
</TD>
</TR>
</TABLE>
<P>Legend:</P>
<P>EA08 = EMBASE Alert<BR/>* = Truncation<BR/>Text word search in the fields: Abstract, Book Title, Document Type, Title, Uncontrolled Term</P>
<P>
<B>Deutsches Ärzteblatt</B> <B>(via DIMDI)</B>
</P>
<TABLE COLS="1" ROWS="1">
<TR>
<TD>
<P>Update status 1 January 1996 to 22 April 2013</P>
<P> </P>
<P>Search date: 24 April 2013</P>
</TD>
</TR>
</TABLE>
<P> </P>
<TABLE COLS="3" ROWS="6">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>No </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Hits  </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Search expression</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>64973 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>AR96</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>UMCKA* OR PELARGONIUM* OR PELARGONIE* OR (EPS* # # 7630*) OR EPS7630*</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>GERANI*, # # # (*AFRI* OR SOUTH* OR SUD* OR SUED* OR SÜD* OR ROOT* OR *WURZEL*)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IKHUBALO OR ICWAYIBA OR *YEZA LEZIKALI OR KALOBA* OR KALWERBOSSI OR (KHOAARA AND NYENYANE) OR RABASSAM OR UVENDLE</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 TO 4</P>
</TD>
</TR>
</TABLE>
<P>Legend:</P>
<P>AR96 = Database Deutsches Ärzteblatt<BR/>Text word search in the fields: Document Type, Section Heading, Text, Title</P>
<P>
<B>Thieme-Publisher (via DIMDI)</B>
</P>
<P>Update status: 6 August 2002 to 27 April 2012<BR/>Search date: 27 April 2012; database not available via DIMDI after 2012. See below: update search via publisher&#8217;s website Thieme-connect </P>
<TABLE COLS="3" ROWS="5">
<TR>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>2 OR 3 OR 4</P>
</TD>
<TD ROWSPAN="5" VALIGN="TOP">
<P>28</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>Ikhubalo or Icwayiba or *Yeza lezikali or kaloba* or Kalwerbossi or (Khoaara and Nyenyane) or Rabassam or Uvendle</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>Gerani*, # # # (*afri* or south* or sud* or sued* or süd* or root* or *wurzel*)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>umcka* or pelargonium* or pelargonie* or (eps* # # 7630*) or eps7630*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>TV01 TVPP  </P>
</TD>
</TR>
</TABLE>
<P>TV01 = Database Thieme<BR/>TVPP = Database Thieme Preprint<BR/>Text word search in the fields: Abstract, Dokumenttyp, Title, Uncontrolled Terms<BR/># # # = within 3 words in any order</P>
<P>
<B>Thieme-Publisher</B> (via <A HREF="http://www.thieme-connect.de">www.thieme-connect.de</A>):</P>
<P>Publication years 2012 to 2013<BR/>Search date 25 April 2013 </P>
<TABLE COLS="5" ROWS="5">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Full-text search</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Mode</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>All years</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Publication</P>
<P>years</P>
<P>2012 to 2013</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Publication years</P>
<P>2012 to 2013</P>
<P>without dupl.</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Eps 7630</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Phrase search</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>49</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P> </P>
<P> </P>
<P>8</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Eps7630</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Umckaloabo*</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>56</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>pelargonium* rando*</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>All words (AND)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>26</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
</TR>
</TABLE>
<P>
<B>Springer publisher</B>
</P>
<P>
<A HREF="http://www.springerlink.com">www.springerlink.com</A>
</P>
<P>Search date 25 April 2013 </P>
<TABLE COLS="2" ROWS="2">
<TR>
<TH VALIGN="TOP">
<P>Query simple search</P>
</TH>
<TH VALIGN="TOP">
<P>Results</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>umckaloabo OR "pelargonium sidoides" OR eps7630  OR "eps 7630"</P>
<P>Refine your search: By discipline  &#8220;Medicine&#8221; and by &#8220;articles&#8221;:</P>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
</TR>
</TABLE>
<P> <B>Cambase</B> (via <A HREF="http://www.cambase.de">www.cambase.de</A>)</P>
<P>Search date 25 April 2013 </P>
<TABLE COLS="3" ROWS="5">
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Query (all words)</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Results</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Results without duplicates</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pelargonium</P>
</TD>
<TD VALIGN="TOP">
<P>41</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>35</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Umckaloabo</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Eps7630</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Eps 7630</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
</TR>
</TABLE>
<P>
<B>LILACS </B>
</P>
<P>via <A HREF="http://lilacs.bvsalud.org/en/">http://lilacs.bvsalud.org/en/</A>
</P>
<P>Update status: 1 March 2013<BR/>Search date 29 April 2013</P>
<TABLE COLS="2" ROWS="2">
<TR>
<TH VALIGN="BOTTOM">
<P>Search by iAH form:</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Results</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>B01.650.940.800.575.100.462.750 [DeCS Category] or pelargonium or eps 7630 or eps7630 or umckaloabo or kaloba [Words]</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
</TR>
</TABLE>
<P>Legend:</P>
<P>DeCS Category  number = Descriptores en Ciencias de la Salud (Descriptors on Health Sciences), identical to MeSH - Medical Subject Headings</P>
<P>
<B>TRIP Database </B>
<A HREF="http://www.tripdatabase.com">www.tripdatabase.com</A>
</P>
<P>Search date: 29 April 2013</P>
<P>Search strategy: pelargonium or umckaloabo or eps7630 or "eps 7630"</P>
<P>Results: 105 (incl. Dupl)<BR/>1.      Evidence: 48 hits incl. dupl.<BR/>2.      MEDLINE Articles:</P>
<P>2.1. Therapy:  17 hits<BR/>Details: (("pelargonium"[MeSH Terms] OR "pelargonium"[All Fields]) OR umckaloabo[All Fields] OR ("EPs 7630"[Supplementary Concept] OR "EPs 7630"[All Fields]) OR ("EPs 7630"[Supplementary Concept] OR "EPs 7630"[All Fields] OR "eps 7630"[All Fields])) AND (randomized controlled trial[Publication Type] OR (randomized[Title/Abstract] AND controlled[Title/Abstract] AND trial[Title/Abstract]))</P>
<P>2.2. Etiology:  5 hits</P>
<P>Details: ((pelargonium or umckaloabo or eps7630 or "eps or 7630")) AND ((relative[Title/Abstract] AND risk*[Title/Abstract]) OR (relative risk[Text Word]) OR risks[Text Word] OR cohort studies[MeSH:noexp] OR (cohort[Title/Abstract] AND stud*[Title/Abstract]))<BR/>Wildcard search for 'stud*' used only the first 600 variations</P>
<P>2.3. Diagnosis:  4 hits</P>
<P>Details: (("pelargonium"[MeSH Terms] OR "pelargonium"[All Fields]) OR umckaloabo[All Fields] OR ("EPs 7630"[Supplementary Concept] OR "EPs 7630"[All Fields]) OR ("EPs 7630"[Supplementary Concept] OR "EPs 7630"[All Fields] OR "eps 7630"[All Fields])) AND specificity[Title/Abstract]</P>
<P>2.4. Systematic Reviews: 3 hits</P>
<P>Details: (("pelargonium"[MeSH Terms] OR "pelargonium"[All Fields]) OR umckaloabo[All Fields] OR ("EPs 7630"[Supplementary Concept] OR "EPs 7630"[All Fields]) OR ("EPs 7630"[Supplementary Concept] OR "EPs 7630"[All Fields] OR "eps 7630"[All Fields])) AND (meta analysis[ptyp] OR meta-analysis[tiab] OR "meta-analysis as topic"[MeSH Terms] OR (systematic[tiab] AND review[tiab]) NOT ((case[ti] AND report[ti]) OR editorial[ptyp] OR comment[ptyp] OR letter[ptyp] OR newspaper article[ptyp]))</P>
<P>Total in TRIP database without duplicates: <B>50</B> hits</P>
<P>
<B>PubMed: component 'Supplied by Publisher' </B>(<A HREF="http://www.pubmed.gov">www.pubmed.gov</A>)</P>
<P>Search date 30 April 2013</P>
<TABLE COLS="3" ROWS="5">
<TR>
<TH>
<P>
<B>Search</B>
</P>
</TH>
<TH>
<P>
<B>Query</B>
</P>
</TH>
<TH>
<P>
<B>Items found</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/advanced">#5</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search <B>#4 AND publisher[sb]</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=5">12</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/advanced">#4</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search <B>(#2 OR #3)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=4">345</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/advanced">#3</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search <B>pelargonium*[tw] OR "eps 7630"[tw] OR eps7630[tw] OR umckaloabo*[tw]</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=3">345</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/advanced">#2</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search <B>"Pelargonium"[MeSH]</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=2">147</A>
</P>
</TD>
</TR>
</TABLE>
<P>Legend:</P>
<P>* = Truncation</P>
<P>[tw] = text word search in the fields: title, abstract, other abstract, MeSH terms, MeSH Subheadings, Publication Types, Substance Names, Personal Name as Subject, Corporate Author, Secondary Source, Comment/Correction Notes<BR/>[MeSH] = Medical Subject Heading with explode-function<BR/>[sb] = subset</P>
<P>
<B>ScienceDirect</B>
</P>
<P>
<A HREF="http://www.sciencedirect.com">www.sciencedirect.com</A>
</P>
<P>Search date 30 April 2013<BR/>Advanced search: </P>
<P>
<B>14</B> articles found for: TITLE-ABSTR-KEY(<B>umckaloabo*)</B>
<BR/>
<B>29</B> articles found for: TITLE-ABSTR-KEY(<B>"eps* 7630*"</B>)<BR/>
<B>60</B> articles found for: TITLE-ABSTR-KEY(<B>pelargonium*</B>)[All Sources(Medicine and Dentistry)]<BR/>Total: <B>103</B>
<BR/>Without duplicates: <B>68</B>
</P>
<P>
<B>Web of Science: Cited Reference Search</B> (forward search) of:</P>
<P>Timmer Cochrane Review 2008 and of 12 selected articles for inclusion in Cochrane Review 2013</P>
<P>Databases=SCI-EXPANDED, SSCI, A&amp;HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SH Timespan=All years</P>
<P>Search date 2 May 2013</P>
<TABLE COLS="3" ROWS="13">
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Set</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Results</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>  </B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>No hits from forward citations of:</P>
<P>Kamin W, Ilyenko LI, Malek FA, Kieser M. Treatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescents. Pediatrics international : official journal of the Japan Pediatric Society. 2012;54(2):219-26.</P>
<P>Kamin W, Maydannik V, Malek FA, Kieser M. Efficacy and tolerability of EPs 7630 in children and adolescents with acute bronchitis - a randomized, double-blind, placebo-controlled multicenter trial with a herbal drug preparation from Pelargonium sidoides roots. Int J Clin Pharmacol Ther. 2010;48(0946-1965 (Print), 0946-1965 (Linking), 3):184-91.</P>
<P>Matthys H, Lizogub VG, Funk P, Malek FA. [Pelargonium sidoides in acute bronchitis - Health-related quality of life and patient-reported outcome in adults receiving EPs 7630 treatment]. Wiener medizinische Wochenschrift (1946). 2010;160(21-22):564-70.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 11</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=53&amp;SID=Q1BloOOke9OkmheBADc&amp;search_mode=CombineSearches">71</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>#10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 10</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=52&amp;SID=Q1BloOOke9OkmheBADc&amp;search_mode=CitedRefIndex">3</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Cited Author=(matthys) AND Cited Work=(curr*) AND Cited Year=(2010)</P>
<P>Matthys, H., et al., Efficacy and tolerability of EPs 7630 tablets in patients with acute bronchitis: a randomised, double-blind, placebo-controlled dose-finding study with a herbal drug preparation from Pelargonium sidoides. Curr Med Res Opin, 2010. 26(6): p. 1413-1422.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 9</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=45&amp;SID=Q1BloOOke9OkmheBADc&amp;search_mode=CitedRefIndex">5</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Cited Author=(matthys) AND Cited Work=(planta*) AND Cited Year=(2008)</P>
<P>Matthys, H. and P. Funk, EPs 7630 improves acute bronchitic symptoms and shortens time to remission. Results of a randomised, double-blind, placebo-controlled, multicentre trial. Planta Med, 2008. 74(6): p. 686-692.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 8</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=39&amp;SID=Q1BloOOke9OkmheBADc&amp;search_mode=CitedRefIndex">2</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Cited Author=(kamin) AND Cited Work=(acta*) AND Cited Year=(2010)</P>
<P>Kamin, W., et al., Efficacy and tolerability of EPs 7630 in patients (aged 6-18 years old) with acute bronchitis. Acta Paediatr, 2010. 99(4): p. 537-543.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 7</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=29&amp;SID=Q1BloOOke9OkmheBADc&amp;search_mode=CitedRefIndex">10</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Cited Author=(bachert) AND Cited Work=(rhinol*) AND Cited Year=(2009)</P>
<P>Bachert, C., et al., Treatment of acute rhinosinusitis with the preparation from Pelargonium sidoides EPs 7630: a randomized, double-blind, placebo-controlled trial. Rhinology, 2009. 1: p. 51-58.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 6</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=22&amp;SID=Q1BloOOke9OkmheBADc&amp;search_mode=CitedRefIndex">21</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Cited Author=(timmer) AND Cited Work=(cochr*) AND Cited Title=(pelargonium*)</P>
<P>Timmer A, Günther J, Rücker G, Motschall E, Antes G, Kern WV. Pelargonium sidoides extract for acute respiratory tract infections. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD006323. DOI: 10.1002/14651858.CD006323.pub2.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 5</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=15&amp;SID=Q1BloOOke9OkmheBADc&amp;search_mode=CitedRefIndex">21</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Cited Author=(matthys) AND Cited Work=(curr*) AND Cited Year=(2007)</P>
<P>Matthys, H. and M. Heger, Treatment of acute bronchitis with a liquid herbal drug preparation from Pelargonium sidoides (EPs 7630): a randomised, multicentre, double-blind, placebo-controlled study. Current Medical Research and Opinion, 2007. 23(2): p. 323-331.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 4</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=12&amp;SID=Q1BloOOke9OkmheBADc&amp;search_mode=CitedRefIndex">17</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Cited Author=(lizogub) AND Cited Work=(explore*) AND Cited Year=(2007)</P>
<P>Lizogub, V.G., D.S. Riley, and M. Heger, Efficacy of Pelargonium Sidoides Preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial. Explore, 2007. 3(6): p. 573-584.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 3</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=9&amp;SID=Q1BloOOke9OkmheBADc&amp;search_mode=CitedRefIndex">8</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Cited Author=(golovatiouk) AND Cited Work=(Phytopharmaka*) AND Cited Year=(2002)</P>
<P>Golovatiouk, A. and A.G. Chuchalin, Efficacy of pelargonium sidoides preparation (Eps (R) 7630) in adults with acute bronchitis. Phytopharmaka. Vol. 7. 2002, Darmstadt: Steinkopff. 3-12.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 2</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=6&amp;SID=Q1BloOOke9OkmheBADc&amp;search_mode=CitedRefIndex">37</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Cited Author=(chuchalin) AND Cited Work=(explore*) AND Cited Year=(2005)</P>
<P>Chuchalin, A.G., B. Berman, and W. Lehmacher, Treatment of acute bronchitis in adults with a pelargonium sidoides preparation (EPs 7630): a randomized, double blind, placebo-controlled trial. Explore, 2005. 1(6): p. 437-445.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 1</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=3&amp;SID=Q1BloOOke9OkmheBADc&amp;search_mode=CitedRefIndex">4</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Cited Author=(bachert) AND Cited Work=(focus*) AND Cited Year=(2006)</P>
<P>Bachert, C., et al. Treatment of acute bacterial maxillary sinusitis with EPs 7630-solution: a randomised, double-blind, placebo-controlled trial. Focus Alternative Complementary Therapy, 2006. 11: p.4.</P>
</TD>
</TR>
</TABLE>
<P>
<B>Study registries:</B> </P>
<P>
<B>ClinicalTrials.gov</B> -  via  <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>
<BR/>
<B>Deutsches Register klinischer Studien DRKS (German Clinical Trials Register) </B>&#8211; <A HREF="http://www.drks.de">www.drks.de</A>
<BR/>
<B>International Clinical Trials Registry Platform (ICTRP) &#8211; WHO ICTRP &#8211; </B>
<A HREF="http://apps.who.int/trialsearch/default.aspx">http://apps.who.int/trialsearch/default.aspx</A>
<BR/>
<B>Current Controlled Trials</B> &#8211; <A HREF="http://www.controlled-trials.com">http://www.controlled-trials.com</A>
<BR/>
<B>EU Clinical Trials Register</B> &#8211;  <A HREF="http://www.clinicaltrialsregister.eu">www.clinicaltrialsregister.eu</A> </P>
<P>Search date: 3 May 2013<BR/>Search terms: </P>
<P>umckaloabo*, pelargoni*, gerani*, eps7630, eps 7630, kaloba*, Kalwerbossi, Rabassam, Uvendle<BR/>
<B>31</B> hits without duplicates</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2013-09-09 10:08:06 +1000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2013-09-09 10:05:29 +1000" MODIFIED_BY="[Empty name]">Clinical study registries search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-09-09 10:08:06 +1000" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="7">
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Study register</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>ClinicalTrials.gov -  via  <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Deutsches Register klinischer Studien DRKS (German Clinical Trials Register) - via <A HREF="http://www.drks.de">www.drks.de</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>International Clinical Trials Registry Platform (ICTRP) &#8211; WHO ICTRP &#8211; via <A HREF="http://apps.who.int/trialsearch/default.aspx">http://apps.who.int/trialsearch/default.aspx</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Current Controlled Trials &#8211; via <A HREF="http://www.controlled-trials.com">http://www.controlled-trials.com</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>EU Clinical Trials Register &#8211; via <A HREF="http://www.clinicaltrialsregister.eu">www.clinicaltrialsregister.eu</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Total without duplicates: 22</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;8 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;10 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;40 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;182 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;874 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;1565 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;71 additional records identified through other sources (56 clinical trial registries, 13 investigator supplied, 2 other)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;144 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;30 full-text articles excluded (19 not eligible, 6 information pending, 7 ongoing)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>